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Abstract 
 
 
Surface engineering of a polyacrylamide (PAA) hydrogel nanoparticle (NP) with the tumor-
targeting ligand, F3 peptide (KDEPQRRSARLSAKPAPPKPEPKPKKAPAKKC), confers 
binding specificity toward Nucleolin overexpressing tumor cells (9L rat gliosarcoma, and MDA-
MB-435 human breast adenocarcinoma). In this study, the endocytic internalization, and 
intracellular trafficking of the non-targeted PAA-NPs (NTNPs), and F3-targeted PAA-NPs 
(F3NPs) in the above-mentioned cell lines, was investigated. Caveolae-mediated internalization 
of both types of PAA-NPs peaked at 2 hours post-delivery, although internalization of the 
NTNPs was ~2-fold greater than for the F3NPs.  In contrast, clathrin-mediated internalization of 
both types of PAA-NPs was markedly faster; the NTNPs and F3NPs both reached similar peak 
colocalization levels with early endosome antigen-1 (EEA1, ~32%) at 30 minutes post-delivery. 
However, at 60 minutes post-delivery, the NTNPs exhibited faster egress from the early 
endosomes than the F3NPs, with a concomitant, sharp increase in trafficking to the lysosomes 
(acidic, degradative vesicles), whereas the F3NPs largely evaded trafficking to the lysosomes. 
Furthermore, the F3 peptides alone exhibited significantly higher accumulation within the 
lysosomes than both the NTNPs, and the F3NPs.  
The p38 Mitogen-Activated Protein Kinases (MAPKs), upon activation, promote (i) 
internalization of caveolae from the cell membrane, and (ii) rapid trafficking of early endosomes 
to the lysosomes by directly phosphorylating Caveolin1 and EEA1, respectively. Phospho-
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proteomic analyses, in MDA-MB-435 cells, revealed that the peak levels of activated p38β and 
p38δ MAPKs (at 2 hours post-delivery) elicited by the F3 peptides alone, and the NTNPs was 
1.5 – 2-fold greater than by the F3NPs. These data therefore provide compelling evidence that 
the intracellular trafficking behavior of the F3 peptides, NTNPs and F3NPs are attributable to 
their differential activation of the p38 MAPKs. Further analysis of the ERK MAPK, JNK MAPK, 
and Akt pathways revealed that the NTNPs elicit a pro-apoptotic signaling profile, whereas the 
F3 peptides, and F3NPs elicit proliferative profiles. The findings of this thesis suggest that the 
design of tumor-targeting nanoparticles also need to consider the MAPK signaling profiles that 
they elicit on the intended target cell type, due to the influence of the p38 MAPKs, in particular, 
on endocytic trafficking, and the survival status of the target tumor cell. 
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Chapter 1: Literature Review 
 
1.1 Introduction 
The earliest documented treatment of cancer dates as far back as 3000BC to the ancient Egyptian 
civilization. The Greek physician, Hippocrates (460-370BC), is accredited with the first 
scientific description of cancer, whereby he used the terms carcinos and carcinoma to describe 
non-ulcerating and ulcerating cancers, respectively. These words refer to a crab, which were 
likely attributed to the disease due to the finger-like projections that emanate from a cancer, thus 
evoking the shape of a crab. The recognition of cancer as a cell-based disease paved the way for 
our understanding of cancers at a physiological, genetic and molecular basis, and concomitantly 
transformed our approaches to its treatment. Whilst tumors originate from apparently normal 
parental cells, cancer cells clearly evolve unique phenotypic characteristics. As such, cancer 
tissues are best conceptualized as a collection of traits or hallmarks, such as invasion of normal 
tissue, immune evasion, autonomous and unrestricted growth, resistance to apoptosis, and 
deregulated cellular energetics.1  
Until 30 years ago however, cancer chemotherapies were restricted to cytotoxic drugs that 
indiscriminately killed rapidly dividing normal and cancer cells. Only in recent decades, has 
there been a shift away from the ‘cytotoxic approach’ toward a ‘targeted molecular approach’ 
that specifically exploits the unique traits of cancer cells so as to selectively kill them.2 The 
advent of nanoparticles (inorganic or organic materials typically ranging from tens to few 
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hundreds of nanometers (10-9 m) in size) has provided versatile multifunctional nanoplatforms3 
upon which various modalities, such as, tumor targeting moieties, synergistic drugs to overcome 
multiple drug resistance (MDR) transporters, and enzymes that degrade the extracellular matrix, 
can be integrated in a single package to enhance drug accumulation within the tumor site, while 
minimizing side effects. Furthermore, nanoparticles (NPs) have a distinct advantage over 
chemotherapeutic drugs in being able to accumulate within the tumor interstitium.4 This is 
largely due to the “physiological barrier” of the tumor that prohibits the diffusion of drug 
molecules into the tumor interstitium. In particular, the disorganized vascular architecture of 
solid tumors (discussed further) presents a significant challenge to the ability of 
chemotherapeutic drugs to infiltrate the tumor tissue from the circulation, which can severely 
limit the effective amount of drug that accumulates within the tumor. As Sun Tzu expounded in 
his famous book, The Art of War, the key to winning battles lies in the knowledge of one’s 
enemy and oneself. Hence, the development of effective drug-delivery strategies is critically 
dependent on an understanding of the tumor pathophysiology, and the ability to tailor the drug-
delivery system accordingly. 
 
1.2 Pathophysiology of Solid Tumor Vasculature 
As normal tissues proliferate and become established, their nascent vasculature is organized into 
a highly structured and hierarchical network of arterioles, capillaries, venules and lymphatic 
vessels that function cooperatively to maintain optimal tissue perfusion. By contrast, the 
physiology of tumors is markedly different to that of normal tissues, in that, it is characterized by 
hypoxia (oxygen depletion), acidosis and high lactate levels within the extracellular compartment, 
glucose and energy deprivation, increased interstitial fluid flow, and interstitial hypertension.5 
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This harsh tumor microenvironment is essentially attributed to rapid, unregulated tumor 
vasculature proliferation that results in immature, structurally and functionally defective 
microvessels. Due to the highly dysfunctional and defective nature of the tumor vasculature, it 
has deservedly been described as an “aberrant monster”.6 Briefly, the tumor vasculature is 
characterized by (i) loss of vessel hierarchy, (ii) excessive and disorganized vessel branching 
accompanied by sinusoidal (blind) endings, (iii) incomplete, or even absent endothelial cell 
linings of vasculature, and interrupted basement membranes, (iv) presence of tumor-cell lined 
vasculature, (v) increased vascular permeability due to enlarged fenestrations (spaces between 
endothelial cells), and (vi) compressed lymphatic vessels with lumens that are commonly 
infiltrated by tumor cells.5 The enlarged vascular fenestrations promote the extravasation of 
blood plasma, as well as, red blood cells into the tumor interstitium (extracellular space). In 
normal tissue, the ratio of Intracellular volume: Interstitial volume: Intravascular volume is 
maintained at ~ 0.73: 0.16: 0.11, whereas in tumor tissue, the interstitial volume is markedly 
enlarged, thus yielding a ratio of ~ 0.50: 0.45: 0.05.5 Subsequently, equilibrium between the 
hydrostatic and oncotic pressures with the tumor microvasculature, and the tumor interstitial 
fluid pressure is achieved. This, in conjunction with poor lymphatic drainage of the tumor 
center,7 results in a dramatic increase in hydrostatic pressure of the tumor interstitium (interstitial 
hypertension). The interstitial fluid pressure in normal tissue ranges between slightly sub-
atmospheric (“negative”), to just above atmospheric pressure (-3 to 6 mmHg),8 whereas the 
interstitial hypertension in tumors reach up to 60-70 mmHg.9 As such, the overwhelming 
interstitial fluid pressure of tumors presents a “physiological barrier” to the delivery of 
therapeutic molecules to the cancer cells, by prohibiting their diffusion into the tumor 
interstitium from the tumor vasculature.10 In addition, the poor perfusion of tumor vasculature 
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further limits the delivery of chemotherapeutic drugs to the tumor interstitium.11 
 
1.3 Passive Tumor Targeting of Nanoparticles 
Nanoparticles are however, able to accumulate within the tumor interstitium by an effect known 
as, “enhanced permeability and retention (EPR)”, which is exclusive to solid tumors.12 The 
“enhanced permeability” of NPs into the tumor interstitium is attributed to the abnormally large 
fenestrations of the tumor vasculature,13 while the “enhanced retention” of NPs within the tumor 
interstitium is due to the compressed lymphatic vessels14 that prohibit the tumor from clearing 
away the nanoparticles that enter it. Following administration into the peripheral bloodstream, 
the NPs distribute indiscriminately throughout the systemic circulation, and over time, a fraction 
of the administered dose will accumulate within the tumor site by the EPR effect. This is known 
as passive tumor targeting. The reason for a fraction of the administered nanoparticle dose 
reaching the tumor site is as follows. Upon contact with the blood stream, NPs acquire a corona 
consisting of serum proteins, adsorbed to their surface, which is known as opsonization. 
Furthermore, the composition of the protein corona is dependent on the size and surface charge 
of the NP.15 The opsonized NPs are then recognized, and subsequently removed from the 
circulation by phagocytic macrophages located in the liver and spleen that comprise the 
mononuclear phagocytic system (MPS).16 The surface-modification of NPs with the 
polyethylene glycol (PEG; a biocompatible, neutral-charged, hydrophilic, linear synthetic 
polymer),17 a process known as PEGylation, confers “stealth” capability to the NPs by reducing 
the protein opsonization, as well as the self-aggregation of the NPs. This reduces their 
recognition and removal by the MPS macrophages,18 and markedly extends their circulating 
lifetime, up to 40-fold longer than uncoated NPs.19  
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However, long-circulating lifetimes, and the EPR effect alone, do not guarantee efficient 
accumulation of the NPs within tumor site for two reasons. First, solid tumors typically grow to 
only a few centimeters in diameter, a small fraction of the total size of a patient.20 Second, not all 
tumors exhibit the EPR effect, since the degree of vascularization and porosity of tumor vessels 
can vary with the type and status of the tumor.21,4 Furthermore, metastasized colonies that have 
not yet established microvasculature will likely evade circulating NPs, thus also rendering the 
passive targeting of NPs based on the EPR effect, ineffective.  
 
1.4 Active Targeting of Tumor Microvasculature and Vascular Zip Codes 
An alternative approach is to functionalize the surface of the NP with targeting ligands (known 
as, active tumor targeting), which bind specifically to markers expressed exclusively on the 
luminal surface of tumor endothelial cells, but not by resting blood vessels of normal tissues 
(Table 1).22 These tumor endothelial markers have been eloquently referred to as “vascular zip 
codes”.23 However, targeting ligands that recognize only tumor endothelial cells will accumulate 
within the tumor vessels, but their penetration into the tumor tissue itself still relies on passive 
mechanisms.24 On the other hand, targeting ligands that recognize tumor cells solely, provide 
little improvement in the accumulation of the targeted NP over the non-targeted NP, as their 
entry into the tumor tissue still depends on the degree to which the target tumor exhibits the EPR 
effect. Employing targeting a ligand that targets receptors expressed by both tumor vessels and 
tumor cells presents is highly-advantageous, in that it combines the limited efficiency of the two 
above-mentioned targeting mechanisms to enhance accumulation of the targeted nanoparticle 
within the tumor tissue.24 One such receptor is Nucleolin (Table 1), which is a ubiquitous nuclear 
and cytoplasmic protein,25 but also overexpressed at the cell surface of tumor cells and tumor 
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endothelial cells.26  
 
Table 1.1 List of cell surface expressed receptors in tumor blood vessels 
Receptor 
RGD-directed integrins (αvβ3 and αvβ5)27,28 
Aminopeptidase N29 
Tumor Endothelial Markers (TEMs)30 
Endosialin31 
Cell surface Nucleolin26 
Cell surface Annexin-132 
Cell surface p32/gC1q receptor33  
Cell surface plectin-134 
Fibronectin ED-B35 
Fibrin-fibronectin complexes36,37 
Interleukin-11 receptor α38 
Protease-cleaved collagen IV39,40 
 
1.4.1 Targeting Surface-Expressed Nucleolin Receptors 
A 31-amino acid fragment (KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK) of the N-terminal 
region of the high mobility group nucleosomal 2 (HMGN2) protein, known as F3 peptide, was 
shown to home to the nuclei of tumor cells and tumor endothelial cells (human HL-60 leukemia, 
and human MDA-MB-435 breast carcinoma) in vivo.41 This effect was later attributed to the 
direct binding of F3 peptide to surface-expressed nucleolin receptors in MDA-MB-435 cells that 
mediate the internalization of the F3 peptide.26 It was recently reported that several tumor cell 
lines constantly induce the expression of nucleolin receptors at their cell surface to mediate 
calcium-dependent ligand internalization from the extracellular environment.42  
 Furthermore, surface-expressed nucleolin has been shown to mediate the internalization of 
several physiological extracellular ligands. These include the carcinogenic ligands, midkine,43 
pleiotrophin,44 and P-Selectin,45 as well as the anti-carcinogenic ligands, lactoferrin,46 and 
endostatin.47 In addition, nucleolin has been shown to exist in cell surface complexes with the 
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urokinase plasminogen activator receptor (uPAR),47 and the α5β1 integrin, whereby nucleolin 
physically interacts, via its C-terminal glycine-arginine-rich domain (GAR domain, 646-707 aa) 
with uPAR (Fig. 1.1). Furthermore, the C-terminal 212 amino acids (the fourth RNA-binding 
domain (RBD) and GAR domain) of cytoplasmically-localized Nucleolin interacts with the 
cytoplasmic domain of HER/ERbB receptors. Overexpression, of both nucleolin and ErbB/HER 
receptors leads to ErbB/HER phosphorylation, dimerization and enhanced cell proliferation (Fig. 
1.1).48,49 Importantly, the uPAR/α5β1 integrin complex has been shown to activate the 
ErbB1/HER1 receptor, which potentiates the mitogenic signaling of ErbB1/HER1.50,51 Hence, 
nucleolin’s involvement with these cell surface mitogenic receptors is to potentiate cellular 
proliferation. This is further supported by the observations that nucleolin-specific antagonists 
suppress both tumor growth and angiogenesis (development of new blood vessels).52,53  
 
 
 
Fig 1.1 Interaction of surface-expressed and cytoplasmic nucleolin with cell surface receptors to potentiate 
mitogenic cell signaling. F3 (F3 peptide), Nuc (Nucleolin receptor), uPAR (urokinase plasminogen activator 
receptor), P-Y (phosphorylated Tyrosine residue), α5β1 (α5β1 integrin: fibronectin receptor).  
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Hence, the ability of nucleolin to readily internalize extracellular ligands, together with the 
crucial role that it plays in supporting cellular proliferation, renders it an ideal receptor target for 
mediating intracellular delivery of nanotherapeutics to tumor cells. Consequently, the F3 peptide 
has been exploited successfully for the in vivo delivery of various therapeutics to tumor cells that 
overexpress cell surface nucleolin receptors.54–56 Also, the overexpression of nucleolin at the 
surface of highly proliferating, and metastatic cells, such as MDA-MB-435 breast carcinoma 
cells,57  permits the targeting of NPs with nucleolin-specific ligands, such as F3 peptide, to 
metastatic tumor colonies that do not have established vasculature. 
 It is important to note at this point that, despite the use of the term “active tumor targeting” 
to denote the surface functionalization of nanoparticles with tumor targeting ligands, such as F3 
peptide, the ligand-targeted NP does not “actively” seek out the tumor, but is still subjected to 
the same systemic distribution as the non-targeted NP. It is therefore advantageous to combine 
the surface targeting of NPs with surface PEGylation,54 so as to enhance the circulating half-life 
of the NPs, and thus increase the likelihood of the NPs encountering the tumor site before their 
removal from the systemic circulation by the MPS macrophages. Furthermore, the large surface 
area of nanoparticles allows the attachment of multiple targeting ligands to the surface of a single 
nanoparticle, thus conferring multivalency (ability to simultaneously bind multiple receptors) 
and high avidity to each nanoparticle. The high avidity of multivalent, ligand-targeted NPs is 
usually due to an unaffected binding rate (on rate [kon]), but a reduction in the dissociation rate 
(off rate [koff]).24 The multivalency effect is therefore especially important when functionalizing 
NPs with ligands, such as peptides, that bind to their targets with modest binding affinities 
(micromolar to low millimolar range). Enhancements in the binding affinities due to the 
multivalency effect are typically 10-104 fold.24  
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1.5 Multifunctional Hydrogel Nanoparticles in Cancer Therapy 
In recent years, hydrogel nanoparticles (10-1000 nm) have received considerable attention as 
promising nanoparticulate drug delivery systems, which is primarily owed to their (i) 
hydrophilicity, (ii) extremely high water content, and (iii) their ability to swell in aqueous 
environments, that can be modulated by environmental changes. Hydrogels are three-
dimensional polymeric networks that can be either physically, or covalently cross-linked, and 
can be synthesized from both natural and synthetic polymers (Table 1.2).  
 
 
Table 1.2 List of natural and synthetic polymers from which hydrogel nanoparticles have been 
synthesized for cancer therapy applications (adapted from Koo Lee and Kopelman)3 
Natural 
polymers 
Polysaccharides 
• Anionic: alignate, hyaluronate, xanthene gum 
• Cationic: chitosan 
• Neutral: agarose, cellulose, dextran, pullalan 
Proteins/polypeptides 
• Albumin, collagen, gelatin, polylysine, elastin-like polypeptide 
Synthetic 
polymers 
• Poly(acrylic acid) 
• Poly(acylamide), poly(N-isopropylacrylamide), poly(2-hydroxyethyl methacrylate), 
poly[2-(N,N-diethylammo)ethyl methacrylate] 
• Poly(ethylene oxide) (PEO), poly(propylene oxide) (PPO), PEO-PPO-PEO block 
copolymers (or Pluronics®), poly(oligo(ethylene oxide) monomethyl ether methacrylate)  
• Poly(vinyl alcohol) 
• Poly(vinyl pyrrolidone) 
• Poly(N-vinylformamide) 
• Poly(ethyleneimine) 
• Poly(N-vinyl caprolactam), block copolymer of methoxy poly(ethylene glycol)-
poly(caprolactone) 
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Their ability to swell in water is attributed to the presence of hydrophilic groups in the polymers 
that form hydrogel structures.58 Furthermore, hydrogels contain several chemical functional 
groups, such as amine, carboxyl, hydroxyl, and aldehyde, which can be exploited for the 
covalent linkage of additional molecules, such as drugs, contrast agents, PEG and targeting 
moieties. In addition to their ability to exploit the EPR effect, and their amenability to surface 
modifications (PEGylation and ligand functionalizations), hydrogel nanoparticles possess 
additional attractive properties that permit their application in cancer therapy. First, hydrogel 
NPs are biocompatible and biodegradable,59–62 which is crucial to reducing the immunogenicity 
of the NP drug delivery system. Second, due to their ability to swell immensely in water, 
hydrogel NPs possess the capacity for high-density co-encapsulation of various types of payloads, 
including (i) a broad range of drugs,63 (ii) contrast agents for biomedical imaging,64–66 (iii) 
Fig 1.2 Schematic diagram of a multifunctional hydrogel nanoparticle for cancer therapy. In reality, no more than 2-
3 modalities would be incorporated into each nanoplatform, in addition to the surface modifications (PEGylation 
and tumor ligand targeting). 
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biosensing probes,67–69 and (iv) photosensitizers to facilitate photodynamic therapy (Fig. 1.2).70–
72 Third, hydrogel NPs can significantly enhance the intracellular accumulation of 
chemotherapeutic drugs by circumventing the multidrug resistance (MDR) transporter pumps 
(located in the cell membranes of tumor cells), which pump out chemotherapeutic drugs that 
diffuse across the cell membrane into tumor cells. This is achieved by the endocytosis 
(internalization) of the hydrogel nanoparticle and its drug payload, upon contact with the cell 
membrane, and its subsequent containment within the cell by an endosomal membrane. Perhaps 
the most attractive property of hydrogel nanoparticles, however, is the potential to engineer them 
for controlled-drug release in response a variety of stimuli. Depending on the type of 
polymer/functional moieties/crosslinkers used in the synthesis of a hydrogel nanoparticle, it can 
be stimulated to release its drug payload in response to either (i) a change in pH,73 (ii) lysosomal 
enzymes,74 (iii) glutathione concentration,75,76 or (iv) temperature.77 Furthermore, designing 
hydrogel nanoparticles to release their drug payload only after internalization by the 
tumor/endothelial cell, serves to further enhance the accumulation of drug within the target cell. 
The ability to incorporate such a diverse array of functionalities into a single hydrogel polymer at 
the nanometer level has permitted the evolution of multifunctional nanoparticles that can 
facilitate cancer theranostics (combination of therapy and diagnostics) (Fig. 1.2). 
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1.6 Endocytosis and Intracellular Trafficking of Hydrogel Nanoparticles 
Upon contact with the cell membrane, both non-targeted and targeted hydrogel nanoparticles are 
internalized by endocytosis. The major endocytic pathways implicated in mediating the 
internalization of nanoparticles include, (i) clathrin-mediated endocytosis, (ii) caveolae-mediated 
endocytosis, and (iii) macropinocytosis (Fig. 1.3).78 In clathrin-mediated endocytosis, the 
Fig 1.3 Schematic diagram of the major endocytic pathways that mediate internalization of nanoparticles. While this 
schematic diagram is not drawn to scale, it is important to note that the vesicles that emanate from each of these 
endocytic mechanisms are of different sizes. 
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nanoparticles are internalized via clathrin-coated pits, which form by the assembly of clathrin 
triskelia (three-legged protein structures) into a basket-like, polyhedral lattice on the cytoplasmic 
surface of the cell membrane.79 This process deforms the cell membrane into a coated pit of 
~150 nm, and formation of the clathrin lattice continues until fission of the invaginating 
membrane from the cell surface is achieved. Fission of the clathrin-coated vesicle requires the 
GTPase enzyme, dynamin, and the size of the resulting endocytic vesicle is typically 100 – 120 
nm.80,81 The NP-laden vesicle is then trafficked to the “early” (or “sorting”) endosomes, which 
are characterized by the presence of the early endosome antigen 1 (EEA1) located in their 
membranes. In addition, the early endosomes are acidified by ATP-dependent proton pumps to ~ 
pH 6. The early endosomes then mature into late endosomes, with continued acidification of the 
endosomal lumen to ~pH 5. The late endosomes subsequently fuse with lysosomes (pH 4.5 - 5.5), 
which are the terminal, degradative subcellular compartments in this pathway (Fig. 1.3).  
Caveolae are flask-shaped membrane invaginations, lined by the dimeric protein caveolin, 
and are characterized by a lipid content enriched in cholesterol and sphingolipids. Caveolae 
typically range between 50 – 80 nm in size. Upon binding to the cell membrane, NPs may be 
translocated to the caveolae invaginations, and maintained by receptor-ligand interactions.80 The 
GTPase dynamin is also necessary for the fission of caveolae from the cell membrane however, 
the internalization kinetics of caveolae-mediated endocytosis are much slower than that of 
clathrin-mediated endocytosis.81 The caveolae-derived vesicle then fuses with the caveosome, 
which is devoid of degradative enzymes, and has a pH ~7. Nonetheless, caveolae-derived 
vesicles have been shown to be trafficked into EEA1-postive early endosomes, and vice versa 
(Fig. 1.3).82,83 Importantly, clathrin-mediated, and caveolae-mediated endocytosis are energy 
dependent processes due to their requirement for the GTPase dynamin to facilitate fission of their 
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respective budding vesicles from the cell membrane. 
Macropinocytosis is a non-specific endocytic process that occurs independently of clathrin- 
and caveolae-mediated endocytosis.84 It is driven by actin-potentiated membrane protrusions that 
collapse back onto and fuse with the cell membrane.81 In the process, “large” volumes of 
extracellular fluid, along with suspended solutes, are internalized by the generated endocytic 
vesicles, which are typically 1 – 5 µm in size.85,81 Unlike, caveolae and clathrin-coated vesicles, 
macropinosomes are devoid of specific coatings, and do not concentrate receptors.86 However, 
macropinosomes do eventually fuse with the lysosomes.84 
Importantly, recent studies have shown that the physicochemical properties of nanoparticles 
influence their internalization, namely: (i) size,87–89 (ii) surface charge,90–92 (iii) morphology,93,94 
and with respect to hydrogel nanoparticles specifically, (iv) elasticity of the hydrogel matrix.95 
With respect to NP surface charge, positively charged NPs exhibit a higher internalization rate 
than neutral, or negatively charged NPs.96 This is attributed to the anchoring effect that the 
negatively charged cell membrane exerts on positively charged NPs, thus favoring endocytosis. 
However, negatively charged NPs also exhibit enhanced internalization with respect to neutral 
NPs, possibly due to their interaction with serum proteins. Accordingly, non-functionalized 
polyacrylamide hydrogel NPs, similar to those employed in the research reported in this thesis, 
were shown to acquire a corona of plasma proteins when incubated with human plasma.97,98 The 
corona of surface-adsorbed proteins can, in turn, influence the cell surface receptor(s) with which 
a non-functionalized NP interacts, and thus its mechanism of internalization. A similar effect is 
also likely to occur with ligand-targeted NPs that are engineered to bind a specific cell surface 
receptor.  
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1.7 Effects of Nanoparticles on Cell Signaling 
A further implication of the interaction of NPs with cell surface receptors is the activation of cell 
signaling pathways, particularly the kinase cascades of the mitogen activated protein kinase 
(MAPK) signaling system. The MAPK system consists of the (i) extracellular signal-regulated 
kinase (ERK) pathways, (ii) c-Jun N-terminal kinase pathway, and (iii) the p38 MAPK pathway. 
The ERK pathway mediates mitogenic (proliferative) signaling, whereas the JNK and p38 
Fig 1.4 Schematic diagram depicting the ERK, JNK and p38 mitogen activated protein kinase (MAPK) signaling 
pathways and their integration 
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MAPK pathways are activated in response to stress signals, and essentially induce apoptosis 
(growth arrest).99 Briefly, each pathway is activated upon phosphorylation of its respective MAP 
kinase kinase kinase (or MAP3K) enzymes by activation of cell surface receptors. The activated 
MAP3K enzymes, then phosphorylate their downstream MAP kinase kinase (or MAP2K) 
enzymes, which in turn mediate dual-phosphorylation of their downstream MAP kinase (or 
MAPK) enzymes. Fig. 1.4 illustrates the MAPK pathways that are most well characterized to 
date, and the downstream factors that they phosphorylate to either promote cell survival 
(ERK1/2), or growth arrest (JNK1-3 and p38α,β,γ,δ). Furthermore, the activated p38 MAPKs 
are known to enhance the rate of caveolae-mediated endocytosis, and intracellular trafficking 
along the clathrin-mediated pathway through direct phosphorylation of Caveolin1 at its 
Tyrosine-14 residue,100 and direct phosphorylation of EEA1 at its Threonine-1392 residue.101  
Studies have demonstrated that carbon NPs induce cell proliferation of lung epithelial cells 
via interaction with, and activation of the epidermal growth factor receptor 
(EGFR/ErbB1/HER1), and β1 integrins, which lead to activation of the ERK, as well as the Akt 
survival pathway.102,103 Importantly, both the surface-associated and cytoplasmic nucleolin 
receptors are known to potentiate the signaling of ErbB/HER receptors and the α5β1 integrins to 
promote cellular proliferation (Fig. 1.1). Further studies with inorganic NPs have also reported 
the activation of MAPK pathways, however via the induction of reactive oxygen species.104–106 
However, to date, there are no documented studies on how non-targeted, or ligand-targeted 
hydrogel nanoparticles modulate the MAPK signaling pathways upon interaction with tumor 
cells. This represents a crucial void in the mechanistic understanding of how hydrogel 
nanoparticles can influence the survival status of their target cells. This urgently needs to be 
addressed so as develop more efficient nanoparticle drug delivery systems, since hydrogel 
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nanoparticles, in particular, show promising potential for targeted and controlled drug release. 
 
1.8 Outline of the Dissertation 
This dissertation documents the study into how the surface functionalization of polyacrylamide 
(PAA) hydrogel nanoparticles with the nucleolin-targeting F3 peptide modulates the 
internalization, and intracellular trafficking of PAA-NPs in tumor cells (MDA-MB-435 and 9L) 
that overexpress Nucleolin at their surfaces. In addition, the effects of the non-targeted PAA-NPs 
(NTNPs), F3-targeted PAA-NPs (F3NPs), and F3 peptide on the activation status of the MAPK 
(ERK, JNK and p38) and Akt signaling pathways were subsequently studied.   
In Chapter 2, the surface PEGylation of the PAA-NPs was first optimized so as to reduce their 
potential for non-specific interaction with, and uptake by tumor cells. Subsequently, the surface 
functionalization of the PEGylated PAA-NPs with F3 peptides was optimized via cell-based 
assays (using the 9L, MDA-MB-435, and MCF7 cell lines) to achieve optimal Nucleolin-
mediated internalization of the F3NPs. Based on these experiments, an F3NP-formulation that 
exhibited saturated cellular sequestration (binding and uptake) in both 9L and MDA-MB-435 
cells was selected, and used to perform subsequent studies. Furthermore, only the 9L and MDA-
MB-435 cell lines exhibited distinct correlations in cellular sequestration of the F3NPs as the F3 
surface ligand density on the PAA-NPs was increased. The 9L and MDA-MB-435 cell lines 
were therefore selected as the optimal cell models in which to study the endocytosis and 
intracellular trafficking of the NTNPs and F3NPs. 
In Chapter 3, the endocytic pathways responsible for mediating the internalization of the F3 
peptide, NTNPs and optimized F3NPs were studied in the 9L and MDA-MB-435 cell lines, 
using endocytic inhibitors against the major endocytic pathways discussed earlier in Chapter 1. 
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Notably, the F3NPs exhibited considerably lower trafficking to the lysosomes than the NTNPs 
(based on colocalization with Lysotracker Red) in the MDA-MB-435 cells. The intracellular 
trafficking of the NTNPs and F3NPs in MDA-MB-435 cells were further dissected by 
immunocytochemistry. The immunocytochemistry studies revealed that while both the F3NPs 
and NTNPs were trafficked into early endosomes (EEA1-positive endosomes) to similar levels at 
30 minutes post-delivery, the NTNPs were trafficked out of the early endosomes faster than the 
F3NPs, and concomitantly exhibited markedly higher colocalization with lysosome associated 
membrane protein 1 (LAMP1), a lysosome marker than the F3NPs. Furthermore, both the 
NTNPs and F3NPs exhibited peak colocalization with caveolin1 at 2 hours post-delivery, albeit 
the level of F3NP-caveolin1 colocalization was lower than that of the NTNP-caveolin1 
colocalization. 
In Chapter 4, the phosphorylation (activation) status of the p38 α,β,γ and δ MAPK isoforms, 
in MDA-MB-435 cells, were studied in response to treatment with the F3 peptide, NTNPs and 
F3NPs by ELISA, and phosphoproteomic arrays. The rationale behind these studies was that the 
NTNPs induce higher levels of phosphorylated (activated) p38 MAPKs than the F3NPs. Indeed, 
we observed that the NTNPs, as well as the F3 peptide alone, elicited significantly higher levels 
of phosphorylated p38β and p38δ MAPK isoforms than the F3NPs. Given that the p38 MAPKs 
directly phosphorylate EEA1 and caveolin1, we therefore present compelling evidence that the 
differential intracellular trafficking of the NTNPs and F3NPs (observed in Chapter 3) can be 
attributed to their differential activation of the p38 MAPKs. Furthermore, we studied the 
phosphorylation status of several other signaling proteins in the ERK, JNK, and Akt pathways 
along with key their downstream target proteins. Based on the collective analyses of these 
signaling phosphoproteins, the F3NPs induce a pro-survival signaling profile in MDA-MB-435 
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cells, while the NTNPs induce a pro-apoptotic signaling profile. We conclude this chapter by 
presenting plausible NP-receptor interactions to explain the observed signaling profiles elicited 
by the NTNPs and F3NPs. 
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Chapter 2 
Surface Engineering of Polyacrylamide Hydrogel Nanoparticles:  
Surface PEGylation and Functionalization with F3 peptides 
 
This chapter has been adapted with minor modification from the following published article: 
L. Karamchand et al., Modulation of Hydrogel Nanoparticle Intracellular Trafficking by Surface 
Engineering with Tumor Targeting Peptide. Nanoscale, 2013; 5(21): 10327-44 
 
2.1 Introduction 
Polyethylene glycol (PEG; H-(O-CH2-CH2)n -OH) is a biocompatible, linear synthetic polymer 
that can be prepared in a range of molecular weights, and with a variety of terminal functional 
groups that permit their bioconjugation to various biomolecules and/or chemically functionalized 
surfaces. The surface modification of nanoparticles (NPs) with PEG molecules, otherwise known 
as PEGylation, is commonly used to confer “stealth capability” to the NPs for in vivo 
applications, specifically to evade their recognition, and removal from the circulation by the 
macrophages of the mononuclear phagocytic system (MPS). The properties of PEG that permit 
its use as a stealth barrier include its hydrophilicity, flexibility, and neutral charge at 
physiological pH in biological fluids. Specifically, surface conjugated PEG molecules reduce the 
opsonization of NPs with serum proteins in the blood stream (adhesion of serum proteins to the 
NP surface in a charge-dependent manner),1 and hence their recognition, and phagocytic removal 
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by the MPS macrophages.2 Furthermore, bare NPs tend to aggregate either via hydrophobic 
interactions, or attractive van der Waals forces, which renders them susceptible to removal from 
the circulation by the MPS macrophages. Surface PEGylation also reduces NP aggregate 
formation in biological fluids, and thus reduces the phagocytic recognition, and elimination of 
the NPs from the circulation. Evading the MPS macrophages is therefore necessary for 
prolonging the circulating half-life of the NPs, so as to increase their likelihood of accumulating 
within the tumor site.3 Since solid tumors typically grow to only a few centimeters in diameter, 
which constitutes only a small fraction of the total size of the patient, the probability of 
systemically injected NPs encountering the tumor site is rather small. This is further 
compounded by the fact that the NPs have to overcome physiological barriers, such as the MPS 
macrophages, in order to reach the tumor site. Hence, the surface PEGylation of NPs has become 
an important NP surface engineering strategy for extending their circulating half-life, so that a 
greater fraction of the systemically administered PEGylated-NP dose accumulates within the 
tumor site over time and delivers its cytotoxic payload, as compared to the non-PEGylated NP 
counterpart.  
The surface PEGylation of polyacrylamide (PAA) NPs for in vivo applications has previously 
been reported by the Kopelman group.4 In addition to functioning as a stealth barrier, the PEG 
molecules also serve as crosslinkers via which tumor-targeting ligands, such as the Nucleolin-
specific F3 peptide (KDEPQRRSARLSAKPAPPKPEPKPKKAPAKKC), can be attached to the 
NP surface. Given the inherent flexibility of the PEG molecules, the PEG-crosslinked targeting 
ligands in turn have a greater range of conformational flexibility, relative to the NP surface, thus 
increasing the probability of the targeting ligands to locate, and bind, their target receptors upon 
contact with the cell membrane. Hence, for the purpose of this in vitro study, the surface 
	   25	  
PEGylation of the PAA-NPs was important, so as to (i) accurately mimic the surface 
physicochemical behavior of the F3-targeted PAA-NPs (F3NPs) designed for in vivo 
applications, and (ii) minimize the opsonization of the PAA-NPs with culture medium serum 
proteins, which would otherwise prevent exclusive F3 peptide/Nucleolin (ligand/receptor)-
mediated interactions of the F3NPs with the tumor cell surfaces. Furthermore, the surface 
PEGylation of the amine-functionalized, positively-charged PAA-NPs also permitted a 
concomitant reduction in the PAA-NP surface charge, which was necessary for prohibiting non-
specific electrostatic interactions of the F3NPs with the negatively-charged cell membrane. The 
underlying chemistry of this phenomenon, and the optimization of the PAA-NP surface 
PEGylation will be discussed further.  
Last, the optimization of the F3 peptide density on the PAA-NP surface is necessary so as to 
maximize the multivalency effect of the F3NPs, i.e., to maximize the number of Nucleolin 
surface receptors that a single F3NP can simultaneously engage. Considering the reaction:  
F3NP + Nucleolin	  ⇌  Nucleolin-F3NP complex 
with kon (association rate) denoting the forward reaction rate, and koff (dissociation rate) denoting 
the reverse reaction rate, a higher number of F3 peptides per PAA-NP has the effect of lowering 
the koff (dissociation rate), while the kon (association rate) typically remains unchanged.5 Hence, 
an F3NP engineered with the ability to simultaneously bind multiple Nucleolin receptors, with a 
low koff rate, effectively acts as a cross-linking agent, which induces localized clustering of 
Nucleolin receptors at the cell surface. This process produces a thermodynamically favorable 
localized decrease in the Gibbs free energy at the membrane site to which the F3NP is bound, 
which in turn induces the cell membrane to wrap around the nanoparticle, and form a membrane-
bound endosome around the F3NP.6   
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In this chapter, the reaction scheme for the synthesis of the PAA-NPs is first presented, followed 
by a systematic description of the step-wise optimization of the (i) surface PEGylation of the 
PAA-NPs, and (ii) surface functionalization of the PEGylated PAA-NPs with F3 peptides. 
 
2.2 Synthesis and characterization of FITC-labeled hydrogel polyacrylamide nanoparticles  
Fig. 2.1 Reaction scheme for the synthesis of FITC fluorophore-labeled, amine-functionalized polyacrylamide 
nanoparticles. First, covalent coupling of FITC to APMA was achieved through the reactivity between the 
isothiocyanate (-CNS) group of fluorescein, and the amine (-NH2 group) of APMA. Second, the FITC-conjugated 
APMA, was combined with additional APMA, Acrylamide monomer, and AHM crosslinker in an aqueous mixture. 
This aqueous monomer mixture was then injected into a stirred reverse micelle system, comprising the detergents 
Brij-30 and sodium dioctyl sulfosuccinate in hexane. The aqueous monomer mixture incorporates into the 
hydrophilic core of the reverse micelles, which essentially serve as ‘nanoscale’ vessels within which the acrylamide 
monomer mixture can be polymerized into polyacrylamide nanoparticles. Third, the addition of the radical initiators 
APS and TEMED to the reaction vessel initiates free radical polymerization of the acrylamide, APMA and AHM 
molecules into hydrogel nanoparticles. Polymerization occurs under an inert (Argon) atmosphere that has been 
purged of oxygen, which would otherwise quench the radicals generated by APS and TEMED. Note that the APMA 
monomer confers amine-functionality to the PAA hydrogel nanoparticles, and that the presence of free amine groups 
at the surface of the PAA hydrogel nanoparticle confers to it a positive zeta potential (surface charge).  
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Amine surface-functionalized hydrogel PAA-NPs were prepared by water-in-oil (reverse micelle) 
microemulsion radical polymerization, as previously reported by our lab.7 Figure 2.1 illustrates 
the reaction scheme by which the PAA-NPs were synthesized. Fluorescein isothiocyanate (FITC) 
fluorophore was conjugated to the NP matrix backbone by covalent linkage to the co-monomer, 
3-aminopropylmethacrylamide (APMA), prior to nanoparticle formation, to facilitate fluorescent 
imaging of the NPs in subsequent cellular binding affinity, and endocytosis experiments. The 
diameter of the spherical hydrogel PAA-NPs was determined to be 21 ± 5 nm by scanning 
electron microscopy (SEM), which is based on the analysis of 50 individual nanoparticle 
structures (Fig. 2.2.1). In aqueous solution, however, the amine-functionalized hydrogel PAA-
NPs exhibited a median hydrodynamic diameter of approximately 60 nm, as determined by 
dynamic light scattering (DLS) (Fig. 2.2.2). DLS measurements indicated narrow size 
distributions for the amine-functionalized hydrogel PAA-NPs, which confirms that the 
nanoparticles do not aggregate in solution. The larger NP diameter obtained by DLS 
characterization is attributed to the characteristic ability of hydrogels to swell in aqueous solution. 
We note that this size may vary with salinity.8 Furthermore, the sample preparation procedure for 
SEM requires dehydration, which indeed causes the hydrogel nanoparticles to shrink and 
accounts for the discrepancy in size measurements between SEM and DLS methods. 
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Fig. 2.2.1 Scanning electron micrograph of the amine-functionalized, non-targeted PAA-NPs (NTNPs). The 
nanoparticles exhibited spherical morphology with a mean diameter of 21 ± 5 nm. Magnification: 100,000x.  
Fig. 2.2.2 Dynamic light scattering data for amine-functionalized, non-targeted PAA-NPs (NTNPs) suspended to a 
final concentration of (1mg.mL-1) in 10 mM PBS buffer. Average diameter: 63.6 nm, Polydispersity index: 0.222 
2.2.2	  
2.2.1	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2.3 Optimization of polyacrylamide nanoparticle surface PEGylation 
Positively charged NPs have a propensity to bind non-specifically to the negatively charged cell 
membranes through electrostatic interactions. Furthermore, the formation of a corona of serum 
proteins around the NP (opsonization) in cell culture media can potentially interfere with the 
ligand-receptor mediated interactions between the ligand-functionalized NP, and its target tumor 
cell. We therefore, first optimized the PEGylation of the amine surface-functionalized PAA-NPs 
in order to attenuate their non-specific cell binding, and opsonization with serum proteins, prior 
to optimizing the surface coverage of the PAA-NPs with F3 peptide. Following synthesis, the 
surfaces of the amine-functionalized FITC-labeled PAA-NPs were modified with 
heterobifunctional succinimidyl ester – Polyethylene glycol – maleimidyl ester (SCM-PEG-
MAL) molecules. Briefly, the reaction was achieved in a two-step process; (i) initial conjugation 
of heterobifunctional PEG molecules via their SCM termini to the primary amine groups (-NH2) 
on the PAA-NP surface (Fig. 2.3), followed by, (ii) conjugation of L-cysteine to the MAL 
termini of the PEG crosslinkers (Cys-capping). The quantity of PEG required to completely 
neutralize the positive surface charge of amine-functionalized PAA-NPs (~ +16 mV) (Fig. 2.4) 
was determined by treating increasing masses of SCM-PEG-MAL (0.4, 2.0 and 4.0 mg) with a 
fixed mass (50 mg) of PAA-NPs, followed by measurement of the zeta potential (surface charge) 
of the resultant PEGylated PAA-NPs (Fig. 2.4). The positive surface charge of the unmodified 
PAA-NPs is attributed to the presence of protonated amine groups (-NH3+) on the PAA-NP 
surface. Figure 2.4 illustrates the concentration dependent reduction in the positive surface 
charge of the PAA-NPs by PEG; a ratio of 4 mg PEG: 50 mg lyophilized PAA-NP achieved a 
reduction in zeta potential from + 16 ± 2.89 mV to – 0.4 ± 0.82 mV without any observable non-
specific binding of these PEGylated PAA-NPs to MDA-MB-435 cells. Figure 2.4 (inset images)  
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Fig. 2.3 Reaction scheme for the surface PEGylation of the amine-functionalized PAA-NPs with heterobifunctional 
maleimidyl ester – Polyethylene Glycol – succinimidyl ester (SCM-PEG-MAL) molecules, and subsequent surface 
functionalization of the PEGylated PAA-NPs with F3-Cys peptide using SCM-PEG-MAL as surface cross-linkers. 
The succinimidyl ester group on the PEG molecule reacts directly with a single surface amine group (-NH2) on the 
PAA-NPs, which results in a stable amide bond between the PAA-NP and the PEG molecule. The maleimidyl ester 
group located on the opposite end of the PEG molecule reacts exclusively with the thiol (-SH) group on the side 
chain of L-Cysteine, located on the C-terminal of F3-Cys peptide.  
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illustrates the direct correlation between the zeta potential of the non-PEGylated/PEGylated 
PAA-NPs, and their degree of non-specific binding to MDA-MB-435 cells. All subsequent PAA-
NP PEGylations were performed according to the above optimal PEG: PAA-NP ratio  (4 mg 
PEG: 50 mg lyophilized PAA-NP) to facilitate further surface functionalization with F3 peptide. 
 
 
 
Fig. 2.4 Optimization of PAA nanoparticle surface PEGylation to minimize non-specific cell surface binding. The 
zeta potential (surface charge) of the various PEGylated PAA nanoparticle formulations were measured by 
electrophoretic light scattering, and compared to their potential for non-specific cell binding to MDA-MB-435 cells. 
The increase in PAA nanoparticle surface coverage with PEG results in a corresponding decrease in the zeta 
potential of the PAA nanoparticle along with its potential for non-specific binding to the negatively-charged cell 
membranes (inset images). Since the ratio of 4 mg PEG: 50 mg PAA nanoparticles effectively reduced the zeta 
potential of the PAA nanoparticles to approximately 0 mV, this formulation was selected for further synthesis of the 
F3-targeted PEGylated PAA nanoparticles. 
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2.4 Optimization of the F3 peptide surface functionalization  
The engineering of NP surfaces with multiple targeting ligands (multivalency) has been shown to 
increase both their cell binding avidity, and rate of internalization by the target cells.9,10 In 
addition, the density and availability of cell surface receptors5 and targeting ligand density on the 
NP surface11–13 regulates the internalization of the NP. This underscores the importance of 
optimizing the physicochemical properties of a hydrogel NP, relative to the receptor profile of 
the target cell, and the desired intracellular trafficking pathway, so as to maximize therapeutic 
efficacy. Given the influence that the degree of ligand coverage on a NP surface exerts on its cell 
binding and internalization, we optimized the surface coverage of the PEGylated PAA-NPs with 
F3 peptide (F3NPs) based on their interaction (in terms of cell surface binding and 
internalization) with three different nucleolin-expressing cell lines.  
Briefly, following surface PEGylation of the PAA-NPs, separate batches of F3NPs, each 
bearing different degrees of F3 peptide surface coverage, were prepared (Fig. 2.3). Thereafter, 
each F3NP batch underwent Cys-capping of their PEG crosslinker MAL termini to ensure that 
the cellular binding of these NPs are governed solely by the interaction between the surface 
conjugated F3 peptides, and cell surface nucleolin receptors. A linear relationship was observed 
between the quantity of F3-Cys peptide conjugated to the PEGylated PAA-NP surfaces, and the 
increase in their zeta potential (surface charge) (Fig. 2.5). This observation is attributed to the 
multiple arginine and lysine residues of F3 peptide whose side-chain amines are positively 
charged at neutral pH. Also, DLS-based size characterization of the F3-targeted PEGylated 
PAA-NPs revealed that their hydrodynamic diameters were not significantly different from that 
of the amine-functionalized, non-targeted PAA-NPs (Figs. 2.6.1 and 2.6.2).  
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Thereafter, the ‘cellular sequestration’ (NP binding + uptake) profiles of the amine-
functionalized, non-targeted PAA-NPs (NTNPs), and the various F3-targeted PEGylated PAA-
NP (F3NP) formulations was studied in three different nucleolin surface-overexpressing live cell 
lines; MDA-MB-435 human breast adenocarcinoma, 9L rat gliosarcoma, and MCF-7 human 
breast adenocarcinoma, using confocal fluorescence microscopy. Here, we define the ‘cellular 
sequestration’ of a NP as the combination of (i) the degree of NP-binding to the cell membrane, 
which is related to the cell binding avidity of that specific NP and, (ii) the degree to which the 
NP is internalized by a particular cell line within a specific period of time. The results are 
summarized in Fig. 2.7, and Table 2.1.  
 
Fig. 2.5 Linear relationship between the degree of surface coverage of the PEGylated PAA-NPs with F3 peptide and 
their corresponding zeta potentials (surface charge). Each F3 peptide has a net charge of +9 at physiological pH 7.4 
due to the protonation of the side chains of its Lysine (K) and Arginine (R) residues. 
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Fig. 2.6.1 Dynamic light scattering data for the amine-functionalized, non-targeted PAA-NPs (NTNPs) suspended to 
a final concentration of (1 mg.mL-1) in 10 mM PBS buffer. Average diameter: 63.6 nm, Polydispersity index: 0.222  
Fig. 2.6.2 Dynamic light scattering data for F3-targeted, PEGylated PAA-NPs (F3NPs) suspended to a final 
concentration of (1 mg.mL-1) in 10 mM PBS buffer. Average diameter: 58.5 nm, Polydispersity index: 0.126 
2.6.1	  
2.6.2	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Several important observations were noted as follows. First, the cellular sequestration of the 
F3NPS increased linearly relative to the degree of surface coverage with F3 peptide up to 5.5 mg 
F3: 50 mg PAA-NPs, with saturation occurring at the 11 mg F3: 50 mg PAA-NP formulation in  
Fig. 2.7 Trend of cellular sequestration versus F3 peptide surface coverage of the PEGylated PAA nanoparticles for 
the MCF-7, MDA-MB-435 and 9L cell lines. In both the MDA-MB-435 and 9L cell lines, cellular sequestration 
reached saturation at a ratio of 11 mg F3 peptide: 50 mg PAA-NC, whereas saturation occurred at a ratio of 2.2 mg 
F3 peptide: 50 mg PAA-NC in the MCF-7 cell line. Inset images: Representative confocal fluorescence images 
depicting varying degrees of cellular sequestration of the F3NPs (11 mg F3: 4mg PEG: 50 mg PAA-NP 
formulation) by the MCF-7, MDA-MB-435 and 9L cell lines. Scale bar: 15 µm. 
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both the MDA-MB-435 and 9L cell lines. In contrast, the cellular sequestration profile of the 
F3NPs in the MCF-7 cell line reached saturation at a 5-fold lower F3 peptide surface coverage 
(2.2 mg F3: 50 mg PAA-NP formulation), although a slight decrease was observed at the 11 mg 
F3: 50 mg PAA-NP formulation (Fig. 2.7). This suggests that the MCF-7 cells express surface 
nucleolin at a markedly lower level and/or internalize the F3NPs at a slower rate than both the 
9L and MDA-MB-435 cell lines. Second, significant differences in cellular sequestration were 
observed across the three different cell lines for each F3NP formulation; the order of cellular 
sequestration, from highest to lowest, was 9L > MDA-MB-435 > MCF-7 (Fig. 2.7). However, all 
cell lines exhibited similar cellular sequestration values for the NTNPs (Fig. 2.7). Third, at the 
highest surface coverage with F3 peptide (11 mg F3 peptide: 50 mg PAA-NP), approximately 
28-fold and 77-fold enhancements in F3NP cellular sequestration were observed for the MDA-
MB-435 cell and 9L cell lines respectively, whereas a relatively weak 5-fold enhancement for 
the MCF-7 cell line was observed relative to the cellular sequestration of the NTNPs for these 
cell lines (Table 2.1). Notably, the difference in cellular sequestrations between the 9L and 
MDA-MB-435 cells remained nearly constant, i.e., ~ 2.7:1, over the entire range of nanoparticle 
surface coverage with F3 peptide. In contrast, the ratio of F3NP cellular sequestrations for both 
Table 2.1 Relative cellular sequestration values for the NTNPs and F3NPs in the MCF7, MDA-MB-435 and 9L 
cell lines (derived from Fig. 2.7).  Cellular sequestration values for the F3NPs were normalized relative to that of 
the unmodified, non-targeted PAA-NPs for each cell line. The 9L cell line consistently exhibited an 
approximately 2.7 times higher cellular sequestration for the F3NPs than the MDA-MB-435 cell line. 
  
 F3 peptide mass (mg)/  
50 mg PEGylated PAA-NPs 0 2.2 5.5 11 
 Relative cellular sequestration values 
MCF-7 1.00 6.07 6.93 4.92 
MDA-MB-435 1.00 13.23 25.34 27.49 
9L 1.00 34.60 71.25 76.92 
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9L and MDA-MB-435 cells relative to MCF-7 cells (9L: MCF-7 and MDA-MB-435: MCF-7) 
increased with each increment in the degree of nanoparticle surface coverage with F3 peptide 
(Table 2.1).  
Since the above assays were performed in live cells, we anticipated that the rates at which 
the F3NPs were endocytosed by each cell line, following binding to the cell membranes, likely 
exerted a significant influence on the observed cellular sequestrations. Therefore, in order to 
eliminate the potential influence of endocytosis, and thus determine the cellular sequestration 
based only on the surface binding of the F3NPs to each cell type, the experiments were repeated 
in both live ATP-depleted and paraformaldehyde-fixed cells (Fig. 2.8) using the ‘11 mg F3: 50 
mg PEGylated PAA-NP’ formulation that exhibited saturation in the cellular sequestration assay 
with live 9L and MDA-MB-435 cells. The F3NP cellular sequestration ratios in fixed and ATP-
depleted cells (9L: MDA-MB-435: MCF-7) were 2.64: 2.82: 1 and 4.36: 4.92: 1, respectively 
(Figure 2.8, Table 2.2). Importantly, both ATP-depletion and paraformaldehyde fixation elicited 
a marked reduction in the difference in magnitude of F3NP cellular sequestration observed 
between 9L and MDA-MB-435 cells, as well as between the MCF-7 cells and 9L/MDA-MB-435 
cells. Most notably, under both cytostatic conditions, the F3NP cellular sequestration was 
slightly weaker in 9L cells than in MDA-MB-435 cells, albeit not statistically significant (Table 
2.2).  
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Table 2.2 Cellular sequestration ratios of F3NPs in paraformaldehyde-fixed and ATP-depleted cells.  The F3NP 
cellular sequestration for the MCF-7 cells remained negligible under both conditions. Therefore, the cellular 
sequestration values for the 9L and MDA-MB-435 cell lines were normalized relative to that of the MCF-7 cells. 
Under both conditions, the 9L cell line exhibited a slightly lower cellular sequestration of the F3NPs than the 
MDA-MB-435 cell line, whereas the cellular sequestration by the MCF-7 cell line, relative to the 9L and MDA-
MB-435 cell lines, remained negligible. Therefore, the 9L and MDA-MB-435 cell lines likely have comparable 
cell surface densities of nucleolin receptors, however the 9L cells internalize the F3NPs at a faster rate than the 
MDA-MB-435 cells. 
 
 MCF-7 MDA-MB-435 9L 
Paraformaldehyde-fixed cells 1.00 2.82 ± 0.23 2.64 ± 0.34 
ATP-depleted cells 1.00 4.92 ± 0.59 4.36 ± 0.39 
Fig. 2.8 Influence of endocytosis on the cellular sequestration of the F3-targeted PAA nanoparticles. Internalization 
of the F3NPs by the 9L, MDA-MB-435 and MCF-7 cell lines were blocked by either (A) paraformaldehyde-fixation 
(Scale bar: 7 µm), or (B) treatment with 2,4-dinitrophenol in order to deplete cellular ATP production (Scale bar: 15 
µm). 
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2.5 Discussion 
The versatility of the PAA nanoparticle is underscored by its compatibility with various 
bioconjugation chemistries that can be employed to incorporate a broad range of functionalities, 
both within the nanoparticle matrix and on its surface. The PAA hydrogel matrix employed in 
this study contained primary amine groups ― originating from an amine-functionalized 
monomer, 3-aminopropylmethacrylamide (APMA) ― both within the interior and on the surface 
of the nanoparticle. These amine groups can be easily functionalized, using diverse chemical 
modifications. Specifically, this permitted both labeling of the hydrogel matrix interior with 
fluorescein isothiocyanate (FITC), and functionalization of the hydrogel nanoparticle surface 
with heterobifunctional SCM-PEG-MAL molecules, by exploiting the reactivity of amines with 
isothiocyanate and succinimidyl ester groups, respectively.  
We now discuss, specifically, the rationale for the hydrogel nanoparticle surface engineering. 
Surface PEGylation improves the colloidal stability of nanoparticles, reduces their surface charge, 
and, more importantly, provides a neutral, hydrophilic steric barrier around the nanoparticle. This 
steric (stealth) barrier reduces both undesirable non-specific binding to, and uptake by, non-
target cells, in vivo, as well as opsonization of the nanoparticle surface by serum proteins, which 
promotes elimination of the nanoparticle from the circulation by the mononuclear phagocyte 
system (MPS).14 These crucial factors must be taken into account when designing a nanoparticle 
system for in vivo application, as failure to optimize surface PEGylation can adversely affect the 
biodistribution, and targeting efficacy of the nanoparticle by the above-mentioned factors. 
However, for the purpose of the present in vitro study, we optimized the surface PEGylation of 
our PAA-NPs with 2 kDa PEG – the minimum molecular weight of PEG required to evade 
elimination by the MPS in vivo14 – in order to (i) accurately replicate the physicochemical 
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properties of the targeted nanoparticle that would be employed for  in vivo applications, and (ii) 
eliminate their potential for non-specific cell binding, which would otherwise be a confounding 
factor in elucidating which endocytic pathway(s) mediate(s) internalization of the F3-targeted 
PAA-NPs. Direct conjugation of the heterobifunctional PEG molecules to the PAA-NP surface 
amine groups facilitated simultaneous reduction of the positive surface charge conferred by these 
amine groups, a positive charge that would otherwise inherently confer to the PAA-NPs a high 
non-specific binding affinity for the negatively-charged cell membranes. Following the reaction 
between a succinimidyl ester group of the heterobifunctional PEG molecule, and a surface amine 
group of the PAA-NP, the PEG chain is covalently linked, via a stable amide bond, to the 
nitrogen atom of the former amine group that participated in the reaction (Fig. 2.3). Hence, the 
reaction of PEG molecules with the surface amine groups concomitantly reduces the number of 
ionizable surface nitrogen atoms present on the surface of the PAA-NPs, thus leading to a 
reduction in positive charge of the PAA-NPs. Furthermore, as the flexible PEG molecules fold 
and adopt various conformations, they may also trap counter-anions close to the surface of the 
PAA-NPs, thus effectively “neutralizing” the positive charge of the protonated amine (-NH3+) 
groups. Figure 2.4 depicts the efficacy of our approach; we observed a progressive decrease in 
zeta potential of the PAA-NPs, from positive toward neutral, as the PAA-NP surface 
functionalization with heterobifunctional PEG increased, concomitant with a progressive and 
substantial reduction in non-specific cell binding to live MDA-MB-435 cells of the PEGylated 
PAA-NPs.  
Once the surface PAA-NP PEGylation was optimized, the F3-targeted PAA-NPs were then 
synthesized from a fresh batch of PEGylated PAA-NPs that did not undergo Cys-capping, by 
covalently coupling the F3-Cys peptides, via their thiol groups, to the MAL termini of the PEG 
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crosslinkers. The coupling of the F3 peptides to the MAL termini of the highly flexible, 2 kDa 
PEG molecules places the targeting peptides further from the nanoparticle surface, thereby 
permitting a greater range of conformations that can be adopted by the targeting peptides, 
compared to the use of shorter, less-flexible crosslinkers, such as succinimidyl-4-(N-
maleimidomethyl)-cyclohexane-1-carboxylate (SMCC), thus enhancing their ability to locate 
nucleolin receptors on the cell surfaces.15 Interestingly, our recent two-photon microscopy study 
of subcellular pH in 9L glioma cells, using pH-sensitive F3-targeted and non-targeted, non-
PEGylated PAA nanoparticles, revealed that the F3NPs, formulated with the crosslinker SMCC, 
evaded accumulation within lysosomes, while the NTNP counterparts were trafficked into 
lysosomes, under similar experimental conditions to those reported in the current study.16 Taking 
into consideration that our PEGylated F3NPs similarly evaded trafficking to lysosomes in this 
current study, we deduce that the use of PEG as a crosslinker, which confers a greater 
conformational ‘flexibility’ to the surface conjugated F3 peptides, does not exert any observable 
influence on the subcellular localization of the F3NPs.  
Importantly, as the surface functionalization of the PEGylated PAA-NPs with F3 peptides 
was increased, we observed a concomitant re-increase in NP zeta potential from ~0 mV (0 mg F3 
peptide) to ~29 mV (11 mg F3 peptide/ 50 mg PEGylated PAA-NPs) (Fig. 2.5). This observation 
is indeed attributed to the multiple arginine and lysine residues of F3 peptide whose side-chain 
amines are positively charged at neutral pH. This re-increase in zeta potential was necessary such 
that the F3-targeted PAA-NPs have the same surface charge polarity as the non-targeted PAA-
NPs, i.e. cationic, as the surface polarity of a NP, in addition to its hydrodynamic radius, is 
known to influence the endocytic mechanism via which it is internalized by a tumor cell, as 
discussed in further detail in Chapter 3. Hence, maintaining consistent physicochemical 
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properties (hydrodynamic radius and surface charge) between the NTNPs and F3NPs, as was 
done in this study, was crucial to accurately determining which endocytic pathway(s) were 
responsible for mediating the internalization of each type of NP (as performed in Chapter 3).  
In the cellular sequestration assays performed with live 9L, MDA-MB-435, and MCF-7 cell 
lines, with the aim of optimizing the level of F3 peptide conjugated to the PEG steric barrier, in 
order to achieve maximal binding, a significant linear increase in cellular sequestration was 
observed up to 5.5 mg F3: 50 mg PAA-NP, with binding saturation occurring at 11 mg F3: 50 
mg PAA-NP in both the 9L and MDA-MB-435 cell lines. The only exception was the MCF-7 
cell line, in which F3NP cellular sequestration saturation was observed at 5.5 mg F3: 50 mg 
PAA-NP. These observations are consistent with the ‘multivalency effect’, whereby an increase 
in the number of cognate ligands on the surface of a nanoparticle, for a particular receptor, 
increases the avidity of the nanoparticle for its target cell. The saturation in cellular sequestration 
observed with the increase in surface coverage with F3 peptide, from 5.5 mg to 11 mg, is likely 
due to the fact that the number of F3 peptide ligands on the surface of the F3NP exceed the 
number of cell surface nucleolin receptors available within the contact surface area, between a 
single F3NP and the cell membrane to which they can bind.17 An approximate 2.7: 1 cellular 
sequestration ratio (9L: MDA-MB-435) was maintained at each increment in PAA-NP surface 
coverage with F3 peptide (Fig. 2.7, Table 2.1). In contrast, the F3NP cellular sequestration ratios 
of both 9L: MCF-7 and MDA-MB-435: MCF-7 increased with each increment in the PAA-NP 
surface coverage with F3 peptide (Fig. 2.7, Table 2.1). These findings suggest that either (i) both 
9L and MDA-MB-435 cells overexpress higher levels of cell surface nucleolin receptors, 
compared to MCF-7 cells, and/or (ii) 9L cells endocytose the F3NPs at a faster rate than that of 
both MDA-MB-435 and MCF-7 cells.  
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In view of the above, so as to exclude the influence of endocytosis on the observed F3NP 
cellular sequestrations, the experiments were repeated on paraformaldehyde-fixed and ATP-
depleted cell lines, using the F3NP formulation that elicited cellular sequestration saturation 
under live cell conditions (11 mg F3: 50 mg PAA-NP) (Fig. 2.8, Table 2.2). These experiments 
revealed that endocytosis did indeed elevate the observed cellular sequestrations of the F3NPs in 
the live 9L and MDA-MB-435 cells. In fact, under both paraformaldehyde-fixed and ATP 
depleted conditions, slightly lower F3NP cellular sequestrations were observed for the 9L cells 
than that for the MDA-MB-435 cells although not statistically significant, while the MCF-7 cells 
still exhibited negligible F3NP cellular sequestrations, under both cytostatic treatments (Fig. 2.8, 
Table 2.2). Slightly higher F3NP cellular sequestrations were observed in ATP-depleted cells 
relative to paraformaldehyde-fixed cells (approximately 1.7 fold difference), which can be 
attributed to the fact that 2,4-dinitrophenol inhibits only the mitochondrial production of ATP, 
and not the production of ATP by the glycolysis pathway. Hence, there remains a basal level of 
ATP production by glycolysis, which can support a residual level of endocytosis, whereas 
paraformaldehyde fixation completely arrests all cellular activity, including endocytosis. 
Nonetheless, these cytostatic treatments indicate that, although the 9L and MDA-MB-435 cells 
do not have significantly different cell surface nucleolin expression levels from each other, they 
both express significantly higher cell surface nucleolin levels than MCF-7 cells. The similarity 
between nucleolin surface expression levels in the 9L and MDA-MB-435 cell lines therefore 
explains why saturation of F3NP cellular sequestration was achieved for both the 9L and MDA-
MB-435 cell lines at about the same level of surface PAA-NP coverage with F3 peptide. In 
addition, this supports our premise that the 9L cells endocytose the F3NPs at considerably higher 
rates than both the MDA-MB-435 and MCF-7 cell lines.  
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According to Hovanessian et al., surface expressed nucleolin is constantly induced in tumor 
cells, to mediate the internalization of ligands that promote tumorigenesis.18 In turn, the rate of 
nucleolin-mediated internalization is dictated by the metabolic rate of the specific tumor cell type. 
Based on our cell culture experiments, 9L cells replicate considerably faster than MDA-MB-435 
and MCF-7 cells, which in turn has to be supported by a higher metabolic rate. Given that 
endocytosis is an ATP-dependent process, as well as the dramatic reduction in the cellular 
sequestration of the F3NPs for 9L cells elicited by both cytostatic treatments, it is therefore 
reasonable to deduce that the more metabolically active 9L cells endocytose cell membrane-
bound F3NPs faster than either MDA-MB-435 and MCF-7 cells. We therefore deduce that the 
consistent 2.7-fold greater cellular sequestration of the F3NPs for the 9L cells, relative to the 
MDA-MB-435 cells in the live cellular sequestration assay (Fig. 2.7, Table 2.1), can be 
accounted for by the higher endocytic rate of the 9L cells. This result reaffirms that the cell 
surface receptors are inextricably linked to the endocytic machinery of the cell, and underscores 
the importance of tailoring a nanoparticle to the target cell type, in order to maximize the 
efficacy of chemotherapy (or activated imaging). Furthermore, the implication of this 
observation is that, by using an appropriately targeted nanoparticle, one could achieve higher 
intracellular concentrations of a chemotherapeutic drug within a given period of time, in highly 
aggressive malignant cells, by exploiting their faster endocytic rates, relative to the ordinary 
diffusion of free drug across the cell membranes of malignant cells from the bloodstream.  
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2.6 Conclusion 
Collectively, these findings reveal that while there is negligible difference in the surface 
nucleolin receptor density between the 9L and MDA-MB-435 cell lines, the former endocytoses 
F3NPs at a faster rate than that of MDA-MB-435 cells. In contrast, the MCF-7 cells 
demonstrated consistently weaker F3NP cellular sequestrations, relative to the 9L and MDA-
MB-435 cell lines, under both paraformaldehyde-fixed and ATP-depleted conditions, indicating 
that MCF-7 cells express a lower surface density of nucleolin receptors and/or exhibit a slower 
rate of endocytosis (Fig. 2.8). In light of the above findings, the MCF-7 cell line was omitted 
from the endocytosis inhibition and immunocytochemistry experiments, as discussed in Chapter 
3. Furthermore, the 11 mg F3 peptide: 4 mg PEG: 50 mg PAA-NP formulation, which exhibited 
saturated cellular sequestration (binding + uptake) in both the 9L and MDA-MB-435 cell lines, 
was selected for studying the intracellular trafficking of the F3-targeted PAA-NPs in these cell 
lines. 
 
2.7 Experimental Section 
2.7.1 Optimization of PAA-NP Surface PEGylation  
Amine-surface functionalized FITC-labeled PAA nanoparticles were synthesized as described in 
Chapter 3. Thereafter, 50 mg lyophilized FITC-labeled PAA-NP was dissolved in 2.5 mL PBS 
buffer (pH 7.4) and sonicated until the solution turned transparent, to which either 0.4, 2 or 4 mg 
heterobifunctional PEG crosslinker (SCM-PEG-MAL) was added, and the mixture stirred 
continuously for 30 min at room temperature. Following washing using an Amicon centrifugal 
filter (Millipore, 100 kDa molecular weight cut-off), the various PEGylated PAA-NP 
formulations were reacted with L-cysteine (62.5 µL, 10 mg.mL-1) for 2 hours at room 
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temperature to cap the maleimidyl ester groups of the PEG crosslinkers so as to prevent their 
reaction with cell surface thiols in subsequent cell-based assays aimed at determining their 
potential for non-specific cell binding. The PEGylated PAA-NPs were then washed five times 
with PBS (pH 7.4) using an Amicon centrifugal filter (100 kDa molecular weight cut-off) at 
5000 xg for 20 minutes, and the various PEGylated PAA-NP formulations resuspended in PBS 
(pH 7.4) to a final volume of 5 mL. The zeta potentials of the non-PEGylated and various 
PEGylated PAA-NP formulations were determined as described in the experimental section of 
Chapter 3. Thereafter, the non-PEGylated and various PEGylated PAA-NP formulations were 
incubated with MDA-MB-435 cells (seeded in 8-chambered multiwell microscopy coverslides; 
~100, 000 cells per well) to a final concentration of 0.1 mg.mL-1 in DMEM supplemented with 
10% Fetal Bovine Serum and 1% PSG for 1 hour at 37 °C in 5% CO2 atmosphere. After 
incubation, the culture media containing unbound non-PEGylated or PEGylated PAA-NPs were 
aspirated from the wells and the cells washed three times with warm DPBS (pH 7.4). The wells 
were replenished with colorless DMEM medium, and the cells imaged on an Olympus inverted 
confocal microscope using a 40x objective lens with 488 nm excitation. All images were 
captured under identical exposure times based on the fluorescence emission of the FITC-labeled 
PAA-NPs. The degree of non-specific cell binding and internalization of the non-PEGylated and 
PEGylated PAA-NP formulations was determined by measuring the FITC fluorescence emission 
intensity from multiple cells in each confocal plane using Metamorph software (Molecular 
Devices). All values are reported as means from three independent experiments.  
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2.7.2 Optimization of Surface Functionalization of PEGylated PAA-NPs with F3 peptide 
Fresh batches of PEGylated PAA-NPs (4 mg SCM-PEG-MAL: 50 mg FITC-PAA-NPs) were 
prepared as described above, however with omission of the Cys-capping stepping of the MAL 
groups on the PEG crosslinkers. After washing to remove unbound PEG crosslinkers, separate 
batches of surface PEGylated PAA-NPs were reacted with different quantities of F3-Cys peptide 
(2.2, 5.5 or 11 mg), and the conjugation reaction allowed to run overnight at room temperature. 
The reaction between the thiol group of the carboxy terminal cysteine of the F3 peptide moieties, 
and the maleimidyl ester terminus of the PEG crosslinkers facilitated covalent conjugation of the 
F3 peptide moieties to the PEG crosslinkers already conjugated to the PAA-NP surfaces. The F3 
surface functionalized PEGylated PAA-NPs (F3NPs) were subsequently incubated with 1.74 mg 
(10 mg.mL-1) of L-cysteine for 2 hours at room temperature to cap any unreacted maleimidyl 
ester groups. Thereafter, the different F3NP batches were washed five times with PBS (pH 7.4) 
using an Amicon centrifugal filter (100 kDa molecular weight cut-off) at 4000 xg for 20 minutes 
and the final volume adjusted to 5 mL with PBS (pH 7.4). The zeta potentials of the various 
F3NP formulations were determined as described in the experimental section of Chapter 3. The 
filtered nanoparticles were kept frozen at -20 °C until use. 
Live cell assays: The MCF-7, MDA-MB-435 and 9L cell lines were seeded in separate 8-
chambered multiwell microscopy coverslides (~ 140, 000 cells per well) in their respective 
complete culture media, and allowed to attached overnight at 37 °C. The following day, the cells 
were treated with the various F3NP formulations at a final concentration of 0.1 mg.mL-1 for 1 
hour at 37 °C. Thereafter, any unbound F3NPs were rinsed away by three changes of culture 
medium. The wells were replenished with colorless culture media, and confocal imaging of the 
F3NP-treated cell lines was performed directly from the multi-well coverslides on an Olympus 
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inverted confocal microscope using a 40x objective lens with 488 nm excitation. Images were 
captured under identical exposure times based on the fluorescence emission of the FITC-labeled 
F3NPs. The F3NP cellular sequestrations were quantified by measuring the pixel intensity of 
each cell from the obtained confocal images using Metamorph software (Molecular Devices). All 
values are reported as means from three independent experiments.  
Fixed and ATP-depleted cell assays: The above experiments were repeated on 
paraformaldehyde (PFA)-fixed and ATP-depleted cells in order to obviate the influence of 
endocytosis on the cellular sequestration of the F3NPs in each cell line. This involved either (1) 
fixing the cells with 4 % (v/v) phosphate-buffered paraformaldehyde (pH 7.4) for 10 minutes at 
room temperature or (2) pre-treating the cells with 2,4-dinitrophenol (2,4-DNP, 1 mM) for 30 
minutes at 37 °C to inhibit mitochondrial ATP-production, prior to incubating the cells with the 
F3NPs. The 11 mg F3: 50 mg PAA-NP F3NP formulation, at which cellular sequestration 
reached saturation in the live cell assays under above incubation conditions, was used for the 
fixed and ATP-depleted cell assays. Confocal imaging of the F3NP-treated cell lines in both 
assays was performed as for the live cells assays. These assays were repeated three times.  
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Chapter 3 
 
Modulation of Hydrogel Nanoparticle Intracellular Trafficking by Multivalent Surface 
Engineering with Tumor Targeting Peptide 
 
This chapter has been adapted with minor modification from the following published article: 
L. Karamchand et al., Modulation of Hydrogel Nanoparticle Intracellular Trafficking by Surface 
Engineering with Tumor Targeting Peptide. Nanoscale, 2013; 5(21): 10327-44 
 
3.1 Introduction 
Targeted multifunctional nanocarriers are generally nanoparticles with integrated, multivalent 
tumor-targeting moieties, diagnostic-imaging agents and therapeutic components, which, in 
combination, facilitate in vivo theranostics, with the aim of overcoming the specificity and 
efficacy limitations of conventional cancer diagnostic and therapeutic approaches.1,2 Successful 
integration of these chemically diverse entities within a single nanoparticle, while retaining their 
respective biochemical/biophysical properties, requires a highly versatile, yet stable and 
biocompatible matrix. The first described multifunctional, multivalent nanocarriers were based 
on the synthetic polymeric hydrogel matrix, polyacrylamide (PAA), which easily facilitates 
multifunctionality due to its chemical flexibility.3–7 In the last decade, both natural and synthetic 
polymeric hydrogels have emerged as promising nanoplatforms for the development of 
biocompatible targeted multifunctional nanocarriers.8 This is enabled by the special properties of 
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hydrogels, namely, hydrophilicity,9 low cytotoxicity,10 biodegradability,11–14 capacity for high-
density co-encapsulation of multiple payload types, including a broad range of drugs,15 contrast 
agents for biomedical imaging,3–8,16–18 biosensing probes, 19–21 and photosensitizer chemicals for 
photodynamic therapy,4–8,22–24 while simultaneously protecting their payloads against 
chemical/enzymatic degradation.25 Another attractive feature of polymeric hydrogel nanocarriers 
is their engineerability for controlled release in response to a broad range of stimuli,26 which 
permits their ‘tuning’ to the physiological environment of tumors, for optimal drug release. A 
question underlying this work is whether nano-drugs with their multiple targeting ligands can 
overcome cellular multi-drug resistance (MDR) faced by single molecule drugs using the very 
same targeting ligands.  
 Optimal drug release from chemically-responsive, controlled-release hydrogel nanocarriers, 
in particular, which are engineered to liberate their therapeutic payloads in response to a specific 
intracellular stimulus, such as pH,27 glutathione28,29 or lysosomal enzymes,30 is predicated on 
their ‘directive targeting’ to the appropriate subcellular compartment. This is dependent on the 
endocytic pathway via which the target cell initially internalizes the hydrogel nanocarrier, and in 
turn, has direct bearing on the efficacy of the drug in its target tumor cell. In non-phagocytic 
cells, the major endocytic pathways that mediate the internalization of nanocarriers include the 
clathrin-mediated, caveolae-mediated and macropinocytosis pathways.31 Nanocarriers that are 
internalized via either the clathrin-mediated or macropinocytosis pathways ultimately 
accumulate within lysosomes (degradative, acidic vesicles), whereas those internalized via 
caveolae-mediated endocytosis typically accumulate within non-degradative vesicles of neutral 
pH, known as caveosomes. Recent studies have demonstrated that the internalization and 
intracellular trafficking of a hydrogel nanocarrier is influenced by its ensemble of unique 
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physicochemical properties, namely; size,32–34 morphology,35,36 elasticity of the hydrogel 
matrix,37 and surface charge.38–40 In addition to these physicochemical parameters, the surface 
engineering of a hydrogel nanocarrier with targeting ligands that bind selectively to specific 
receptors, which are overexpressed exclusively on the cell membrane of tumor and/or tumor 
endothelial cells, also influences the internalization and, subsequently, the intracellular 
trafficking of the nanocarrier. This strategy of nanocarrier ‘molecular addressing’ serves to 
enhance the nanocarrier’s binding affinity for, and internalization by, the target 
tumor/endothelial cell, while relying on the assumption that the ligand-bearing nanocarrier will 
be internalized and trafficked along the same endocytic pathway as the ligand alone.  
 Targeting of drug-laden nanocarriers to cell surface receptors that are overexpressed on the 
surface of tumor and/or tumor endothelial cells, with the specific capacity of translocation into 
the nucleus, is especially crucial to the efficacy of chemotherapeutic drugs whose site of action is 
in the nucleus. Nucleolin, a nucleolar phosphoprotein that possesses a bipartite nuclear 
localization signal (NLS),41 is such a receptor that is overexpressed on the surface of tumor 
endothelial cells, as well as on some other types of tumor cells.42 Nucleolin has already been 
exploited for the targeted in vivo delivery of multifunctional PAA hydrogel nanocarriers to 
tumors in which it is overexpressed.7,43 This has been achieved using the F3 peptide, a 32 amino 
acid sequence (KDEPQRRSARLSAKPAPPKPEPKPKKAPAKKC),44 as the nucleolin-targeting 
ligand. However, an important consideration in the NLS receptor-mediated transport of 
nanocarriers/nanoparticles into the nucleus is the size-restriction imposed by the nuclear pore 
complexes (~40 nm) on the entry into the nucleus of cargo that exceeds this size-restriction,45 as 
well as the intracellular fate of such ligand-targeted nanocarriers/nanoparticles. Recent studies in 
our lab on nucleolin-overexpressing cell lines, involving two-photon microscopy analysis of F3-
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targeted and non-targeted, pH-sensing PAA nanocarriers (68 nm) and silver core/PAA shell 
nanocarriers (90 nm and 130 nm), revealed that, although the F3-targeted PAA nanocarriers were 
not transported into the nuclei, they were instead sequestered within membrane-bound vesicles, 
but did not accumulate within lysosomes, whereas non-targeted PAA nanocarriers accumulated 
within lysosomes.46,47 This observation led us to pose the question, which forms the basis of this 
present study: How transferable is the intracellular targeting property of the F3 peptide to a 
hydrogel nanocarrier surface functionalized with this ligand? Remarkably, we observed that 
while the inhibition of clathrin-mediated endocytosis promoted the internalization of the 
untethered, monovalent F3 peptides and their translocation into the nucleus, the inhibition of this 
pathway instead strongly inhibited the internalization of the F3-targeted PAA nanocarriers. 
Furthermore, in the absence of inhibitors of the clathrin endocytic pathway, the untethered, 
monovalent F3 peptides normally accumulate within lysosomes without translocation to the 
nuclei, whereas the F3-targeted PAA nanocarriers accumulate within endosome-type vesicles, 
but evades trafficking to the lysosomes. This novel finding suggests that the coupling of multiple 
F3 peptides to the surface of the PAA nanocarrier, i.e. its multivalency, significantly alters the 
intracellular trafficking property of the peptide, and underscores the importance of not assuming 
that a ligand-bearing nanocarrier will follow the same intracellular trafficking pathway as that of 
the ligand alone. To the best of our knowledge, this study constitutes the first attempt at 
elucidating the influence exerted by the F3 peptide surface functionalization of a 
nanocarrier/nanoparticle on both its internalization and intracellular trafficking in tumor cells. 
Furthermore, we believe that the approach presented here will also be applicable to elucidate the 
endocytosis and intracellular trafficking pathways employed by nanocarriers functionalized with 
other targeting moieties, aimed at other cell surface-expressed proteins, with the goal of  
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Fig. 3.1 Schematic summary of the endocytic pathways of internalization for F3 peptide, non-targeted and F3-
targeted PAA nanocarriers (NTNCs and F3NCs) in the nucleolin-overexpressing MDA-MB-435 cell line. The 
F3NCs are predominantly internalized via the clathrin-mediated endocytic pathway, denoted by the potent inhibition 
of their internalization by Chlorpromazine (CPZ). In addition, the F3NCs employ a mechanism that circumvents 
their trapping within the degradative lysosomes; rather they accumulate within vesicles devoid of LAMP1 protein 
(Lysosome-associated membrane protein 1) in the perinuclear space. The caveolae-mediated and macropinocytosis 
endocytic pathways also contribute to the internalization of the F3NCs, but to a lesser extent than the clathrin-
mediated pathway. In contrast, single, monovalent F3 peptides are normally trafficked to lysosomes following 
internalization. However, inhibition of the clathrin-mediated endocytic pathway, by both CPZ and Potassium 
depletion, promotes the direct translocation of F3 peptides into the nucleus. The clathrin-mediated and caveolae-
mediated endocytic pathways contribute approximately equally to the internalization of the NTNCs, while 
macropinocytosis mediates their internalization to a lesser extent. Notably, the NTNCs co-internalize with LAMP1 
proteins from the cell surface following which they are trafficked to lysosomes, as denoted by the intense 
colocalization between the NTNCs and LAMP1 proteins (~50%) compared to the significantly lower colocalization 
between the F3NCs and LAMP1 (~8%). Given the similarities observed between the MDA-MB-435 and 9L cell 
lines with respect to the endocytosis inhibition and Lysotracker Red colocalization profiles of the F3 peptides, 
NTNCs and F3NCs, this scheme also applies to the 9L cell line, and, presumably, to other cell types expressing high 
levels of Nucleolin on their cell membranes. 
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overcoming the multidrug resistance of cancer cells. We present here the overall result in 
schematic form (as suggested by a reviewer), so as to assist the reader with following the details 
of the study that lead to this conclusion (see Fig. 3.1). 
 
3.2 Results and Discussion 
 
3.2.1 Endocytic Inhibition of Nanocarrier Internalization in Nucleolin-overexpressing cell 
lines 
Different endocytic pathways, particularly clathrin-mediated and caveolae-mediated endocytosis 
and macropinocytosis, have been implicated in the cellular internalization of nanocarriers, 
depending on the physicochemical properties of the nanocarrier.31 Given the influence of a 
hydrogel nanocarrier’s physicochemical properties on its cellular internalization, we employed 
an F3-targeted PAA hydrogel nanocarrier (F3NC), which is similar to that of an unmodified, 
non-targeted PAA hydrogel nanocarrier (NTNC) in terms of physicochemical properties, i.e. size 
and surface charge (see Chapter 2). We employed the inhibitors, chlorpromazine (CPZ), 
genistein (GEN) and cytochalasin D (CD), which specifically disrupt the above-mentioned 
endocytic pathways, respectively, and compared the behavior of the multivalent FITC-labeled 
F3NCs, under the same conditions, with that of the FITC-labeled NTNCs and FITC-labeled 
monovalent, molecular F3 peptides (molecular-F3 peptides), in separate cultures of live 9L and 
MDA-MB-435 cells. These cells are known to overexpress nucleolin receptors at their surfaces. 
The additional labeling of the lysosomes with a pH-sensitive fluorophore, Lysotracker Red 
DND-99, permitted simultaneous assessment of whether the fluorescent F3NCs, NTNCs and 
molecular-F3 peptides accumulate within lysosomes, in the absence or presence of any of the  
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Fig 3.2 Identification of the endocytic pathway(s) that mediate internalization of single F3 peptides (green; 3.2.1.a-
d), non-targeted PAA nanocarriers (NTNCs; green; 3.2.2.a-d), and F3-targeted PAA nanocarriers (F3NCs; green; 
3.2.3.a-d) in the 9L rat gliosarcoma cell line with the endocytic inhibitors Cytochalasin D (macropinocytosis 
inhibitor), Chlorpromazine (clathrin-mediated endocytosis inhibitor), and Genistein (caveolae-mediated endocytosis 
inhibitor). Controls constituted 9L cell cultures that received either F3 peptides, NTNCs or F3NCs in the absence of 
endocytic inhibitors (3.2.1.a, 3.2.2.a and 3.2.3.a). Lysosomes (red) were labeled with the pH-sensitive fluorophore 
Lysotracker DND-99. Regions of yellow/orange fluorescence denote colocalization between lysosomes and either 
F3 peptides, NTNCs or F3NCs, as indicated by white arrowheads. Scale bar: 10 µm 
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Fig 3.3 Identification of the endocytic pathway(s) that mediate internalization of single F3 peptides (green; 3.3.1.a-
d), NTNCs (green; 3.3.2.a-d), and F3NCs; (green; 3.3.3.a-d) in the MDA-MB-435 human breast adenocarcinoma 
cell line with the endocytic inhibitors Cytochalasin D, Chlorpromazine, and Genistein. Controls constituted MDA-
MB-435 cell cultures that received either F3 peptides, NTNCs or F3NCs in the absence of endocytic inhibitors 
(3.3.1.a, 3.3.2.a and 3.3.3.a). Lysosomes (red) were labeled with the pH-sensitive fluorophore Lysotracker DND-
99. Regions of yellow/orange fluorescence denote colocalization between lysosomes and either F3 peptides, NTNCs 
or F3NCs, as indicated by white arrowheads. Scale bar: 8 µm 
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endocytosis inhibitors. All confocal images were analyzed according to three criteria, namely, (i) 
the degree of cellular uptake, (ii) the degree of colocalization with Lysotracker Red and, (iii) the 
absence or presence of nuclear accumulation of molecular-F3 peptides/ NTNCs/ F3NCs.  
 Interestingly, neither of the inhibitors completely blocked the endocytosis of molecular-F3 
peptide, in both 9L and MDA-MB-435 cell lines. While both CD and GEN elicited comparably 
low levels of inhibition (~20-30%) on the internalization of molecular-F3 peptide, CPZ instead 
enhanced the internalization of molecular-F3 peptide in both cell lines, relative to the untreated 
controls (Figs. 3.4.1 and 3.4.2). Furthermore, CPZ promoted prominent accumulation of 
molecular-F3 peptide in the nuclei of both 9L (Fig. 3.2.1.c) and MDA-MB-435 (Fig.3.3.1.c) 
cells, with the accumulation of molecular-F3 peptide being highest in the nucleolar regions of the 
nuclei. Potassium depletion, a potent non-pharmacological inhibitor of clathrin-mediated 
endocytosis, also promoted prominent nuclear accumulation of molecular-F3 peptide, in both the 
9L and MDA-MB-435 cells (Appendix A3.1). However, molecular-F3 peptide was not observed 
in the nuclei of the control, CD- or GEN-treated 9L (Figs. 3.2.1.a, b, d) and MDA-MB-435 cells 
(Figs. 3.3.1.a, b, d). Colocalization (yellow/orange fluorescent punctate foci) between molecular-
F3 peptide (green) and Lysotracker Red was observed in the control (no inhibitors), CD- and 
GEN-treated 9L (Figs. 3.2.1.a, b, d) and MDA-MB-435 (Figs. 3.3.1.a, b, d) cells, although the 
degree of colocalization in MDA-MB-435 cells (~90%, Fig. 3.5.2) was markedly greater than 
that in 9L cells (~35%, Fig. 3.5.1). However, in both CPZ-treated 9L and MDA-MB-435 cells 
(Figs. 3.2.1.c and 3.3.1.c), the degree of colocalization between molecular-F3 peptide and 
Lysotracker Red was markedly lower (7.2 % and 3.5 % respectively) than in the control, CD- 
and GEN-treated cells (Figs. 3.5.1. and 3.5.2.).  
 In contrast to the observations for the molecular-F3 peptide, both CPZ and GEN elicited  
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Fig 3.4 Comparison of the influence of the endocytic inhibitors, Cytochalasin D (CD), Chlorpromazine (CPZ) and 
Genistein (GEN) on the internalization of the F3 peptides, NTNCs and F3NCs in the 9L (3.4.1) and MDA-MB-435 
cell lines (3.4.2). Mean intracellular fluorescence intensities of the F3 peptides, NTNCs and F3NCs in each inhibitor 
treatment are expressed as percentages relative to the mean fluorescence intensities of their respective control cells, 
which were not treated with the inhibitors, in each cell line. Error bars show standard deviations. P-values are 
indicated as follows: P<0.05 (*); P<0.01 (**); P<0.001 (***); P<0.0001 (****). Brackets are color-coded to denote 
significant differences in uptake of F3 peptide (blue), NTNCs (red) and F3NCs (green) across different inhibitor 
treatments. Black brackets denote significant internalization differences between F3 peptide, NTNCs and F3NCs 
within the same inhibitor treatment. Asterisks indicated directly on bars denote significant difference from their 
respective controls (with no inhibitors).  
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Fig 3.5 Comparison of the influence of the endocytic inhibitors, CD, CPZ and GEN on the degree of colocalization 
of the F3 peptides, NTNCs and F3NCs with Lysotracker Red DND-99 in the 9L (3.5.1) and MDA-MB-435 (3.5.2) 
cell lines. All values are based on the Manders’ M2 colocalization coefficients expressed as mean percentages. 
Errors bars show standard deviations. P-values are indicated as follows: P<0.05 (*); P<0.01 (**); P<0.001 (***); 
P<0.0001 (****). Brackets are color-coded to denote significant differences in colocalization of F3 peptide (blue), 
NTNCs (red) and F3NCs (green) with Lysotracker Red DND-99 across different inhibitor treatments. Black 
brackets denote significant colocalization differences between F3 peptide, NTNCs and F3NCs within the same 
inhibitor treatment. 
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marked reductions in the internalization of the NTNCs in both cell lines; 38.1% and 55.5% 
internalization respectively for 9L cells (Fig. 3.4.1), and 42.1% and 52.8% internalization 
respectively for MDA-MB-435 cells (Fig. 3.4.2). The greater inhibitory effect of CPZ on the 
internalization of the NTNCs is evident from the NTNCs being confined mostly to the cell 
peripheries (Figs. 3.2.2.c and 3.3.2.c). In both cell lines, CD exerted a lower inhibitory effect on 
the internalization of the NTNCs, which was similar to the level of inhibition exerted on the 
internalization of molecular-F3 peptide in the respective cell lines (Figs. 3.4.1 and 3.4.2). 
Importantly, over the duration of the experiment (2-3 hours), the NTNCs did not enter the nuclei 
of the controls (Figs. 3.2.2.a and 3.3.2.a) or any of the endocytosis-inhibitor treatments, in either 
of the cell lines (Figs. 3.2.2.b-d and 3.3.2.b-d). The degree of colocalization between the NTNCs 
and Lysotracker Red was 2-fold higher in the MDA-MB-435 control cells (46.5%) than in the 9L 
control cells (22.1%) (Figs. 3.5.1 and 3.5.2). All endocytic inhibitors decreased the degree of 
colocalization between the NTNCs and Lysotracker Red, relative to the control, in MDA-MB-
435 cells, whereas only CD and CPZ decreased the degree of colocalization between the NTNCs 
with Lysotracker Red, relative to the control, in 9L cells. Nonetheless, the degree of NTNC-
Lysotracker Red colocalization in CD- and GEN-treated MDA-MB-435 cells remained higher 
than the corresponding inhibitor treatments in the 9L cells. Notably, CPZ was the most potent 
inhibitor in reducing the colocalization between the NTNCs and Lyostracker Red in both cell 
lines; 7.1% and 7.2% colocalization for the 9L and MDA-MB-435 cells, respectively (Figs. 3.5.1 
and 3.5.2).  
 As observed for the NTNCs, F3NC internalization was most potently inhibited by CPZ in 
both the 9L (23.3%; Figs. 3.2.3.c and 3.4.1) and MDA-MB-435 cells (37.7%; Figs. 3.3.3.c and 
3.4.2). Notably, F3NC internalization in both CPZ-treated cell lines were lower than, although 
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not significantly different from, NTNC internalization in the CPZ-treated 9L (38.1%) and MDA-
MB-435 (42.1%) cells. In contrast, F3NC internalization in the GEN-treated 9L (65.7%) and 
MDA-MB-435 (78.9%) cells were higher than NTNC internalization in the GEN-treated 9L 
(55.5%) and MDA-MB-435 (52.8%) cells (Figs. 3.34.1 and 3.4.2). Interestingly, F3NC 
internalization was lower in CD-treated MDA-MB-435 cells (63.1%) than CD-treated 9L cells 
(81.2%), although these levels of F3NC internalization were not significantly different from 
NTNC internalization in CD-treated 9L (77.8%) and MDA-MB-435 (67.4%) cells (Figs. 3.4.1 
and 3.4.2). Most importantly, there was no observable permeation of the F3NCs into the nuclei 
of the controls (Figs. 3.2.3.a and 3.3.3.a), or for any of the endocytic inhibitor treatments (Figs. 
3.2.3.b-d and 3.3.3.b-d), in either cell line. The absence of nuclear entry by the F3NCs, 
particularly in the presence of CPZ, is especially interesting in light of the nuclear accumulation 
of molecular-F3 peptide when mediated by CPZ (Figs. 3.2.1.c and 3.3.1.c). Most strikingly, the 
degree of colocalization of the F3NCs with Lysotracker Red was significantly lower than for 
molecular-F3 peptide and NTNCs in the control, CD- and GEN-treated 9L and MDA-MB-435 
cells (Figs. 3.5.1 and 3.5.2). For example, in the 9L control cells, F3NC-Lysotracker Red 
colocalization was 3-fold and 1.8-fold lower than for molecular-F3 peptide and the NTNCs, 
respectively, while in the MDA-MB-435 control cells, F3NC-Lysotracker Red colocalization 
was 6.4-fold and 3.3-fold lower than for molecular-F3 peptide and the NTNCs, respectively. As 
observed for molecular-F3 peptide and the NTNCs, the degree of F3NC-Lysotracker Red 
colocalization was most potently reduced by CPZ in both 9L (6.0%) and MDA-MB-435 (4.7%) 
cells, relative to the untreated control 9L (12.5%) and MDA-MB-435 (14.2%) cells (Figs. 3.5.1 
and 3.5.2). These levels of colocalization were also similar to those observed for molecular-F3 
peptide and the NTNCs in the CPZ-treated 9L and MDA-MB-435 cells (Figs. 3.5.1 and 3.5.2).  
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 The observations from the endocytosis inhibition experiments indicate that: (i) neither 
macropinocytosis, clathrin-mediated, nor caveolae-mediated endocytosis are utilized by the 
molecular-F3 peptide as its primary pathway of cellular entry into either 9L or MDA-MB-435 
cells; (ii) the above endocytic pathways each promote, to varying degrees, the internalization of 
the NTNCs and F3NCs, of which clathrin-mediated endocytosis is the major internalization 
pathway; and (iii) the F3NCs are more efficient than both the molecular-F3 peptide and the 
NTNCs at evading trafficking to the lysosomes and thus accumulate within different 
‘endosomal-type’ vesicles, with this disparity being most prominent in the MDA-MB-435 cell 
line. Given the observation that a greater fraction of the endocytosed NTNCs, compared to the 
F3NCs, accumulate within lysosomes in MDA-MB-435 cells, we subsequently probed the 
intracellular trafficking of these two types of nanocarriers, independently of each other, in MDA-
MB-435 cells, by immunocytochemistry, to gain further insight into the mechanism behind the 
selective accumulation of the targeted and non-targeted nanocarriers within different subcellular 
vesicles. 
 
3.2.2 Spatiotemporal Probing of Nanocarrier Intracellular Trafficking by 
Immunocytochemistry 
Separate batches of MDA-MB-435 cells, treated with either NTNCs or F3NCs, were fixed at 
various time points up to 6 hours after delivery of the NCs, following which, the cells were 
labeled for lysosome associated membrane protein 1 (LAMP1) and either early endosome 
antigen 1 (EEA1), which is associated with clathrin-mediated pathway, or caveolin 1 (caveolae 
marker), and analyzed by confocal microscopy. The rationale behind this approach was to obtain 
snapshots of any potential interaction between the FITC-labeled NTNCs/F3NCs and the above- 
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Fig 3.6 Spatiotemporal probing of the intracellular trafficking of the FITC-labeled NTNCs (green; 3.6.1.a-f) and 
FITC-labeled F3NCs (green; 3.6.2.a-f) along the clathrin-mediated endocytic pathway in MDA-MB-435 cells at 
various time points up to 6 hours post-delivery, in relation to the early endosomes (Early Endosomal Antigen 1 
(EEA1); blue) and lysosome-associated membrane protein 1 (LAMP1; red). Regions of yellow/orange fluorescence 
denote colocalization between LAMP1 and either the NTNCs or F3NCs (dashed white arrows), regions of light-blue 
fluorescence denote colocalization between EEA1 and either the NTNCs or the F3NCs (solid white arrows), and 
regions of white fluorescence denote colocalization between the NTNCs, LAMP1 and EEA1 (white triangles). Scale 
bar: 5 µm. 
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Fig 3.7 Spatiotemporal probing of the intracellular trafficking of the FITC-labeled NTNCs (green; 3.7.1.a-f) and 
FITC-labeled F3NCs (green; 3.7.2.a-f) along the caveolae-mediated endocytic pathway in MDA-MB-435 cells at 
various time points up to 6 hours post-delivery, in relation to the caveolae (Caveolin 1; blue) and lysosome-
associated membrane protein 1 (LAMP1; red). Regions of yellow/orange fluorescence denote colocalization 
between LAMP1 and either the NTNCs or F3NCs (dashed white arrows), regions of light-blue fluorescence denote 
colocalization between Caveolin1 and either the NTNCs or the F3NCs (solid white arrows), and regions of white 
fluorescence denote colocalization between the NTNCs, LAMP1 and Caveolin1 (indicated by white triangles). Scale 
bar: 5 µm. 
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Fig 3.8 Comparisons of the colocalization profiles of the NTNCs and F3NCs with EEA1 (3.8.1), Caveolin1 (3.8.2) 
and LAMP1 (3.8.3) protein markers from 10 minutes up to 6 hours post-delivery in the MDA-MB-435 cell line. All 
values are based on the Manders’ M2 colocalization coefficients expressed as mean percentages. Error bars show 
standard deviations. P-values are indicated as follows: P<0.05 (*); P<0.01 (**); P<0.001 (***); P<0.0001 (****). 
Black brackets denote significant colocalization differences between the NTNCs and F3NCs at the same time point. 
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mentioned markers from internalization, and throughout their intracellular trafficking within the 
MDA-MB-435 cells. Therefore, the absence or presence of colocalization between the 
NTNCs/F3NCs and these markers facilitated further examination of the endocytic pathway(s) 
responsible for internalizing each of these NCs and, more importantly, if the F3NCs are indeed 
able to evade trafficking to the lysosomes. All confocal images were analyzed on the basis of (i) 
the degree of colocalization between the NTNCs/F3NCs with EEA1, Caveolin1 or LAMP1 and, 
(ii) the absence or presence of nuclear accumulation of the NTNCs/F3NCs. Distinct differences 
were observed between the F3NCs and NTNCs with respect to their interaction with, and 
intracellular trafficking within, the MDA-MB-435 cells.  
 The most prominent feature of the F3NC-treated MDA-MB-435 cells is the distinct 
delineation of their cell membranes with the green-fluorescent F3NCs. These cell membrane 
delineations were evident at all time points, up to 180 min post-delivery (Figs. 3.6.2.a-e & 
3.7.2.a-e); however by 360 min post-delivery, the cell membrane delineations had markedly 
diminished, concomitant with prominent endosomal accumulation of the F3NCs (Figs. 3.6.2.f 
and 3.7.2.f). This observation suggests that, by 360 min post-delivery, the majority of the cell-
membrane-bound F3NCs were endocytosed by the MDA-MB-435 cells. Interestingly, despite 
the high avidity of the F3NCs for the nucleolin over-expressing MDA-MB-435 cells, the 
appearance of F3NC-laden endosomes within the cytoplasm was most evident only at 30 minutes 
(Figs. 3.6.2.b and 3.7.2.b) and onward of delivery (Figs. 3.6.2.c-f, 3.7.2.c-f).    
 At 10 minutes after delivery, only 7.8% of the F3NCs colocalized with EEA1 (Figs. 3.6.2.a, 
3.8.1), which then peaked to 32.7% colocalization at 30 minutes post-delivery (Fig. 3.6.2.b, 
3.8.1), and thereafter decreased progressively to 3.9% colocalization by 360 minutes post-
delivery (Figs. 3.6.2.c-f, 3.8.1). Colocalization between the F3NCs and Caveolin1 was diffuse 
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and confined exclusively to the cell surface; unlike the distinct punctate foci of colocalization 
observed between the F3NC-laden endosomes and EEA1 within the cytoplasm. At 10 minutes 
after delivery, 6.9% of the cell membrane-bound F3NCs colocalized with Caveolin1 (Fig. 
3.7.2.a), which then peaked to 14.5% colocalization at 120 minutes post-delivery (Fig. 3.7.2.d), 
and thereafter decreased progressively to 6.2% by 360 minutes post-delivery (Figs. 3.7.2.e,f, 
3.8.2). Furthermore, only scant colocalization between the F3NCs and LAMP1 was observed at 
the various time points (Figs. 3.6.2.a-f and 3.7.2.a-f; dashed white arrows). At 10 minutes after 
delivery, only 7.9% of the F3NCs colocalized with LAMP1, which then peaked to 8.2% 
colocalization at 30 minutes post-delivery, and thereafter decreased progressively to 4.7% 
colocalization by 360 minutes post-delivery (Fig. 3.8.3). Most notably, from 60 minutes after 
delivery and onward, larger F3NC-laden endosomes that exhibited an absence of colocalization 
with the EEA1, Caveolin1 and LAMP1 markers, began to accumulate, which suggests that the 
F3NCs are sequentially trafficked from the early endosomes to late endosomal vesicles (Figs. 
3.6.2.c-f and 3.7.2.c-f), since the late endosomes are devoid of EEA1 and Caveolin1 markers. 
Moreover, some of these ‘larger’ F3NC-laden endosomes appeared within the perinuclear region 
from as early as 120 minutes after delivery and onward (Figs. 3.6.2.e,f and 3.7.2.d-f), although 
there was no observable entry or accumulation of F3NCs within the nuclei of the cells (Figs. 
3.6.2.d-f and 3.7.2.d-f).   
 In stark contrast to the F3NC-treated cells processed for immunocytochemistry, cell 
membrane delineations were not observed with the NTNCs at any of the time points investigated 
(Figs. 3.6.1.a-f and 3.7.1.a-f). Given the inherent non-specific affinity of the NTNCs for 
negatively charged cell membranes, due to their modest positive surface charge (~ +16 mV, See 
Chapter 2), in addition to the appearance of NTNC-laden endosomes in the periphery of the 
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cytoplasm just 10 minutes after delivery (Figs. 3.6.1.a and 3.7.1.a), these observations suggest 
that the NTNCs are endocytosed slightly faster than the F3NCs upon contact with the cell 
membrane. In contrast to the F3NCs, a greater fraction of the NTNC-laden endosomes (23.4%; 
Fig. 3.8.1) were colocalized with EEA1 at 10 minutes after delivery (Figs. 3.5.1.a, solid white 
arrows), which correlated with the faster appearance of NTNC-laden endosomes in the 
cytoplasm at this time point. As observed for the F3NCs, the degree of colocalization between 
the NTNC-laden endosomes and EEA1 peaked to 32.6% colocalization at 30 minutes post-
delivery (Fig. 3.6.1.b), and thereafter decreased progressively, but still remained as high as 
14.8% by 360 minutes post-delivery (solid white arrows; Figs. 3.6.1.c-f, 3.8.1). Distinct punctate 
colocalization was observed between the NTNCs and Caveolin1 – positive endosomes both at 
the cell surface and within the cytoplasm (Figs. 3.7.1.d-f; solid white arrows). This contrasts with 
the colocalization between the F3NCs and Caveolin1, which was scant and confined exclusively 
to the cell surface (Figs. 3.7.2.a-f; solid white arrows). At 10 minutes after delivery, 6.6% of the 
NTNCs colocalized with Caveolin1 (Fig. 3.7.1.a), which then peaked to 28.5% colocalization at 
120 minutes post-delivery (Fig. 3.7.1.d), and thereafter decreased to 8.6% colocalization by 360 
minutes post-delivery (Figs. 3.7.1.e,f, 3.8.2). In stark contrast to the F3NC-treated cells, the 
NTNCs colocalized strongly with LAMP1, appearing as distinct punctate foci of orange/yellow 
fluorescence (dashed white arrows), both at the cell surface and in NTNC-laden endosomes 
within the cytoplasm (Figs. 3.6.1.a-f and 3.7.1.a-f). At 10 minutes after delivery, 20.3% of the 
NTNCs colocalized with LAMP1 (compared to 7.9% F3NC-LAMP1 colocalization at 10 
minutes), which increased sharply to 44.9% colocalization at 60 minutes post-delivery, and 
peaked to 49.2% colocalization at 180 minutes post-delivery (Fig. 3.8.3). A slight decrease to 
45.3% colocalization was observed at 360 minutes post-delivery, however this was not 
	   70	  
significantly different from the degree of colocalization at 180 minutes post-delivery (Fig. 3.8.3).  
Therefore, the degree of colocalization between the NTNCs and LAMP1 increased with time and 
was significantly higher than that for the F3NCs at each time point, whereas the colocalization 
between the F3NCs and LAMP1 decreased with time. Moreover, NTNC-laden endosomes that 
exhibited dual-colocalization with LAMP1 and either EEA1 or Caveolin1 were also observed 
(Figs. 3.6.1.a, c-f and 3.7.1.e,f; white triangles). Importantly, as observed for the F3NCs, the 
NTNC-laden endosomes did not enter the nuclei, and largely remained dispersed throughout the 
cytoplasm. 
 
3.2.3 Cell Membrane Interaction Profiles of Non-targeted and F3-targeted PAA-NCs  
 Our immunocytochemical analyses revealed a fundamental difference between the F3NCs 
and NTNCs, with respect to their interactions with the cell membranes of MDA-MB-435 cells in 
that, the F3NCs elicited prominent delineation of the MDA-MB-435 cell membranes, whereas 
this effect was not observed with the NTNCs. Cell membrane delineations were however 
observed for the NTNC-treated cells in the endocytosis inhibition images, but were less 
prominent than that observed for the F3NC-treated cells. Interestingly, prominent appearance of 
the F3NC-laden endosomes in the cytoplasm occurred only 30 minutes after delivery, whereas 
NTNC-laden endosomes appeared in the cytoplasm as early as 10 minutes after delivery. These 
observations indicate that the F3NCs first accumulate on the cell membrane, upon binding, for a 
significant period of time before being internalized, whereas the NTNCs do not accumulate on 
the cell membrane and are internalized fairly rapidly upon contact with the cell membrane. Thus, 
there must be a difference between the F3NCs and NTNCs in their interaction with the MDA-
MB-435 cell membrane. Notably, the binding of positively charged nanoparticles to negatively 
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charged cell membranes is driven by non-specific electrostatic interactions. Furthermore, it has 
been demonstrated that the binding of amine-surface modified polystyrene nanoparticles to 
dipalmitoyl phosphocholine (DPPC) liposomes induces a lipid phase transition, from gel to fluid, 
at the nanoparticle-membrane interface,48 which may potentiate the detachment of invaginating 
endosomes that form around the nanoparticle from the cell membrane.49 Hence, our positively 
charged, amine-surface modified NTNCs may elicit a similar lipid phase transition in the regions 
of the MDA-MB435 cell membranes to which they bind, thereby potentiating their rate of 
endocytic uptake.  
In contrast, while the F3NCs have a higher positive surface charge (~ +30 mV) than the 
NTNCs (~ +16 mV; See Chapter 2), the interaction of the former with the MDA-MB-435 cell 
membrane is limited to the binding interaction between their surface-conjugated F3 peptides and 
the cell surface bound nucleolin receptors. Furthermore, targeted nanoparticles of 50 nm in 
diameter and greater bind numerous receptors simultaneously with very high avidity (~1-3 x 10-
13 M),50 such that the internalization of further nanoparticles is limited by the redistribution of 
additional receptors on the cell membrane by lateral diffusion in order to compensate for the 
depletion of unbound cell surface receptors in the contact region between the cell membrane and 
nanoparticle.51 The uptake of additional nanoparticles may be further limited by the rate at which 
new receptors are delivered to the cell membrane,52 in order to compensate for those receptors 
that have been internalized along with the bound nanoparticle, as is the case with nucleolin.53 
This phenomenon provides a plausible explanation for the slightly longer lag time observed 
between the delivery of the F3NCs and their first appearance in the cytoplasm, compared to the 
NTNCs. This is attributed to the properties of the F3NCs, i.e. their hydrodynamic size of ~60 nm 
and their ligand surface coverage that elicits cell binding saturation (See Chapter 2), and is in 
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accordance with previous observations.50,51 
 Evidence in support of the specificity of the interaction between the F3-surface 
functionalized PAA-NCs and the nucleolin receptors is provided by a control experiment that 
was performed in a recent study published by our lab,54 whereby we functionalized PAA-NCs 
with either the wild-type F3 peptide or a scrambled F3 peptide (identical amino acid 
composition, length and charge, but scrambled sequence) and compared the uptake of these 
functionalized nanocarriers in the nucleolin surface-expressing 9L cell line. The wild-type F3 
peptide promoted uptake of the PAA-NCs, whereas the scrambled F3 peptide did not. This 
observation indicates that only the wild-type F3 peptide sequence is capable of adopting the 
correct secondary and/or tertiary conformation that is necessary for binding to the cell-surface 
nucleolin receptors, and thus promoting uptake of the nanocarriers. 
 
3.2.4 Internalization and Intracellular Trafficking Profiles of F3 peptide, F3-targeted and 
Non-targeted PAA-NCs 
 After internalization, the drug-laden nanocarrier should ideally be delivered to the specific 
subcellular compartment within which that drug molecule elicits its mechanism of action, in 
order to circumvent extrusion of these drug molecules by the cell membrane-resident multidrug 
resistance (MDR) efflux pumps, and thereby retain the efficacy of therapy. Although recent 
studies have demonstrated that the physicochemical properties of a nanocarrier modulates its 
intracellular trafficking,55,56 it still remained unclear, prior to our current study, as to how the 
presence of multiple copies of a targeting ligand on the surface of a nanocarrier, i.e. its 
multivalency, influences its intracellular trafficking and subcellular accumulation, relative to its 
non-targeted counterpart, or even relative to the targeting ligand alone. An important observation 
	   73	  
from our endocytosis inhibition study is that neither of the endocytic inhibitors, CD, CPZ or 
GEN, completely blocked the internalization of the NTNCs or F3NCs, but each one decreased 
the internalization of the various nanocarriers to varying degrees. Since only one endocytic 
inhibitor was used at a time, so as to minimize cytotoxicity, the other endocytic pathways would 
have been still operational, and thus able to promote the uptake of the nanocarriers. This would 
account for why we did not observe complete inhibition of the uptake of the NTNCs and F3NCs 
in the presence of any one inhibitor.  
 Our endocytosis inhibition data demonstrated that (i) the intracellular trafficking of 
molecular-F3 peptide in its monovalent form is markedly different compared to when it is 
coupled to the surface of hydrogel PAA-NCs and (ii), although the non-targeted and F3-targeted 
PAA-NCs share common pathways of internalization, albeit to varying degrees, they each 
accumulate in distinct types of subcellular vesicles. We acknowledge that although the F3 
peptides used in our experimental setup were not in their ‘native form’ i.e. they were chemically 
labeled with FITC fluorophore, the significantly smaller size of the FITC fluorophore (389 Da), 
compared to that of a single F3 peptide (3536 Da) or a single PAA-NC, has negligible, if any, 
effect on the behavior of the F3 peptide. Furthermore, the FITC fluorophore has only one 
reactive isothiocyanate group, and is therefore incapable of cross-linking multiple F3 peptides, so 
as to generate a multivalent peptide complex, which would likely alter the binding avidity of the 
F3 peptide for Nucleolin as well as alter its intracellular trafficking. The intracellular trafficking 
of monovalent molecular-F3 peptide is particularly interesting in that it inherently accumulated 
in lysosomes, with neither of the endocytic inhibitors CD or GEN being able to completely 
prohibit its cellular entry or accumulation in lysosomes. While CPZ also failed to prohibit the 
cellular entry of molecular-F3 peptide, it however promoted a diversion in the trafficking of the 
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molecular-F3 peptide from the lysosomes to the nucleus. We observed the same result for 
molecular-F3 peptide in both the 9L and MDA-MB-435 cell lines when the cells were subjected 
to potassium depletion (Appendix A3.1), which acts as a potent non-pharmacological inhibitor of 
the clathrin-mediated endocytic pathway. This phenomenon is therefore not unique to 
chlorpromazine, and we conclude that the inhibition of the clathrin-mediated pathway, 
irrespective of the inhibitor, promotes accumulation of molecular-F3 peptide within the nuclei of 
9L and MDA-MB-435 cells. Notably, our observations are consistent with the study by Legrand 
et al., which first documented that the cellular uptake of the human Lactoferrin protein (hLf) is 
mediated by nucleolin and that the majority of these nucleolin-hLf complexes colocalize with 
EEA1, a marker specifically associated with clathrin in early endosomes.57 Our findings 
therefore confirm that the cell’s surface-bound nucleolin is associated with the clathrin-mediated 
endocytic pathway, which likely overrides the nuclear localization signal (NLS) of nucleolin and 
thus promotes the routing of the molecular-F3 peptide into the lysosomes. However, upon 
inhibiting the clathrin-mediated endocytic pathway by CPZ, the NLS function of nucleolin 
apparently predominates, thereby allowing translocation of nucleolin, together with any bound 
molecular-F3 peptide, directly into the nucleus. Given our observations with molecular-F3 
peptide, we might have anticipated a similar intracellular trafficking pattern for the F3NCs, 
however this was not the case. Remarkably, in the absence, as well as the presence, of endocytic 
inhibitors, the F3NCs exhibited markedly lower accumulation within lysosomes as compared to 
molecular-F3 peptide and to the NTNCs, in both 9L and MDA-MB-435 cells. Most notably, 
CPZ was the only inhibitor that elicited a marked reduction in both the endocytosis and 
lysosomal accumulation of the F3NCs, in either cell line. A similar result was observed for the 
NTNCs in both the CPZ-treated 9L and MDA-MB-435 cells. Therefore, these data suggest that 
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while the F3NCs and the NTNCs share clathrin-mediated endocytosis as a common pathway of 
internalization, the multivalent nature of the F3-targeted PAA nanocarrier significantly alters its 
intracellular trafficking within these cell lines, so as to avoid accumulation within the lysosomes. 
It should be noted that while not all endocytosed NTNCs were found to colocalize with 
Lysotracker Red at 1 hour after delivery, it is likely that these NTNCs were sequestered within 
early and/or late endosomes that were still en route for fusion with lysosomes. Evidence in 
support of this premise is provided by our immunocytochemistry data in which only the NTNCs 
exhibited a time-dependent increase in colocalization with lysosome associated membrane 
protein 1 (LAMP1), over the 6-hour period during which the intracellular trafficking of the 
NTNCs was observed (Fig. 3.8.3).  
 The immunocytochemical analysis also corroborated the findings of the endocytosis 
inhibition experiment in MDA-MB-435 cells that clathrin-mediated endocytosis contributed 
approximately equally to the internalization of the NTNCs and F3NCs, while the caveolae-
mediated pathway mediated greater internalization of the NTNCs than the F3NCs. This is 
evident from the observations that (i) CPZ decreased the internalization of the NTNCs and 
F3NCs to similar levels (Fig. 3.4.2), while the colocalization of the NTNCs and F3NCs with 
EEA1 both peaked at 30 minutes post-delivery to similar levels (Fig. 3.8.1), and (ii) in GEN-
treated cells, the level of NTNC internalization was approximately 1.49-fold lower than that of 
the F3NCs (Fig. 3.4.2), while the peak NTNC-Caveolin1 colocalization at 120 min post-delivery 
was approximately 1.96-fold higher than that of the F3NC-CAV1 colocalization at the same time 
point (Fig. 3.8.2). These observations suggest that the presence of multiple F3 peptides on the 
surface of the F3NCs biases their internalization via the clathrin-mediated endocytic pathway, as 
compared to the NTNCs. From 60 min post-delivery, a progressive decrease in the colocalization 
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with EEA1, for both the F3NCs and NTNCs, was observed, suggesting that both types of 
nanocarriers were being transported into the late endosomes, which lack the EEA1 marker. 
Interestingly, for both the F3NCs and NTNCs, the peak in colocalization with Caveolin1 was 
achieved only at 120 minutes post-delivery. This observation may be due to the existence of 
bidirectional communication between the clathrin-mediated and caveolae-mediated endocytic 
pathways, whereby cargo that is internalized via caveolae-mediated endocytosis can be trafficked 
into EEA1 – positive endosomal compartments, and vice versa.58,59 It was also interesting to note 
that the macropinocytosis inhibitor, Cytochalasin D, exerted a slightly greater inhibitory effect 
than Genistein on the internalization of the F3NCs in the MDA-MB-435 cells. This may be 
attributed to the previously reported observation that cell surface expressed Nucleolin is 
associated with the actin cytoskeleton,60 and that Cytochalasin D inhibits macropinocytosis by 
disrupting actin polymerization.  
 
3.2.5 F3-targeted PAA-NCs, but not Non-targeted PAA-NCs, evade co-internalization with 
LAMP1 at the cell surface 
The most striking difference between the F3NCs and NTNCs in their intracellular trafficking is 
the presence of prominent punctate colocalization between the NTNCs and LAMP1, both at the 
cell surface and during their transport into the interior of the cells, at all time points, whereas 
such colocalization between the F3NCs and LAMP1 was scant over the 6-hour period during 
which their intracellular trafficking was tracked. This observation must be understood in the 
context of the trafficking of the newly synthesized lysosome-associated membrane proteins 
(LAMPs) themselves, and the role that these proteins play in the interaction between endosomes 
and lysosomes. First, the transport of newly synthesized LAMPs from the trans-Golgi network 
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(TGN) to the lysosomes may follow either a direct or indirect pathway.61,62 The direct pathway is 
a completely intracellular route whereby newly synthesized LAMPs are transported from the 
TGN to either early or late endosomes and then to lysosomes. In the indirect pathway, the 
LAMPs are first transported from the TGN to the extracellular surface of the cell membrane, 
subsequently internalized by the clathrin-mediated endocytic pathway,63 and then sequentially 
delivered to the early endosomes, late endosomes and finally the lysosomes. Second, LAMPs are 
essential for facilitating fusion between phagosomes and lysosomes in macrophages,64 and may 
very well be necessary for facilitating fusion between the late endosomes and lysosomes in other 
non-phagocytic cell types. It is therefore apparent from the positive cell surface labeling of the 
MDA-MB-435 cells with anti-LAMP1 antibody that (i) the indirect LAMP trafficking pathway 
is indeed operational in the MDA-MB-435 cell line, and (ii) the NTNCs, but not the F3NCs, are 
co-internalized with LAMP1 proteins from the cell surface via the clathrin-mediated pathway, 
which commits these NTNC-laden, EEA1-positive endosomes to undergo fusion with the 
lysosomes, as illustrated by their colocalization with Lysotracker Red in our live cell endocytosis 
inhibition experiment. Furthermore, the presence of NTNC-laden endosomes exhibiting dual-
colocalization with LAMP1, and with either EEA1 or Caveolin1, indicates that, despite being 
trafficked via either the clathrin-mediated or caveolae-mediated endocytic pathways, the NTNC-
laden endosomes are still committed to undergo fusion with the lysosomes. Moreover, the time-
dependent increase in colocalization between the NTNCs and LAMP1 confirms that the NTNCs 
do accumulate within the lysosomes over time. Figure 3.1 illustrates the internalization and 
intracellular trafficking profiles of molecular-F3 peptide, the F3NCs and NTNCs in nucleolin-
overexpressing cells based on our observations. 
 Considering that LAMP1 is necessary for facilitating fusion between phagosomes and 
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lysosomes, it is plausible that the absence of LAMP1 proteins in the F3NC-laden, EEA1-positive 
endosomes would abrogate the ability of these F3NC-laden late endosomes to fuse with 
lysosomes. The presence of large, punctate F3NC-laden, EEA1/LAMP1 – negative vesicles 
within the perinuclear space, 360 minutes after delivery, supports our postulate that the F3NCs 
accumulate within late endosomes, but without subsequent fusion with lysosomes. Given that the 
late endosomes can also fuse with the TGN, we speculate that the F3NCs may be transported 
into the nucleus via retrograde transport, through the endoplasmic reticulum, over longer periods 
of time. Exploiting this pathway would therefore serve as an alternative mechanism for 
delivering into the nucleus nanocarriers whose hydrodynamic diameters exceed the cut-off limit 
of the nuclear pore complexes, as is the case with our hydrogel polyacrylamide nanocarriers. 
Further studies are underway in our lab to determine the long-term subcellular localization of the 
F3NCs in nucleolin-overexpressing cells. 
 Our observation that molecular-F3 peptide is normally trafficked to the lysosomes is 
consistent with a recent study which reported that nucleolin colocalizes with LAMP1 in the 
phagosomal compartment of macrophages.65 Importantly, previous studies have also 
demonstrated that LAMP proteins are overexpressed at the surface of highly metastatic tumor 
cells.66,67 The prominent cell surface labeling of the highly metastatic MDA-MB-435 cells68 with 
anti-LAMP1 antibody in our study is therefore consistent with these studies. When taken into 
consideration with these previous reports, our observations suggest that the high surface density 
of LAMP1 proteins in the highly metastatic MDA-MB-435 cells increases the likelihood of 
nucleolin being co-internalized with LAMP1 proteins, which in turn commits the nucleolin-laden 
endosome to fusion with the lysosomes. However, this is not the case when the F3NCs engage 
nucleolin receptors at the surface of MDA-MB-435 cells and are internalized.  
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3.2.6 Conclusion 
Our investigation demonstrates that the presence of F3 peptide on the surface of the 
polyacrylamide hydrogel nanocarrier significantly modulates the nature of the nanocarrier’s 
interaction with the cell membrane of the target cell, including not only its internalization but 
also its intracellular trafficking and subcellular localization, relative to the non-targeted 
nanocarrier. Furthermore, the ability of the F3-targeted hydrogel nanocarriers, but not of the 
molecular-F3 peptide, to evade trafficking to the lysosomes, strongly suggests that the 
multivalent nature of the F3-targeted hydrogel nanocarrier is responsible for this effect. The 
implications of our observations are two-fold. First, from a general perspective, it cautions 
against making the assumption that a targeted nanocarrier’s fate within cells is solely determined 
by the targeting ligand, or solely the carrier, or by a combination of the respective properties of 
the ligand and carrier (which might adversely affect the efficacy of therapy). Second, and more 
specifically, our findings are particularly relevant to the targeting of highly metastatic tumor 
cells, and thus may provide new insights into a possible mechanism of preventing the co-
internalization of drug nanocarriers with LAMP1, in order to circumvent their trafficking to 
lysosomes. This appears to have important implications regarding the potential advantages of 
nano-drugs with multivalent ligand targeting, compared to individual drug molecules containing 
an identical single targeting ligand, especially when it comes to overcoming the multi-drug 
resistance (MDR) of metastatic cancer cells. Also of much interest is the possibility of 
engineering nanoparticles that mimic natural pathogens’ ability to overcome the cell’s defence 
mechanisms. Further studies are being conducted in our lab to elucidate the mechanism by which 
the F3-targeted hydrogel nanocarriers circumvent trafficking to the lysosomes in nucleolin-
overexpressing cell lines. 
	   80	  
3.2.7 Experimental Section 
Reagents and Materials 
Acrylamide (AA), 3-(acryloyloxy)-2-hydroxypropylmethacrylate (AHM), ammonium persulfate 
(APS), N,N,N`,N`-tetramethylethylenediamine (TEMED), sodium dioctyl sulfosuccinate (AOT), 
Brij 30, L-cysteine, fluorescein isothiocyanate (FITC) and phosphate-buffered solution (PBS) 
tablets were purchased from Sigma-Aldrich (St. Louis, MO). N-(3-aminopropyl)-
methacrylamide hydrochloride (APMA) was purchased from Polysciences (Warrington, PA). 
Ethanol (100 %) and hexane were purchased from Fisher Scientific (Pittsburgh, PA). 
Heterobifunctional polyethyleneglycol (MAL–PEG–SCM, MW: 2,000 Da) was purchased from 
Creative PEG Works (Winston Salem, NC). The 9L rat gliosarcoma and MDA-MB-435 human 
breast adenocarcinoma cell lines were obtained from American Type Culture Collection 
(Manassas, VA, USA). Dulbecco’s modified Eagle medium (DMEM), Rosswell Park Memorial 
Institute (RPMI-1640) medium, Gibco 0.05 % Trypsin-EDTA, Gibco 100x PenStrep-Glutamine 
and Gibco Heat-Inactivated Fetal Bovine Serum (HI-FBS) were purchased from Invitrogen 
(Carlsbad, CA). Endocytosis inhibitors, Cytochalasin D, Chlorpromazine, and Genistein were 
obtained from Sigma-Aldrich. Cysteine terminated F3 peptide (F3-Cys: 
KDEPQRRSARLSAKPAPPKPEPKPKKAPAKKC) was purchased from SynBioSci 
(Livermore, CA).  Mouse monoclonal anti-EEA1, rabbit polyclonal anti-Caveolin1 and goat 
polyclonal anti-LAMP1 antibodies were purchased from Santa Cruz Biotechnology, Inc (Santa 
Cruz, CA, USA). Lysotracker Red DND-99, donkey anti-mouse (H+L) Alexa Fluor 568 (AF-
568), donkey anti-rabbit (H+L) AF-568 and donkey anti-goat (H+L) Alexa Fluor 647 (AF-647) 
antibodies were obtained from Invitrogen. Normal donkey serum was purchased from LAMPIRE 
Biological Laboratories (Pipersville, PA). Methanol-free electron microscopy grade 20% (w/v) 
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paraformaldehyde solution was purchased from Electron Microscopy Services (Hatfield, PA, 
USA). All solutions were prepared in 18 MΩ water purified in a Barnstead 1 Thermolyne 
Nanopure II system. All reagents and materials were used as received without further 
purification. 
 
Synthesis of FITC-labeled amine surface-functionalized hydrogel polyacrylamide 
nanocarriers  
A monomer mixture consisting of 1 mg FITC, 711 mg acrylamide, 55 mg APMA, and 460 µL 
AHM were dissolved in PBS buffer (pH 7.4) and mixed together for 2 hours at room 
temperature. The mixture was emulsified in organic media containing surfactant (45 mL hexane, 
1.6 g AOT, and 3.1 g Brij30) by continuous stirring for 20 minutes under Argon atmosphere in 
order to purge the reaction mixture of oxygen. Thereafter, polymerization was triggered by 
addition of radical initiator (100 µL of 10 % (w/v) ammonium persulfate in DI water and 100 µL 
of TEMED). The reaction proceeded for 2 hours under mild argon purging and was terminated 
by exposing the reaction to normal atmosphere (radical quenching by atmospheric oxygen). The 
product was recovered through multiple separation steps: (i) removal of hexane by rotary 
evaporation, and (ii) multiple rinses with 100 % (v/v) ethanol to remove unconjugated FITC dye 
and surfactants, followed by multiple rinses with DI water to remove residual surfactants using 
an Amicon stirred cell fitted with a 300 kDa molecular weight cut-off filter. The final product 
was lyophilized and kept frozen at -20 °C until use. 
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Surface functionalizations of PAA nanocarriers 
Lyophilized FITC-labeled PAA-NCs (50 mg) were dissolved in 2.5 mL PBS buffer (pH 7.4) and 
sonicated until the solution turned transparent, to which 4 mg heterobifunctional PEG (SCM-
PEG-MAL) was then added and the mixture stirred continuously (~600 rpm) for 2 hours at room 
temperature. The reaction between the succinimidyl ester group of the PEG crosslinker and the 
primary amine groups on the surface of PAA-NCs yielded maleimidyl ester-terminated PEG-
conjugated PAA-NCs. Thereafter, the PEGylated PAA-NCs were washed three times with DI 
water by centrifugation using an Amicon centrifugal filter (Millipore, 100 kDa molecular weight 
cut-off) at 5000xg for 20 min. The procedure was repeated twice more with PBS buffer (pH 7.4). 
After washing to remove unbound PEG crosslinkers, the surface PEGylated PAA-NCs were 
reacted with 11 mg F3-Cys peptide in PBS buffer (pH 7.4) and the conjugation reaction allowed 
to run overnight at room temperature under continuous stirring at ~600 rpm. The reaction 
between the thiol group of the carboxy terminal Cys residue of the F3 peptide moieties and the 
maleimidyl ester termini of the PEG crosslinkers facilitated covalent coupling of the F3 peptide 
moieties to the PEG crosslinkers already conjugated to the PAA-NC surfaces. The F3 surface 
functionalized PEGylated PAA-NCs (F3NCs) were subsequently incubated with 1.74 mg L-
cysteine under continuous stirring for 2 hours at room temperature to cap any unreacted 
maleimidyl ester groups so as to prevent their reaction with cell surface thiols. Thereafter, the 
F3NCs were washed five times with PBS (pH 7.4) using an Amicon centrifugal filter (100 kDa 
molecular weight cut-off) at 4000xg for 20 minutes and the final volume adjusted to 5 mL with 
PBS (pH 7.4). The filtered nanocarriers were kept frozen at -20 °C until use. All steps were 
performed shielded from light. Note that the mass ratios of heterobifunctional PEG and F3 
peptide to PAA-NCs were optimized via cell-based assays as described in Chapter 2. 
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Synthesis of FITC-labeled F3 peptide 
Stock solutions of F3-Cys peptide (100 µg.µL-1 in 10 mM phosphate buffer, pH 8.0) and FITC 
(160 µg.µL-1 in DMSO) were initially prepared. Thereafter, 10 µL of the FITC stock was added 
to 390 µL of F3-Cys solution in a clean glass vial and sonicated for 5 minutes. The final volume 
of the sonicated solution was increased to 10 mL with 10 mM phosphate buffer (pH 8.0), and the 
conjugation reaction was allowed to proceed overnight with continuous stirring at 37 °C while 
shielded from light. The following day, the FITC-labeled F3 peptides were subjected to 15 
washes with a 3 kDa molecular weight cut-off Amicon centrifugal filter (4000xg for 20 minutes) 
to remove any unreacted FITC molecules. The filtered FITC-labeled F3 peptides were aliquoted 
and stored at -20 °C until further use. 
 
Nanocarrier sizing and morphology 
The size of the prepared F3NCs was determined via two different methods; scanning electron 
beam microscopy (SEM) and dynamic light scattering (DLS). Lyophilized F3NCs were 
dissolved in DI water to a final concentration of 0.2 mg.mL-1. A droplet of the NC solution was 
loaded onto a SEM stub, dried and subsequently coated with gold using a gold sputter coater. 
SEM imaging was performed using the FEI Nova NanoLab dualbeam SEM system. For all DLS 
sizing measurements, the lyophilized NCs were dissolved in DI water to a final concentration of 
1 mg.mL-1 and analyzed with a Beckman-Coulter Delsa Nano C particle analyzer. 
 
Nanocarrier zeta potential measurement  
Zeta potential measurements of unmodified PAA-NCs (without PEG or F3 peptide), PEGylated 
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PAA-NCs and the F3NCs were performed in order to determine their respective surface charges. 
All zeta potential measurements were performed on 1 mg.mL-1 solutions of each type of 
nanocarrier, prepared in DI water, using a Beckman-Coulter Delsa Nano C particle analyzer. All 
measurements were performed in triplicate.  
 
Cell culture  
Three different nucleolin-overexpressing tumor cell lines, 9L rat gliosarcoma, MDA-MB-435 
human ductal adenocarcinoma/ melanoma, and MCF-7 human breast adenocarcinoma were 
cultured aseptically at 37 °C under 5 % CO2 humidified atmosphere in either BD Falcon 
Primaria tissue culture dishes (100 mm x 20 mm) or Multiwell 6-well plates. The 9L and MCF-7 
cell lines were cultured in Rosewell Park Memorial Institute (RPMI) medium supplemented with 
10 % (v/v) heat inactivated fetal bovine serum (FBS) and MDA-MB-435 cell was cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10 % (v/v) FBS and 1 % 
(v/v) penicillin-streptomycin-glutamine (PSG). Cell cultures were passaged during exponential 
growth phase by incubating the cells with 0.05 % Trypsin-EDTA solution at 37 °C until the cells 
attained rounded morphology, followed by resuspension of the detached cells in their respective 
culture media, and sub-culturing into new sterile culture dishes or multiwell plates. All F3NC 
and unmodified PAA-NC suspensions were sterile filtered with a 0.2 µ syringe filter prior to use 
in all cell culture experiments. 
 
Endocytosis inhibition 
The internalization of FITC-labeled F3 peptides, FITC-labeled F3NCs and FITC-labeled 
unmodified PAA-NCs were studied separately in the MDA-MB-435 and 9L cell lines in the 
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presence of the endocytosis inhibitors chlorpromazine (CPZ; 10 µg.mL-1), genistein (GEN; 200 
µM) or cytochalasin D (CD; 50 µM), which block the clathrin-mediated, caveolae-mediated and 
macropinocytosis pathways respectively. These inhibitor concentrations were previously 
reported to inhibit the respective endocytic pathways in vitro.69,70 Furthermore, the in vitro 
cytotoxicity of these inhibitors were tested independently by MTT assay on both the 9L and 
MDA-MB-435 cell lines. Concentrations higher than the abovementioned values were avoided 
due to cell viability issues (Appendix A3.2). All inhibitors were dissolved in DMSO as 100-fold 
concentrated stocks and diluted to their final concentrations in culture medium. MDA-MB-435 
or 9L cells, cultured on Corning No.1½ circular glass coverslips, were incubated with either of 
the above inhibitors at their respective final concentrations for 30 minutes at 37 °C. Thereafter, 
either F3 peptides, F3NCs or unmodified (non-targeted) PAA-NCs were delivered to the cell 
cultures at a final concentration of 0.1 mg.mL-1 and incubated in the presence of the endocytic 
inhibitors for an additional 1 hour at 37 °C. Thereafter, the culture media containing endocytic 
inhibitors and unbound NCs were aspirated and the cells gently rinsed three times with fresh pre-
warmed culture media. The cells were then labeled with Lysotracker Red DND-99 fluorophore at 
a final concentration of 300 nM at 37 °C for 5 minutes and washed once more prior to confocal 
imaging. Confocal imaging was performed on an Olympus inverted confocal microscope and all 
images were acquired with a 100x oil immersion objective lens. The FITC and Lysotracker Red 
DND-99 fluorophores were sequentially excited with the 488 nm and 568 nm lines respectively. 
The effects of the endocytosis inhibitors on the uptake of the F3 peptides, NTNCs and F3NCs 
were measured directly from the respective confocal images using ImageJ v.1.46n software. 
Briefly, the FITC fluorescence emission intensities were measured only within regions of interest 
(ROI) drawn around individual cells in each image. These ROIs were drawn so as to exclude the 
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cell membrane, and thus any FITC fluorescence emissions from either F3 peptides or 
nanocarriers that were only attached to the cell membrane and had not yet been internalized. 
Uptake values for each inhibitor are represented as percentages of mean FITC fluorescence 
intensity relative to the mean of the corresponding control ±SD. 
 
Immunocytochemistry  
Immunocytochemical labeling of the membrane-bound Caveolin1, EEA1 and LAMP1 proteins 
was employed to study the intracellular trafficking of F3-targeted PEGylated and unmodified 
PAA-NCs in MDA-MB-435 cells. Cell monolayers, grown on Corning No.1½ circular glass 
coverslips, were treated with either unmodified PAA-NCs or F3NCs (final concentration of 0.1 
mg.mL-1) for 10, 30, 60, 120, 180 and 360 minutes respectively. Following treatment, the cells 
were rinsed briefly three times with warm GIBCO DPBS solution and fixed in 4 % (v/v) 
phosphate-buffered paraformaldehyde (10 mM PBS, pH 7.2) for 10 minutes at room 
temperature. Immediately following fixation, the cells were subjected to three 10-minute washes 
with 10 mM PBS (pH 7.2) with gentle agitation on a rocking-shaker. The cells were 
subsequently permeabilized in permeabilization buffer (0.05 % (v/v) Tween-20, 10 mM PBS, pH 
7.2) for 10-minutes at room temperature with gentle agitation on a rocking shaker, followed 
immediately by three washes with 10mM PBS (pH 7.2). The permeabilized cells were blocked 
overnight at 4°C in donkey serum buffer (10% (v/v) normal donkey serum; 0.05 % (v/v) Tween-
20; 0.05 % (w/v) sodium azide; 10 mM PBS pH 7.2). Following blocking, the cells were 
incubated in primary antibody labeling solution (either anti-EEA1 and anti-LAMP1 or anti-
Caveolin1 and anti-LAMP1 antibodies diluted 1:20 in primary antibody dilution buffer (1 % 
(v/v) normal donkey serum; 0.05 % (v/v) Tween-20; 0.05 % (w/v) sodium azide; 10 mM PBS 
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pH 7.2) at room temperature in a humidified chamber for 3 hours. Immediately following 
incubation, the coverslips were washed three times with PBS at room temperature (10 minutes 
per wash) to remove excess primary antibody. The secondary antibody incubation buffers were 
prepared by diluting the appropriate antibodies in a 1:500 ratio in secondary antibody dilution 
buffer (0.05 % (v/v) Tween-20; 0.05 % (w/v) sodium azide; 10 mM PBS pH 7.2). Incubation in 
secondary antibody labeling solution for 1 hour as described above for the primary antibody 
incubation. Following antibody labeling, the coverslips were washed three times with PBS at 
room temperature (10 minutes per wash) with gentle agitation on a rocking shaker. After the last 
wash, the coverslips were mounted (cell-surface down) onto glass slides with Dako Fluorescent 
Mounting Medium and stored overnight at 4 °C prior to fluorescence confocal imaging. Imaging 
was performed on an Olympus inverted confocal microscope and all images were acquired with 
a 100x oil immersion objective lens. The FITC, AF-568 and AF-647 fluorophores were 
sequentially excited with the 488 nm, 568 nm and 647 nm laser lines respectively.  
 
Colocalization Analyses 
All confocal images were subjected to fluorophore colocalization analysis in ImageJ v.1.64n 
software using the JACoP plugin.71 Briefly, colocalization analyses were performed on a cell-by-
cell basis by first drawing ROIs around individual cells in each native confocal image. Each 
image was then split into its component red, green and blue channels, and each ROI 
subsequently applied to the separated channels respectively. Thereafter, colocalization analyses 
between pairs of color channels (either green: FITC vs. red: Lysotracker Red/LAMP1-AF647 or 
green: FITC vs. blue: EEA1-AF568/ Caveolin1-AF568) for each ROI were then performed in 
JACoP using automatic thresholding for each channel. Manders’ M2 coefficients based on the 
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threshold settings were generated for each analysis, where the M2 coefficient is defined as the 
fraction of the green channel (FITC) overlapping either the blue channel (EEA1/ Caveolin1) or 
red channel (Lysotracker Red/LAMP1). Colocalization values for each condition are based on 
the mean M2 coefficients represented as percentages ±SD. 
 
Statistical Analyses 
The endocytosis inhibition and colocalization data for each cell line were statistically analyzed 
by One-Way ANOVA followed by Tukey’s multiple comparisons test using GraphPad Prism 
v6.00 software for Mac OSX. In instances where selected pairs of columns in a data set were 
compared against each other, Bonferroni’s multiple comparisons test was used in conjunction 
with the One-Way ANOVA test. All analyses were performed with a confidence interval set at 
95 %. P-values <0.05 were considered significant.  
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Appendix  
A3.1 Effect of Potassium Depletion on Subcellular Localization of F3 Peptide 
  
Figure A3.1 Effect of potassium depletion induced inhibition of clathrin-mediated endocytosis on the subcellular 
localization of F3 peptide in nucleolin-overexpressing 9L rat gliosarcoma and MDA-MB-435 human melanoma cell 
lines. As observed for 9L and MDA-MB-435 cells treated with Chlorpromazine, a pharmacological inhibitor of 
clathrin-mediated endocytosis (Figs. 3.1.1.c and 3.2.1.c), potassium-depletion promoted the accumulation of FITC-
labeled F3 peptide (green) within the nuclei of both 9L and MDA-MB-435 cells. In the control 9L and MDA-MB-
435 cells however, which were treated with potassium-supplemented HEPES buffer, F3 peptide was sequestered 
either in endosomes, or lysosomes (labeled with Lysotracker Red DND-99) as denoted by regions of yellow 
fluorescence.  
	   94	  
A3.2 Endocytic Inhibitor Cytotoxicity Assays 
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Figure A3.2.1-3.3.3 Cytotoxicity profiles of Cytochalasin D (CD), Chlorpromazine (CPZ) and Genistein (GEN), 
respectively, in the 9L and MDA-MB-435 cell lines, as determined by the Methylthiazol tetrazolium (MTT) 
microtiter assay. All drug incubations were performed for 90 minutes, at 37 °C, prior to delivery of the MTT reagent 
to the cells. This inhibitor incubation period was used for all subsequent endocytosis inhibition assays. Maximal 
concentrations of 50 µM, 10 µg.mL-1, and 200 µM, for CD, CPZ and GEN, respectively, were selected for the 
endocytosis inhibition assays. In the cases of CD and CPZ, concentrations higher than the abovementioned values 
were avoided for the endocytosis inhibition assays so as to limit cytotoxicity. Furthermore, concentrations higher 
than 50 µM CD adversely affected the morphology of both 9L and MDA-MB-435 cells. For GEN, concentrations 
higher than 200 µM enhanced the viability of both 9L and MDA-MB-435 cells, and were thus avoided, so as to 
prevent potential stimulation of the F3 peptide or nanoparticle uptake by other endocytic pathways in the presence of 
GEN. Interestingly, GEN reduced the viability of 9L cells up to 200 µM, but increased their viability, as well as that 
of the MDA-MB-435 cells, above that of the control cells (107% and 129% for 9L; 104% and 118% for MDA-MB-
435) at 250 and 300 µM respectively. A similar trend was reported for GEN in other cell lines.1 All values are 
represented as means of quadruplicate wells ± SD. 
	   96	  
Experimental Section 
Methylthiazol tetrazolium (MTT) Assay of Endocytic Inhibitor Cytotoxicity 
Suspensions of 9L and MDA-MB-435 cells, prepared in 10% FBS-supplemented RPMI-1640 
and DMEM 11965 media respectively, were seeded into the wells of separate Corning 96-well 
microtiter plates at approximately 10,000 cells per well, and allowed to attach to the wells for 24 
hours at 37 °C in 5% CO2 humidified atmosphere prior to initiating treatment with the endocytic 
inhibitors, Cytochalasin D (CD), Chlorpromazine (CPZ) and Genistein (GEN). All inhibitors 
were prepared in DMSO as 100-fold concentrated stocks, and tested in quadruplicate at the 
following final concentrations; CD: 5, 10, 25, 50, 75 and 100 µM; CPZ: 2.5, 5, 10, 15, 20 and 30 
µg/mL; GEN: 100, 150, 200, 250 and 300 µM. Importantly, all drugs were diluted to the above 
final concentrations in either RPMI-1640 or DMEM 11965 media such that all dilutions 
contained equal concentrations of DMSO, which did not exceed 1% v/v. At the start of the assay, 
all microtiter wells were aspirated of their original culture media and refilled with 200 µL of the 
appropriate culture medium containing either CD, CPZ or GEN at one of the above 
concentrations. The vehicle controls constituted 9L and MDA-MB-435 cells treated only with 1% 
v/v DMSO. The cell lines were then incubated with endocytic inhibitors for 90 min at 37 °C in 5% 
CO2 humidified atmosphere. At the end of incubation, all microtiter wells were aspirated of their 
culture media and replenished with 100 µL of either phenol red-free RPMI-1640 without FBS 
(for 9L cells) or phenol red-free DMEM culture media without FBS (for MDA-MB-435 cells). 
Thereafter, 20 µL of 5 mg/mL MTT stock solution (prepared in either phenol red-free RPMI or 
DMEM media) was added to each well and mixed, followed by further incubation for 4 hours at 
37 °C in 5% CO2 humidified atmosphere. At the end of incubation, the culture media were 
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carefully aspirated from all wells and the purple MTT formazan product in each well was 
solubilized by addition of 200 µL 100% DMSO solvent, followed by agitation on a rocking 
shaker overnight at room temperature. Absorbance readings were taken the following day at 550 
nm (620 nm reference).  
Potassium depletion Assay 
Suspensions of 9L and MDA-MB-435 cells, prepared in 10% FBS-supplemented RPMI-1640 
and DMEM 11965 media respectively, were seeded into the wells of 8-chambered No. 1 
microscopy coverglasses (MatTek Corporation) at approximately 25,000 cells per well and 
allowed to attach to the coverglasses for 24 hours at 37 °C in 5% CO2 humidified atmosphere 
prior to initiating the assay. At the start of the assay, all wells were aspirated of their culture 
media. Thereafter, the wells containing either 9L or MDA-MB-435 cells designated for 
potassium depletion were washed once with potassium-depletion buffer (20 mM HEPES, 140 
mM NaCl, 1 mM CaCl2, 1mM MgCl2, 1 mg/mL D-glucose) and incubated in hypotonic 
potassium depletion buffer (1:1 ratio of potassium depletion buffer: dH2O) for 5 minutes at 37 °C. 
Thereafter, the potassium-depletion wells were washed three times with potassium-depletion 
buffer, and the cells subsequently incubated with FITC-labeled F3 peptides (0.1 mg/mL) for a 
further 30 minutes at 37 °C in the same buffer. The control 9L and MDA-MB-435 cells were 
subjected to the same treatment protocol except with potassium-supplemented buffer (potassium 
depletion buffer supplemented with 10 mM KCl). At the end of the incubation, all cells were 
labeled with Lysotracker Red DND-99 (300 nM for 5 minutes at 37 °C). The potassium-
depletion and control wells were subsequently washed three times with their respective buffers to 
remove excess F3 peptides and Lysotracker Red DND-99. The potassium-depletion and control 
treatments were performed in triplicate for each cell line. The cells were imaged on an Olympus 
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inverted disc-spinning confocal microscope, equipped with an environmental chamber and 
Semrock BrightLine® Sedat filter set, using a 40x oil-immersion lens. The FITC and TRITC 
filters were used to excite the FITC-F3 peptides and Lysotracker Red DND-99 fluorophore 
respectively. 
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Chapter 4 
Modulation of MAPK signaling profiles by non-targeted and multivalent tumor-targeting 
hydrogel nanoparticles in breast adenocarcinoma 
 
4.1 Introduction 
Multifunctional nanoparticles (NP) form the basis of modern cancer-targeted nanoscale 
theranostics, and incorporate the potential for surface functionalizations with the capacity to 
carry a diverse range of molecular payloads for various therapeutic and diagnostic modalities.1,2 
Polymeric hydrogels, in particular, have been employed successfully as nanoscale theranostic 
agents.3,4 The physicochemical properties of a hydrogel NP, namely: size,5–7 morphology,8,9 
polymer elasticity,10 surface charge11–13 and surface chemical functionalizations14 collectively 
influence the pathway of internalization, and of subcellular localization of the NP within the 
tumor cell.15 In turn, this can directly influence the efficacy of chemotherapeutic drugs. 
Multivalent surface functionalization of hydrogel NPs with targeting moieties – specific toward a 
particular cell-surface receptor uniquely overexpressed on tumor cells – is exploited to enhance 
the hydrogel NP’s binding affinity for the target tumor cell, and promote receptor-mediated 
endocytosis of the targeted NP.16,17 Importantly, however, it cannot be assumed that the 
multivalent ligand-targeted hydrogel NP will undergo intracellular trafficking identical to that of 
the monovalent ligand alone, or the non-targeted NP, for that matter.  
We recently demonstrated that multivalent surface functionalization of polyacrylamide (PAA) 
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hydrogel NPs with the Nucleolin-binding F3wt peptide (wild-type sequence: 
KDEPQRRSARLSAKPAPPKPEPKPKKAPAKKC) modulates the intracellular trafficking, and 
the subcellular localization of the targeted PAA-NPs (F3wtNP), relative to the non-targeted PAA-
NPs (NTNPs), and to the monovalent F3wt peptide targeting ligand alone.14 Specifically, the 
F3wtNPs exhibited significantly lower trafficking to the lysosomes (acidic, degradative vesicles 
of the cell) than either the NTNPs, or the monovalent F3wt peptide alone, in Nucleolin-
overexpressing tumor cells (9L and MDA-MB-435). Furthermore, the F3wtNPs exhibited 
significantly lower colocalization with Caveolin-1 than the NTNPs, particularly at 2 and 3 hours 
after delivery of both types of PAA-NPs to MDA-MB-435 cells. The difference in intracellular 
trafficking of the F3wtNPs compared to the NTNPs was remarkable, given that the clathrin- and 
caveolae-mediated endocytic pathways predominantly facilitated internalization of both types of 
PAA-NPs. These observations suggested that the F3wtNPs and NTNPs likely elicit different cell 
signaling profiles that directly influence their mechanism of internalization and intracellular 
trafficking. 
In particular, the p38 Mitogen-Activated Protein Kinases (MAPKs) have been shown to 
enhance the rate of clathrin-mediated endocytosis by phosphorylating Early Endosomal Antigen 
1 (EEA1), a protein located in the membranes of early endosomes, specifically on residue 
Threonine-1392 (Thr/T-1392) (Fig. 4.1).18 EEA1 is essential for the mediating the homotypic 
fusion between different early endosomes,19 and Thr-1392-phosphorylation of EEA1 prevents 
such homotypic fusion. As a result, the early endosomes bearing Thr-1392-phosphorylated 
EEA1 rapidly mature into late endosomes. This process is further promoted by the exchange of 
Rab5 GTPase in the early endosome membranes with Rab7 GTPase,20 the latter of which 
catalyzes fusion of the late endosomes with lysosomes.21,22 In addition, the phosphorylation of 
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the N-terminus of Caveolin-1α at Tyrosine-14 (Tyr/Y-14), by the activated p38 MAPKs,23 has 
been shown to promote the scission of caveolae from the cell membrane, thus promoting their 
internalization from the cell surface (Fig. 4.1).24 Hence, the activation of the p38 MAPK pathway 
exerts a direct, and important regulatory role on both the clathrin- and caveolae-mediated 
endocytic pathways.  
Recent studies have demonstrated the potential of a broad range of nanomaterials to activate 
the p38, as well as the extracellular-regulated signal kinase (ERK) and c-Jun N-terminal kinase 
(JNK) MAPK pathways, upon interaction with cell surface receptors.25,26 However, a precise 
understanding of how a multivalent, ligand-functionalized hydrogel NP modulates the 
abovementioned MAPK pathways in target cells, relative to its non-targeted counterpart 
exhibiting similar size and surface charge properties, has been lacking to date. In the present 
Fig. 4.1 Schematic diagram depicting the mechanisms by which the activated (dual-phosphorylated) p38 MAPKs 
modulate intracellular trafficking via the caveolae-mediated (left) and clathrin-mediated (right) endocytic pathways, 
by directly phosphorylating Caveolin-1 at Tyrosine-14 (Tyr-14), and Early Endosome Antigen-1 (EEA1) at 
Threonine-1392 (Thr-1392), respectively. 
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study, we tested the hypothesis that the F3wtNPs induce lower levels of phosphorylated p38 
MAPKs than the NTNPs, as a plausible mechanism, by which the F3wtNPs exhibit markedly 
lower (i) lysosomal-accumulation, and (ii) colocalization with Caveolin-1, than the NTNPs, in 
MDA-MB-435 breast adenocarcinoma cells. Moreover, activation of the ERK pathway promotes 
cell survival and proliferation, which is antagonized by the p38 and JNK pathways, the latter two 
MAPKs being typically pro-apoptotic signaling phosphoproteins. Crucially, the ratio of 
phosphorylated ERK (p-ERK) to phosphorylated p38 (p-p38) has been shown to determine 
whether a cell proliferates, or undergoes apoptosis. We therefore performed a comprehensive 
phosphoproteomic analysis of the ERK, p38 and JNK MAPK pathways, including the Akt 
pathway (a mitogenic pathway), and their key downstream targets in MDA-MB-435 cells, so as 
to elucidate how each of the F3wtNPs, NTNPs, and the F3wt peptide, modulate the MAPK 
signaling profile of the tumor cells. Furthermore, we discuss the implications of the distinct 
signaling profiles, elicited by these different treatments, on the survival status of the tumor cell, 
as well as present plausible mechanisms by which each of these signaling profiles is induced.  
 
4.2 Results and Discussion 
4.2.1 Phospho-p38α  MAPK ELISA 
Four isoforms of p38 MAPK, p38α, p38β, p38γ and  p38δ, are expressed in human tissue. In 
all p38 isoforms, dual phosphorylation of the Threonine (Thr/T) 180 and Tyrosine (Tyr/Y) 182 
residues (pT180/pY182) in the Thr-Gly-Tyr motif of the activation loop, by the upstream MAP 
kinase kinases (MAP2Ks) MKK3 and MKK6, is required for complete activation.27 Since the 
role of the p38α isoform in phosphorylating EEA1 at Thr-1392 has been well characterized,18 we 
initially determined the phosphorylation status of p38α in MDA-MB-435 cells, by phospho-
	   103	  
Fig. 4.2 Time-dependent change in concentration of phosphorylated p38α MAPK (pT180/pY182) in MDA-MB-435 
cells in response to treatment with (4.2a) F3wt peptide (0.22 mg/mL), NTNPs (1 mg/mL), F3wtNPs (1 mg/mL), and 
(4.2b) Anisomycin (10 µg/mL), a potent inducer of p38 MAPK phosphorylation. Histograms represent means ± 
standard deviations of two experiments. P-values denote: P<0.05 (*), P<0.01 (**), P<0.001 (***), P<0.0001 
(****). Black brackets denote significant difference between different treatments at a specific time-point. Orange 
brackets denote significant difference between the untreated control and different treatments. Columns bearing 
identical numbers of similarly colored asterisks are significantly different from each other (4.2a). Purple brackets 
denote significant difference between consecutive Anisomycin treatments of different durations (4.2b). 
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p38α sandwich ELISA, in response to either (i) F3wt peptide alone (0.22 mg/mL), (ii) NTNPs  (1 
mg/mL) or (iii) F3wtNPs (1 mg/mL), relative to the control (untreated) MDA-MB-435 cells (Fig. 
4.2a). The F3wt peptide and the F3wtNPs treatments induced gradual time-dependent up-
regulation in the phosphorylated p38α (p-p38α) concentration, with maxima occurring at 1 hour 
and 2 hours post-delivery, respectively, followed by marked down-regulation in p-
p38α concentrations at 3 hours post-delivery for both treatments (P<0.001, 2-hour vs. 3-hour p-
p38α concentrations for both F3wt peptide and F3wtNPs). In contrast, the NTNPs elicited a 
steeper up-regulation in p-p38α phosphorylation, achieving maximal p-p38α concentration at 2 
hours post-delivery, followed also by a marked down-regulation at 3 hours post-delivery (P<0.01, 
2-hour vs. 3-hour concentrations). Notably, significant differences between all three treatments 
(F3wt peptide alone, NTNPs and F3wtNPs) were observed only at 2-hours post-delivery; the 
NTNP-induced p-p38α concentration at this time-point was 1.67-fold and 1.32-fold higher than 
in the F3wt peptide, and F3wtNPs treatments, respectively (P<0.01), while the F3wtNP-induced p-
p38α concentration was 1.27-fold greater than for the F3wt peptide alone treatment (P<0.05) (Fig. 
4.2a). Furthermore, the p-p38α concentrations in all three treatments were significantly higher 
than the untreated control only at 2-hours; the F3wt peptide, NTNP and F3wtNPs treatments 
induced 1.30-fold, 2.17-fold and 1.65-fold higher p-p38α concentrations, respectively, than in 
the control (Fig. 4.2a). We also confirmed the activity of the p38 pathway in MDA-MB-435 cells 
with Anisomycin (10 µg/mL), a known potent activator of p38 MAPKs (Fig. 4.2b). The p38 
pathway in MDA-MB-435 cells is indeed responsive to external stimuli with Anisomycin being 
a clearly more potent activator of p38α than the F3wt peptide, NTNPs and F3wtNPs. Nonetheless, 
all treatments only transiently activated p38α, which is consistent with the deactivation of 
phosphorylated p38 MAPKs by phosphatase enzymes, such as PP2C (Ser/Thr phosphatase).28,29 
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In our previous intracellular trafficking study in MDA-MB-435 cells, the F3wt peptide and 
NTNPs exhibited 6.4-fold and 3.3-fold higher colocalization with Lysotracker Red (a lysosome-
specific fluorophore), respectively, than the F3wtNPs,14 which cannot be explained solely by the 
respective p38α phosphorylation profiles of the F3wt peptide, NTNPs and F3wtNPs as observed 
in this study. Thus, our previously reported intracellular trafficking data of the F3wt peptide, 
NTNPs and F3wtNPs, taken into account with their corresponding p38α phosphorylation profiles, 
led us to consider the possibility of the p38β, p38γ and/or p38δ isoforms being more influential 
than the p38α isoform alone, on the intracellular trafficking of the F3wt peptide, NTNPs and 
F3wtNPs.  
 
4.2.2.1 Phosphoproteomic Arrays (p38 MAPK Pathway) 
Using MAPK phosphoproteomic arrays with pre-selected phospho-specific antibodies (Appendix 
A4.2), we then determined the phosphorylation status of all four p38 isoforms, including 20 
other signaling proteins belonging to the ERK, JNK and Akt pathways, in response to either the 
F3wt peptide alone, NTNPs, or F3wtNPs (Appendix A4.2). In addition, the phosphorylation 
profiles of these proteins were determined in response to treatment with scrambled-F3NPs 
(F3scramNPs; PAA-NPs surface functionalized with the scrambled-F3 sequence, 
PKAARALPSQRSRPPEKAKKPPDKPAPEKKKC) as a further control to the F3wtNPs. Notably, 
the F3scramNPs share similar physicochemical characteristics with the F3wtNPs in terms of 
hydrodynamic radius, and surface charge (NP hydrodynamic radius and zeta potential 
characterizations presented in Appendix A4.1). More crucially, however, the F3scramNPs also 
mimicked the surface chemical properties (multivalency) of the F3wtNPs, as their surfaces were  
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Fig. 4.3a Complete phosphoproteomic profiles of Akt, ERK, p38 and JNK pathway signaling proteins isolated from 
MDA-MD-435 cells treated with F3wt peptide, NTNPs, F3wtNPs and F3scramNPs for 2 hours. Notably, Akt1, Akt2, 
Akt pan, Glycogen Synthase Kinase (GSK)-3α/β, GSK-3β, ERK2, and p38γ exhibited markedly higher basal 
phosphorylation levels than the other kinases. All treatments were repeated three times, and protein isolates from all 
three replicates of a specific treatment were pooled and probed on separate Phospho-Proteome MAPK array 
membranes. Histograms represent means ± standard deviations obtained from measurements of duplicate spots for 
each protein probed on the array membrane (See Appendix Fig. A4.2). 
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Fig. 4.3b Partial phosphoproteomic profiles of Akt, ERK, p38 and JNK pathway signaling proteins isolated from 
MDA-MD-435 cells treated with F3wt peptide, NTNPs, F3wtNPs and F3scramNPs treated for 2 hours. Notably, Akt1, 
Akt2, Akt pan, Glycogen Synthase Kinase (GSK)-3α/β, GSK-3β, ERK2, and p38γ exhibited markedly higher basal 
phosphorylation levels than the other kinases. Hence, a partial phosphoproteomic profile of the Akt, ERK, p38 and 
JNK pathways from which signals for Akt1, Akt2, Akt pan, GSK-3α/β, GSK-3β, ERK2, and p38γ have been 
omitted so as to clearly illustrate the profiles of the kinases that exhibited lower levels of phosphorylation. 
Histograms represent means ± standard deviations obtained from measurements of duplicate spots for each protein 
probed on the array membrane (See Appendix Fig. A4.2). 
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functionalized with flexible polyethylene glycol (PEG) molecules, to which multiple peptides 
that bear identical amino acid composition, and charge to the F3wt peptides, albeit without 
binding specificity toward the Nucleolin receptors, were conjugated. All treatments were 
performed at the optimal duration of 2-hours, as determined by phospho-p38α sandwich ELISA 
(Fig. 4.2a). Of the four p38 isoforms, p38γ (pT183/pY185) exhibited the highest basal 
phosphorylation level in the untreated control (average of 13.07-fold higher than basal p-p38α, β 
and δ isoforms) which, however, did not vary significantly from the basal phosphorylation level 
in response to any of the different treatments (Figs. 4.3a, Table 4.1, Appendix A4.3.2). In 
contrast, the various treatments elicited more pronounced differences in the p-p38β 
(pT180/pY182) and p-p38δ (pT180/pY182) levels, as compared to the p-p38α isoform (Fig. 4.3b, 
Table 4.1). In ascending order, the p-p38β, and p-p38δ levels were up-regulated, relative to the 
untreated control, as follows, (i) F3wtNPs: 1.53-fold for both p38β and p38δ isoforms, (ii) 
F3scramNPs: 1.79-fold and 1.81-fold respectively, (iii) F3wt peptide: 2.29-fold and 2.96-fold 
respectively, and (iv) NTNPs: 3.01-fold and 3.27-fold respectively (Table 4.1). In this assay, the 
up-regulation in p-p38α levels by the F3wt peptide (1.99-fold) and F3wtNPs (1.94-fold) were 
nearly identical, while the NTNPs and F3scramNPs induced 2.46-fold and 2.61-fold increases in p-
p38α levels, respectively (Fig. 4.3b, Table 4.1). Although the array-derived fold-enhancements 
in p-p38α levels were higher than that observed in the p-p38α ELISA assay for the 
corresponding treatments, the ratio of p-p38α level enhancements particularly between the 
NTNPs and F3wtNPs, essentially remained unchanged (~1.30-fold). Notably, the absolute p-
p38α, β and δ levels induced by the F3wtNPs were reasonably consistent (Fig. 4.3b), however the 
F3wt peptides alone, and NTNPs elicited markedly higher p-p38β and p-p38δ levels as compared 
to their corresponding p-p38α levels (Fig. 4.3b). Also, the F3scramNPs elicited consistently higher 
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p-p38α, β and δ levels than the F3wtNPs. The possible reason for this observation will be 
discussed further on.  
 
 
 
Table 4.1 Summary of the fold changes in the phosphorylation levels of the MAP2K phosphoproteins, 
MKK3 and MKK6, and the phosphorylation levels of the downstream p38α, β, δ and γ MAPK 
isoforms, elicited by the various treatments relative to the untreated control 
Phosphoprotein/ 
Phosphorylation sites 
detected 
Untreated 
Control F3wt Peptide NTNPs F3wtNPs F3scramNPs 
MKK3 (pS218/pT222) 1.00 3.53 5.80 1.92 3.90 
MKK6 (pS207/pT211) 1.00 2.90 2.52 1.73 1.31 
p38α  (pT180/pY182) 1.00 1.99 2.46 1.94 2.61 
p38β  (pT180/pY182) 1.00 2.29 3.01 1.53 1.79 
p38δ  (pT180/pY182) 1.00 2.96 3.27 1.53 1.81 
p38γ  (pT183/pY185) 1.00 1.03 1.03 1.03 1.01 
 
 
Table 4.2 Summary of the correlation strength between the phosphorylation levels of the MAP2K 
phosphoproteins, MKK3 and MKK6, and the phosphorylation levels of the p38α, β, and δ MAPK 
isoforms 
Phosphorylated MAP2K vs. 
Phosphorylated p38 MAPK Correlation Strength (Linear correlation coefficient (R
2)) 
pMKK3 vs. p-p38α  0.691 
pMKK3 vs. p-p38β  0.897 
pMKK3 vs. p-p38δ  0.764 
pMKK6 vs. p-p38α  0.165 
pMKK6 vs. p-p38β  0.675 
pMKK6 vs. p-p38δ  0.843 
Average p-MKK3/6 vs. p-p38α  0.449 
Average p-MKK3/6 vs. p-p38β  0.953 
Average p-MKK3/6 vs. p-p38δ  0.991 
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The phosphorylation levels of the upstream MAP2K enzyme MKK3 exhibited stronger linear 
correlations than MKK6 with the p-p38α (R2 coefficient: 0.691) and p-p38β (R2 coefficient: 
0.897) levels (Table 4.2, Appendix A4.4.1), whereas the phosphorylation levels of MKK6 
correlated better than MKK3 with p-p38δ levels (R2 coefficient: 0.843; Table 4.2, Appendix 
A4.4.1). Overall, strong linear correlations were observed between the average MKK3/6 
phosphorylation levels, and the p-p38β (R2 coefficient: 0.953) and p-p38δ (R2 coefficient: 0.991) 
levels (Table 4.2, Appendix A4.4.2), however the correlation between the average MKK3/6 
phosphorylation levels and the p-p38α levels was weaker (R2 coefficient: 0.449; Table 4.2, 
Appendix A4.4.2). Given that the MKK3 and MKK6 enzymes lie directly upstream of the p38 
isoforms in the p38 MAPK signaling cascade, these data suggest that the signals generated by the 
F3wt peptide, NTNP, F3wtNPs and F3scramNPs treatments are channeled by MKK3 and MKK6 
preferentially to the p38β and p38δ isoforms, in MDA-MB-435 cells. However, of these two p38 
isoforms, it is likely that p38β predominantly phosphorylates EEA1 at its Thr-1392 residue. This 
is supported by, (i) the observation that the p38β isoform, in addition to p38α, is responsible for 
phosphorylating EEA1 at its Thr-1392 residue,18 and (ii) the p38δ isoform likely having lower 
substrate specificity for EEA1 at the location of the Thr-1392 residue. The latter point can be 
explained by the fact that the p38β isoform has 75% amino acid sequence identity to the 
p38α isoform, while the p38δ isoform has only 61% sequence identity to the p38α isoform.30  
In our previously reported intracellular trafficking study with our NTNPs and F3wtNPs in 
MDA-MB-435 cells, the NTNPs and F3wtNPs both achieved similar peak colocalization levels 
with EEA1-positive endosomes (~32%) at 30 minutes post-delivery, however the NTNPs 
exhibited a significantly sharper decrease in EEA1-colocalization at 60 minutes than the 
F3wtNPs.14 This was further accompanied by a significant, sharp increase in colocalization 
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Fig. 4.4 Schematic summary of the endocytic pathways of internalization for F3wt peptide, non-targeted and F3wt-
targeted PAA nanoparticles (NTNPs and F3wtNPs), and their activation of the p38 MAPK pathway in the nucleolin-
overexpressing MDA-MB-435 cell line. The F3wtNPs are predominantly internalized via the clathrin-mediated 
endocytic pathway, denoted by the potent inhibition of their internalization by Chlorpromazine (CPZ). The F3wtNPs 
accumulated within vesicles devoid of LAMP1 protein (Lysosome-Associated Membrane Protein 1) in the 
perinuclear space. The caveolae-mediated and macropinocytosis endocytic pathways also contribute to the 
internalization of the F3wtNPs, but to a lesser extent than the clathrin-mediated pathway. The clathrin-mediated and 
caveolae-mediated endocytic pathways contribute approximately equally to the internalization of the NTNPs, while 
macropinocytosis mediates their internalization to a lesser extent. Notably, the NTNPs co-internalize with LAMP-1 
proteins from the cell surface following which they are trafficked to lysosomes, as denoted by the intense 
colocalization between the NTNPs and LAMP1 proteins (~50%) compared to the significantly lower colocalization 
between the F3wtNPs and LAMP1 (8%). Furthermore, the F3wt peptide, and NTNPs more potently activated the 
p38β and p38δ MAPK isoforms than the F3wtNPs. Activated p38 MAPKs phosphorylate Early Endosomal Antigen1 
(EEA1), located in early endosomes, at Thr-1392, which abrogates the ability of EEA1 to mediate homotypic fusion 
of early endosomes. Hence, the F3wt peptide-laden and NTNP-laden EEA1-postive, early endosomes rapidly mature 
into late endosomes and fuse with lysosomes (LAMP-1 positive). In contrast, the F3wtNPs exhibited slower egress 
from the EEA1-positive early endosomes, and lower colocalization with LAMP1-positive lysosomes. In addition, 
the activated p38 MAPKs phosphorylate Caveolin-1 at Tyr-14, which promotes the scission of caveolae from the 
cell membrane, and their subsequent internalization. While both the NTNPs and F3wtNPs exhibited peak p38 MAPK 
activation at 2 hours post-delivery, the greater activation of the p38 MAPKs elicited by the NTNPs correlates with 
the higher colocalization, and internalization of the NTNPs with Caveolin-1 at 2 hours post-delivery than the 
F3wtNPs. 
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between the NTNPs and Lysosome-Associated Membrane Protein-1 (LAMP1) from ~20% at 30 
minutes post-delivery, to ~45% colocalization at 60 minutes post-delivery, whereas the F3wtNPs-
LAMP1 colocalization levels remained fairly constant (~8%) at 30 and 60 minutes post-
delivery.14 This suggested that at 60 minutes post-delivery the NTNPs, but not the F3wtNPs, were 
rapidly trafficked out of the EEA1-positive endosomes, and into the LAMP1-positive lysosomes. 
Hence, the intracellular trafficking profiles of the NTNPs and F3wtNPs also correlate well with 
their p-p38α ELISA profiles in that, of the NTNPs and F3wtNPs, only the NTNPs induced a 
significant increase in the p-p38α concentration, from the 30 minute to 60 minute treatment time 
points (Fig. 4.2a). Although we did not perform time-dependent phosphorylation response assays 
for the p38β and p38δ isoforms, it is reasonable to deduce that these isoforms follow a similar 
phosphorylation trend to that of the p38α isoform. It has been established that activated p38 
MAPKs can be recruited to early endosomes, and subsequently suppress the ability of EEA1 to 
catalyze homotypic fusion of early endosomes via phosphorylation of its Thr-1392 residue. We 
therefore present compelling evidence that the faster trafficking of the NTNPs out of the EEA1-
positive early endosomes, with their concomitantly higher accumulation within the LAMP1-
positive lysosomes, in MDA-MB-435 cells, can be attributed to the greater stimulation of p38 
MAPK phosphorylation by the NTNPs than the F3wtNPs.  
Also, as previously reported by our group, the NTNPs and F3wtNPs both reached peak 
colocalization with Caveolin-1 at 2 hours post-delivery, followed by subsequent decreases in 
colocalization for both types of PAA-NPs, at 3 hours post-delivery, and onward.14 However, 
only at 2 hours and 3 hours post-delivery did we observe that the degree of NTNP-Caveolin-1 
colocalization (28.47 ± 9.43(2hr) and 21.95 ± 4.97(3hr)) was significantly higher than the degree of 
F3wtNP-Caveolin-1 colocalization (14.50 ± 3.94(2hr) and 8.25 ± 2.93(3hr)). It has already been 
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established that the activated p38 MAPKs mediate Tyr-14-phosphorylation of Caveolin-1, a 
critical requirement for the internalization of caveolae from the cell surface (Fig. 4.1).23,24 These 
trends in NTNP-Caveolin-1, and F3wtNP-Caveolin-1 colocalization indeed correlate with the 
trends in p38 MAPK phosphorylation (activation) elicited by the NTNPs and F3wtNPs, 
respectively (Figs. 4.2a and 4.3b), i.e., NTNP-Caveolin-1 colocalization was ~2-fold greater than 
F3wtNP-Caveolin-1 colocalization at 2 hours post-delivery, and at the same time-point, the 
NTNPs induced ~2-fold greater phosphorylation levels of p38β and p38δ than the F3wtNPs (Fig. 
4.3b, Table 4.1). Hence, our p38 MAPK data provide a compelling signaling mechanism to 
support our prior observation that, despite both the NTNPs and F3wtNPs reaching peak 
colocalization with Caveolin-1 only 2 hours after delivery to the MDA-MB-435 cells, the 
NTNPs exhibited ~2-fold higher colocalization with Caveolin-1 than the F3wtNPs. We present a 
revised schematic diagram that integrates the internalization, and intracellular trafficking of the 
F3wt peptide, NTNPs and F3wtNPs of our previous study, with the cell signaling data presented in 
this study (Fig. 4.4).  
 
Table 4.3 Summary of the fold changes in phosphorylation levels of the p38α, β, γ and δ isoforms, and 
phosphorylation levels of their downstream targets, the Heat Shock Protein (Hsp) 27 and tumor-
suppressor protein p53, elicited by the various treatments relative to the untreated control 
Phosphoprotein/ 
Phosphorylation sites 
detected 
Untreated 
Control F3wt Peptide NTNPs F3wtNPs F3scramNPs 
p38α  (pT180/pY182) 1.00 1.99 2.46 1.94 2.61 
p38β  (pT180/pY182) 1.00 2.29 3.01 1.53 1.79 
p38δ  (pT180/pY182) 1.00 2.96 3.27 1.53 1.81 
p38γ  (pT183/pY185) 1.00 1.03 1.03 1.03 1.01 
p53 (pS46) 1.00 18.52 25.77 10.10 23.42 
Hsp27 (pS78/pS82) 1.00 1.84 2.28 1.46 1.67 
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The phosphorylation levels of two key target proteins of the p38 MAPKs, (i) tumor 
suppressor protein p53, phosphorylated at serine 46 (p53pS46),31 and (ii) Heat Shock Protein 27, 
phosphorylated at serine 78 and serine 82 (Hsp27pS78/pS82),32 were also assayed in the 
phosphoproteomic array (Fig. 4.3b, Table 4.3). Ser-46-phosphorylation of p53 promotes its 
transcription of several pro-apoptotic genes, which ultimately leads to apoptotic cell death (Fig. 
4.5).33 Hsp27, only when in its oligomeric high molecular weight state, inhibits apoptosis by 
interacting directly with cytochrome c, thus preventing formation of the apoptosome.34 Ser-
78/Ser-82-phosphorylation of Hsp27 promotes disassembly of Hsp27 oligomers, thus impairing 
its ability to prevent initiation of apoptosis (Fig. 4.5).35 Hence, p38-mediated phosphorylation of 
both p53 and Hsp27 proteins, at their respective serine residues, shifts the cell toward a pro-
apoptotic state (Fig. 4.5). Importantly, the trends in the enhancement of the phosphorylated p38β 
and p38δ levels were also reflected in the enhancement of the phosphorylated Hsp27 
Fig. 4.5 Schematic diagram depicting the mechanisms by which activated p38 MAPKs promote apoptotic cell death 
by directly phosphorylating the p53 tumor suppressor, and Heat Shock Protein (Hsp) 27 proteins at specific Serine 
residues on the respective proteins. 
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(Hsp27pS78/pS82) levels (Fig. 4.3b, Table 4.3), i.e., the order of Hsp27pS78/pS82 enhancement was: 
Untreated Control < F3wtNPs < F3scramNPs < F3wt peptide < NTNPs. The order of enhancement 
in the phosphorylated p53 (p53pS46) levels was however slightly different: Untreated Control < 
F3wtNPs < F3wt peptide < F3scramNPs < NTNPs (Fig. 4.3b, Table 4.3). It is interesting to note that 
despite the absolute levels of p53pS46 being markedly lower than the absolute levels of 
Hsp27pS78/pS82 across all treatments, the greatest fold-increases in phosphorylation levels, relative 
to the untreated control, were observed for p53 (Table 4.3). Nonetheless, it is evident that the 
higher enhancements in p-p38β and p-p38δ levels elicited by the F3wt peptide, NTNPs and 
F3scramNPs, translated into higher Hsp27pS78/pS82 and p53pS46 levels than those observed for the 
F3wtNPs treatment. 
 
 
4.2.2.2 Phosphoproteomic Arrays (JNK MAPK Pathway) 
It is particularly interesting that the trend in enhancement of phosphorylated p-JNK1 
(pT183/pY185) and p-JNK3 (pT221/pY223) levels were not only similar to each other, despite 
having different phosphorylation sites, but also similar to that of the p38β and p38δ isoforms 
(Fig. 4.3b, Appendix A4.3.2). The enhancement in p-JNK1/3 levels was as follows: Untreated 
control < F3wtNPs < F3scramNPs < F3wt peptide < NTNPs; albeit, only small differences in p-
JNK1/3 levels between the F3wtNPs and F3scramNPs treatments, as well as between the F3wt 
peptide and NTNPs treatments were observed (Table 4.4). The phosphorylation profile for p-
JNK2 (pT183/pY185), however, deviated from this trend; F3wt peptide induced the highest p-
JNK2 level (1.89-fold), while the NTNPs and F3wtNPs induced similar p-JNK2 levels (1.56- and 
1.52-fold, respectively), while p-JNK2 remained at basal levels in the F3scramNPs treatment (Fig.  
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4.3b, Table 4.4). Although the absolute levels of p-JNK2 were markedly higher than the p-JNK1 
and p-JNK3 levels in the corresponding treatments, the greatest enhancements were observed for 
p-JNK1 and p-JNK3 (Table 4.4, Appendix 4.3.2).  
Nonetheless, the similarity between the p-p38β/δ and p-JNK1/3 phosphorylation profiles is 
not surprising since most stimuli that activate the p38 MAPKs typically also activate the JNK 
MAPKs. This is due to the p38 MAPKs and JNK MAPKs, along with their respective upstream 
MAP3K and MAP2K proteins, being assembled on common scaffold proteins, known as JNK-
interacting proteins (JIP) (Fig. 4.9).36 The MAP2K enzymes that directly phosphorylate the 
JNK1-3 MAPKs are the MKK4 and MKK7 phosphoproteins. Of the four characterized JIP 
scaffolds, JIP1, JIP2, JIP3 and JLP, the JIP1 and JIP2 bind only MKK7, the JLP binds only 
MKK4, while the JIP3 binds both MKK4 and MKK7. JLP binds only JNK1, while JIP1-3 bind 
all JNK MAPK isoforms. Furthermore, only JIP2 and JIP4 serve as scaffolds for assembling the 
p38 MAPKs, and their upstream MAP2K enzymes MKK3 (JIP1 and JLP) and MKK6 (JLP only). 
In addition, all JIPs can form homo-oligomers, while JIP2 can hetero-oligomerize with JIP1 and 
JIP3,36 thus facilitating integration of extracellular signals into the p38 and JNK MAPK 
pathways. We were, however, unable to determine the phosphorylation levels of MKK4 and 
Table 4.4 Summary of the fold changes in phosphorylation levels of the JNK1, JNK2, and JNK3 
isoforms, elicited by the various treatments relative to the untreated control. The JNK pan represents 
the average phosphorylation level of the JNK1, 2, and 3 isoforms collectively. 
Phosphoprotein/ 
Phosphorylation sites 
detected 
Untreated 
Control F3wt Peptide NTNPs F3wtNPs F3scramNPs 
JNK1 (pT183/pY185) 1.00 3.91 4.23 2.39 2.90 
JNK2 (pT183/pY185) 1.00 1.89 1.56 1.52 1.03 
JNK3 (pT221/pY223) 1.00 3.44 3.84 1.87 2.43 
JNK pan  
(pT183/pY185/pT221/pY223) 1.00 1.50 1.27 1.33 0.85 
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MKK7, due to the exclusion of the phospho-specific antibodies for these proteins from the 
phosphoproteomic arrays used in this study, which would otherwise have provided further 
insight into the phosphorylation profiles of the JNK1-3 MAPKs. In addition, the tumor 
suppressor protein p53 is also a direct target of the JNK MAPKs. However, the JNK MAPKs 
phosphorylate p53 at Thr-81 (p53pT81),37 as opposed to Ser-46, the residue phosphorylated by the 
p38 MAPKs. Thr-81 phosphorylation stabilizes p53, thereby promoting its transcriptional 
activities, and ability to induce apoptosis.37 Thus, Ser-46 and Thr-81 phosphorylation of p53 by 
the p38 and JNK MAPKs, respectively, act cooperatively in stabilizing p53, and promoting its 
transcriptional activity to induce apoptotic cell death. Although we were unable to determine the 
levels of p53pT81 in this phosphoproteomic array, it is reasonable to postulate that the trend in 
enhancement of p53pT81 levels would be similar to that of p53pS46, given the strong similarity 
between the p-p38β/δ and p-JNK1/3 enhancement profiles.  
 
 
4.2.2.3 Phosphoproteomic Arrays (ERK MAPK Pathway) 
In contrast to the p38 and JNK MAPK pathways, the ERK MAPK pathway promotes cell 
survival and proliferation. The basal phosphorylated p-ERK2 (pT185/pY187) levels were ~24-
fold greater than basal phosphorylated p-ERK1 (pT202/pY204) levels (Fig. 4.3a). However, the 
p-ERK2 levels essentially remained unchanged even after MDA-MB-435 cells were subjected to 
the various treatments (Fig. 4.3a, Table 4.5, Appendix A4.3.2), whereas the p-ERK1 levels 
elicited by the various treatments were significantly different from each other, and the untreated 
control (Fig. 4.3b, Table 4.5, Appendix A4.3.2). Most notably, the NTNPs and F3scramNPs 
treatments both down-regulated p-ERK1 levels relative to the untreated control (0.80-fold and  
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Table 4.5 Summary of the fold changes in phosphorylation levels of the ERK1 and ERK2 MAPK 
phosphoproteins, and phosphorylation levels of their downstream targets, MSK2, RSK1, RSK2 and 
CREB, elicited by the various treatments relative to the untreated control.  
Phosphoprotein/ 
Phosphorylation sites 
detected 
Untreated 
Control F3wt Peptide NTNPs F3wtNPs F3scramNPs 
ERK1 (pT202/pY204) 1.00 1.92 0.80 1.68 0.44 
ERK2 (pT185/pY187) 1.00 1.00 1.00 1.00 1.01 
MSK2 (pS360) 1.00 2.22 2.24 1.61 1.20 
RSK1 (pS380) 1.00 1.11 1.09 1.09 1.07 
RSK2 (pS386) 1.00 2.52 2.97 1.72 1.57 
CREB (pS133) 1.00 0.93 0.86 1.00 0.65 
Fig. 4.6 Schematic diagram depicting the mechanism by which phosphorylated (activated) ERK MAPKs promote 
cell survival through direct phosphorylation of the RSK1, RSK2 and MSK2 proteins, which in turn phosphorylate 
and activate the transcriptional activator protein, CREB, at its Ser-133 residue. ERK1/2 directly phosphorylate 
and activate RSK1 and RSK2 at Thr-573 and Thr-577, respectively, located in the activation loops of their C-
terminal kinase domains. The phosphorylated C-terminal kinase domains of RSK1 and RSK2 in turn auto-
phosphorylate their hydrophobic motifs at Ser-380 and Ser-386, respectively. Phosphorylated residues detected on 
the various phosphoproteins in this study are highlighted in blue text. 
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0.40-fold, respectively), while the F3wt peptide and F3wtNPs up-regulated p-ERK1 levels relative 
to the untreated control (1.92-fold and 1.68-fold, respectively) (Fig. 4.3b, Table 4.5, Appendix 
A4.3.2). The phosphorylation status of the ERK1/2-target proteins, MSK2 (mitogen- and stress-
activated kinase 2), RSK 1 and RSK2  (p90 ribosomal S6 kinases 1 and 2), and the further 
downstream target CREB (cAMP response element-binding protein) were also determined in this 
phosphoproteomic array (Fig. 4.6). MSK2 is potently activated in vivo by ERK1/2 and p38, but 
not by JNK1-3, by direct phosphorylation of Ser-360 located in its turn motif,38 which was 
detected in this assay (Fig. 4.6). Both the F3wt peptide and NTNPs elicited essentially similar 
enhancements in Ser-360-phosphorylated MSK2 (MSK2pS360) (2.22-fold and 2.24-fold 
respectively), followed by the F3wtNPs (1.61-fold) and F3scramNPs (1.20-fold) (Fig. 4.3b, Table 
4.5, Appendix 4.3.2).  
RSK1 and RSK2, however, are activated only by ERK1/2 by direct phosphorylation of their 
Thr-573 and Thr-577 residues, respectively (located in the activation loop of their C-terminal 
kinase domains), which in turn auto-phosphorylate their hydrophobic motifs at Ser-380 and Ser-
386, respectively (Fig. 4.6).39,40 Only the Ser380- and Ser386-phosphorylated sites of RSK1 and 
RSK2, respectively, were detected in this phosphoproteomic array (Fig. 4.6). All treatments 
enhanced the levels of Ser-380-phosphorylated RSK1 (RSK1pS380), however there were only 
marginal differences in the RSK1pS380 levels between the different treatments (Fig. 4.3b, Table 
4.5, Appendix A4.3.2). Although basal RSK1pS380 levels were ~8-fold higher than Ser-386-
phosphorylated RSK2 (RSK2pS386) levels, there were distinct differences in the RSK2pS386 levels 
between the different treatments (Fig. 4.3b, Table 4.5, Appendix A4.3.2). Surprisingly, the 
NTNPs, which down-regulated pERK1 levels (0.80-fold relative to untreated control), induced 
the highest RSK2pS386 levels of all the treatments (2.97-fold), followed by the F3wt peptide (2.52-
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fold), the F3wtNPs (1.72-fold) and F3scramNPs (1.57-fold). It is important to note however, that 
additional sites in the activation loop and N-terminal kinase domains of RSK1 and RSK2 also 
require phosphorylation for these kinases to achieve full activation.41,42 Hence, the RSK1pS380 
and RSK2pS386 phosphorylation levels alone are insufficient to accurately assess the activation 
status of RSK1 and RSK2, and require in-depth investigation.  
The phosphorylation of CREB at Ser-133 (CREBpS133) is crucial for its activation, and is 
facilitated by multiple kinases, including MSK1/2,38,43 RSK2,44 and Akt (Fig. 4.6).45 Briefly, 
CREB is an important DNA-binding protein transcription factor, which upon activation up-
regulates the expression of a broad range of cellular survival genes.46 Remarkably, the 
CREBpS133 level in F3wtNPs-treated cells remained at basal level, whereas the F3wt peptide, 
NTNPs, and F3scramNPs treatments progressively down-regulated CREBpS133 levels relative to the 
untreated control (0.93-fold, 0.86-fold and 0.65-fold, respectively) (Fig. 4.2b, Table 4.5, 
Appendix A4.3.2). This observation suggests that the F3wt peptide, NTNPs, and F3scramNPs 
treatments, but not the F3wtNPs, promote dephosphorylation of CREB at Ser-133. This is 
particularly interesting considering that both the F3wt peptide and NTNPs treatments induced 
higher MSK2pS360 and RSK2pS386 levels than the F3wtNPs. However, it has been shown that 
CREB is potently dephosphorylated by the phosphatase enzyme Protein Ser/Thr Phosphatase 
Type 2A (PP2A),47 which is typically activated between 0.5 to 1 hour after initiation of an 
apoptotic stress, and remains active for several hours therafter.48 Given that PP2A is activated by 
the p38 MAPKs, with the F3wt peptide, NTNPs and F3scramNPs being the most potent activators 
of p38β and p38δ (Fig. 4.3b, Table 4.1, Appendix 4.3.2), and that our phospho-proteomic 
experiment was performed on 2-hour post-treatment cell lysates, it is therefore likely that these 
treatments antagonize the activation of CREB via p38-mediated activation of the PP2A enzyme. 
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4.2.2.4 Phosphoproteomic Arrays (Akt Pathway) 
The Akt pathway is an important signal transduction pathway that regulates cellular functions 
including cell growth, nutrient metabolism, transcriptional regulation and cell survival.49 Three 
Akt isoforms, Akt1, Akt2, and Akt3, mediate signaling through this pathway, and require dual 
phosphorylation of their Thr-308/Ser-473 (Akt1), Thr-309/Ser-474 (Akt2), and Thr-305/Ser-472 
(Akt3) residues respectively, to achieve full activation.50 The phospho-specific antibodies 
employed in this array, however, detected only the Ser-473-, Ser-474- and Ser-472-
phosphorylated forms of Akt1, Akt2 and Akt3, respectively (Fig. 4.7). Nonetheless, based on the 
limited data on the activation status of the Akt isoforms (Akt1pS473, Akt2pS474 and Akt3pS472), 
Akt3pS472 had the lowest basal level of phosphorylation, but was the only Akt isoform that 
exhibited markedly varying degrees of phosphorylation enhancement in response to the different 
treatments (Figs. 4.3a and 4.3b, Table 4.6, Appendix 4.3.2). The F3wt peptide elicited a 1.97-fold 
enhancement of Akt3pS472 levels relative to the untreated control, followed by the NTNPs (1.90-
fold), F3wtNPs (1.61-fold) and F3scramNPs (1.41-fold), however the difference between the F3wt 
peptide and NTNPs treatments, as well as between the F3wtNPs and F3scramNPs treatments were 
not significant (Fig. 4.3b, Table 4.6, Appendix 4.3.2).  
The downstream targets directly phosphorylated by the activated Akt isoforms include, GSK-
3α and GSK-3β  (glycogen synthase kinase-3α/β),51 TOR (target of rapamycin),52 and CREB.45 
Briefly, GSK-3α and GSK-3β are responsible for regulating a broad range of cellular processes 
including, glycogen and protein metabolism, cell cycle regulation and proliferation. Akt-
mediated phosphorylation of GSK-3α at Ser-21, and GSK-3β at Ser-9 (as detected in this 
phosphoproteomic array) inhibits both isoforms.51 Furthermore, p70 ribosomal S6 kinase 
(p70S6k)- and RSK2-mediated phosphorylation of GSK-3α and GSK-3β at Ser-21 and Ser-9,  
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Table 4.6 Summary of the fold changes in phosphorylation levels of the Akt1, Akt2 and Akt3 
isoforms, and phosphorylation levels of their downstream targets, Glycogen synthase kinase-3α/β, 
TOR and p70S6 Kinase, elicited by the various treatments relative to the untreated control. The Akt 
pan represents the average phosphorylation level of the Akt1, 2 and 3 isoforms, collectively.  
Phosphoprotein/ 
Phosphorylation sites 
detected 
Untreated 
Control F3wt Peptide NTNPs F3wtNPs F3scramNPs 
Akt1 (pS473) 1.00 1.01 1.00 1.01 0.98 
Akt2 (pS474) 1.00 1.04 1.03 1.04 1.03 
Akt3 (pS472) 1.00 1.97 1.90 1.61 1.41 
Akt pan 
(pS473/pS474/pS472) 1.00 1.03 1.02 1.03 0.88 
GSK-3α /β  (pS21/pS9) 1.00 1.02 0.97 1.01 1.03 
GSK-3β  (pS9) 1.00 1.01 0.98 0.99 0.99 
TOR (pS2448) 1.00 1.65 2.09 1.21 1.00 
p70S6k (pT421/pS424) 1.00 1.59 1.27 1.53 0.94 
  
Fig. 4.7 Schematic diagram depicting the feedback phosphorylation relationship between Akt1, TOR and p70S6 
kinase phosphoproteins. The p70S6 kinase is predominantly responsible for phosphorylating TOR at its Ser-2448 
residue. Ser-2448-phosphorylated TOR is, in turn, incorporated within the mTORC1 and mTORC2 multi-protein 
complexes. mTORC1 subsequently phosphorylates p70S6 kinase at Thr-389, which, however, was not detected in 
the phosphoproteomic assay employed in this study. mTORC2 further phosphorylates Akt1 at its Ser-473 residue. 
Phosphorylated residues detected on the various phosphoproteins in this study are highlighted in blue text.  
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respectively, also inhibits both GSK-3 isoforms.53,54 However, neither treatment elicited 
significant changes in the phosphorylated levels of either GSK-3 isoform, compared to their 
respective basal phosphorylated levels in the untreated control (Fig. 4.3a, Table 4.6, Appendix 
A4.3.2).  
TOR is a highly conserved protein kinase that functions as a central coordinator of cell growth, 
by positively and negatively regulating several anabolic and catabolic processes, respectively. 
The p70S6k, and to a lesser extent Akt, directly phosphorylates TOR at Ser-2448 (TORpS2448; as 
detected in this phosphoproteomic array), which lies within its C-terminal regulatory region (Fig. 
4.7).52,55,56,57 Furthermore, TORpS2448 is found in both the functional multi-protein complexes 
mTORC1 and mTORC2,58 which in turn phosphorylate and activate p70S6k (at Thr-389), and 
Akt1 (at Ser-473), respectively. However, even though TORpS2448 is found in both the mTORC1 
and mTORC2 complexes, the level of Ser-2448-phosphorylated TOR was found to correlate 
only with the mTORC1 activity, and not with the mTORC2 activity.58 That is, despite Akt1 
being directly phosphorylated at Ser-473 by mTORC2, the level of TORpS2448 did not correlate 
directly with the levels of Akt1pS473 as a direct measure of mTORC2 activity. The NTNPs 
elicited the greatest enhancement in TORpS2448 levels (2.09-fold), relative to the untreated control, 
followed by the F3wt peptide (1.65-fold), and the F3wtNPs (1.21-fold), while the F3scramNPs 
treatment elicited no change from the basal TORpS2448 level of the untreated control (Fig. 4.3b, 
Table 4.6, Appendix 4.3.2). The various treatments however, did not elicit a similar trend in the 
levels of Akt1pS473 to that of TORpS2448. Hence, our observations are in agreement with the 
findings of Rosner et al.,58 that the levels of Akt1pS473 do not correlate directly with the levels of 
TORpS2448.  
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In addition to phosphorylation at Thr-389, p70S6k is also phosphorylated at residues Ser-411, 
Ser-418, Ser-421 and Ser-424, which are located in the auto-inhibitory domain of Module IV in 
p70S6k (Fig. 4.7).59 These residues are hypo-phosphorylated in quiescent cells, and become 
hyper-phosphorylated upon serum-induced activation. Of the above-mentioned residues, the 
phospho-specific antibody, used in this phospho-proteomic array, detected the phosphorylated 
forms of only the Ser-421 and Ser-424 residues of p70S6k (Fig. 4.7), thus providing only a 
limited view into the activation status of p70S6k. Also, the absence of data on the Thr-389-
phosphorylation levels of p70S6k, which would be a direct indicator of mTORC1 activity, 
precludes us from making direct correlations with the levels of TORpS2448, since it is one of the 
functional components in the mTORC1 complex.  Nonetheless, the F3wt peptide and F3wtNPs 
elicited the highest enhancement in the p70S6kpS421/424 levels (1.59-fold and 1.53-fold, 
respectively), relative to the untreated control, followed by the NTNPs (1.27-fold); on the other 
hand, the F3scramNPs elicited a slight, but not significant, down-regulation in p70S6kpS421/424 
levels (0.94-fold) (Fig. 4.3b, Table 4.6, Appendix A4.3.2). Given that p70S6k is a positive 
regulator of protein synthesis, cytoskeletal rearrangements, mRNA processing, proliferation, and 
of cell survival,60 these data suggest that the F3wt peptide and F3wtNPs are more supportive of 
cellular proliferation than the NTNPs, and the F3scramNPs.  
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4.2.2.5 p-ERK/p-p38 MAPK Signaling Profiles and Implications for Cell Survival 
It is now known that the activation of the p38 and JNK MAPK pathways, with concurrent 
inhibition of the ERK MAPK pathway, is necessary for cells to undergo apoptosis.61 Moreover, 
it has been shown that a high p-ERK/p-p38 ratio in tumor cells favors proliferation, whereas a 
low p-ERK/p-p38 ratio favors dormancy.62,63 Given that ERK1, and p38α, p38β and p38δ were 
the only isoforms of their respective MAPK pathways that were phosphorylated to varying 
degrees in response to the different treatments in this study, we determined the ratio of p-ERK1 
to average p-p38(α, β and δ) for each treatment and the untreated control (Fig. 4.8). The resultant 
p-ERK1/p-p38 ratios suggest that the F3wtNPs, and to a lesser extent the F3wt peptide, promote 
cellular proliferation, whereas the NTNPs and F3scramNPs promote growth arrest. Further support 
for this hypothesis lies in the observations that the NTNPs, and F3scramNPs treatments elicited 
higher phosphorylated levels of the pro-apoptotic Hsp27pS78/pS82 and p53pS46 proteins, but lower 
phosphorylated levels of the pro-survival CREBpS133 and p70S6kpS421/424 proteins, than the 
F3wtNPs treatment (Fig. 4.3b, Tables 4.3, 4.5, 4.6, Appendix A4.3.2). Interestingly, the F3wt 
Fig. 4.8 Schematic diagram depicting the effects of the F3wt peptide, NTNPs, F3wtNPs and F3scramNPs treatments on 
the ratio of phosphorylated ERK1 (pERK1) to average phosphorylated p38 (p-p38α, β and δ isoforms) MAPKs in 
MDA-MB-435 cells. MDA-MB-435 cells, proliferating under standard cell culture conditions, exhibited a basal 
pERK/p-p38 ratio of 2.42: 1. Of the various treatments, the F3wtNPs elicited the highest pERK/p-p38 ratio, which 
was marginally higher than that of the untreated control MDA-MD-435 cells, followed by F3wt peptide (1.92 : 1), 
NTNPs (0.66 : 1), and F3scramNPs (0.53 : 1).  
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peptide treatment elicited intermediate levels of phosphorylated Hsp27pS78/pS82 and p53pS46 
proteins (higher than in the F3wtNPs treatment, but lower than in the NTNPs treatment), but 
higher phosphorylated levels of the CREBpS133 and p70S6kpS421/424 proteins than the NTNPs 
treatment (Fig. 4.3b, Tables 4.3, 4.5, 4.6, Appendix A4.3.2). Considering these data together 
with the p-ERK1/p-p38 ratio of 1.92: 1 elicited by the F3wt peptide treatment, the cells treated 
with F3wt peptide may therefore still proliferate, albeit at a slower rate than the untreated control 
cells, and the F3wtNPs-treated cells. Table 4.7 summarizes the physicochemical properties of the 
various peptides, and nanoparticles, as well as the pertinent signaling profiles elicited by each. 
 
Table 4.7 Summary of the physicochemical properties of the F3wt peptide, F3scram peptide, NTNPs, 
F3wtNPs and F3scramNPs, and the pertinent signaling profiles elicited by each. ND: not determined  
 
Physicochemical 
Properties 
F3wt  
Peptide 
F3scram 
Peptide NTNPs F3wtNPs F3scramNPs 
Hydrodynamic 
diameter (nm) - - 52.5 nm 53.0 nm 52.2 nm 
Peptide charge/  
Zeta Potential (mV) +9 +9 +20.56 mV +25.89 mV +25.74 mV 
Surface PEGylation No No No Yes Yes 
Valency/ 
Receptor Specificity 
Monovalent/ 
Nucleolin 
 
Monovalent/ 
Scavenger 
Receptors? 
No surface 
conjugated 
peptides/ 
LRP-1? 
Multivalent/ 
Nucleolin 
 
Multivalent/ 
Scavenger 
Receptors? 
p-ERK1/p-p38α ,β ,δ  MAPK Signaling Ratio  
(Proliferative ratio highlighted in green; Pro-apoptotic ratio highlighted in red) 
p-ERK1/p-p38α ,β ,δ   1.92: 1 ND 0.66: 1 2.48: 1 0.53: 1 
Fold changes in phosphorylation levels of anti-apoptotic phosphoproteins (relative to untreated control) 
(Proliferative changes highlighted in green; Pro-apoptotic changes highlighted in red) 
CREB (pS133) 0.93-fold ND 0.86-fold 1.00-fold 0.65-fold 
p70S6k (pT421/pS424) 1.59-fold ND 1.27-fold 1.53-fold 0.94-fold 
Fold changes in phosphorylation levels of pro-apoptotic phosphoproteins (relative to untreated control) 
(Proliferative changes highlighted in green; Pro-apoptotic changes highlighted in red) 
p53 (pS46) 18.52-fold ND 25.77-fold 10.10-fold 23.42-fold 
Hsp27 (pS78/pS82) 1.84-fold ND 2.28-fold 1.46-fold 1.67-fold 
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4.2.2.6 Proposed Cell Surface Receptor-NP Interactions 
Since each of these treatments elicited different p-ERK1/p-p38 ratios, the question remains as to 
what the underlying mechanism(s) are by which these different MAPK signaling profiles are 
elicited. First, the low p-ERK1/p-p38 ratio (0.66: 1) elicited by the NTNPs suggests that they 
bind to a cell surface receptor which favors signaling predominantly via the p38 MAPK 
pathway. One such cell surface receptor is LRP-1 (low-density lipoprotein receptor-related 
protein-1), which is a large, transmembrane scavenger receptor that recognizes and mediates the 
internalization of 51 known structurally distinct biological macromolecules from the 
extracellular environment.64 LRP-1 is also inextricably involved in cell signaling via association 
of its cytoplasmic domain with the scaffold proteins JIP1 and JIP2 (JNK-associated interacting 
proteins), and the adapater protein Shc.64 As mentioned earlier, JIP2 provides scaffolding 
functions for the assembly of both p38 and JNK signaling modules, while JIP1 exclusively 
promotes the assembly of JNK modules.36 Shc interacts with Grb2 and Sos to activate Ras, 
ultimately leading to the activation of the ERK1/2 MAPKs. However, strong activation of the 
p38 and JNK pathways rapidly promote down-regulation of the ERK pathway, as observed with 
the NTNPs. This is achieved by p38-mediated activation of the phosphatase (dephosphorylating) 
enzyme PP2A,65 typically between 0.5 and 1 hour after stimulation, and JNK-mediated 
expression of the dual-specificity phosphatases, MKP-1 and MKP-2,66 typically between 1 and 3 
hours after stimulation.48 PP2A has been shown to bind directly to, and inhibit the 
phosphorylation of Shc, thereby inhibiting activation of Ras, and signaling further downstream to 
ERK1/2 67 (Fig. 4.9). Furthermore, PP2A can also directly dephosphorylate, and inactivate both 
MEK1/2 and ERK1/2; MEK1/2 being the upstream MAP2Ks that directly phosphorylate 
ERK1/2 when activated68,69 (Fig. 4.9). The phosphatases MKP-1 and MKP-2 activated by JNK  
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Fig. 4.9 Proposed receptor complex interactions of the NTNPs and F3wtNPs at the cell surface of MDA-MD-435 
cells as plausible mechanisms by which the NTNPs elicit a low p-ERK/high p-p38 ratio, and the F3wtNPs elicit a 
high p-ERK/low p-p38 ratio. α5β1 (α5β1 Integrin receptors), AT III (Antithrombin III), DSP (Dual-specificity 
Phosphatase), p125 FAK (Focal Adhesion Kinase), JIP1/2 (JNK Interacting Protein 1/2), LRP1 (Low-density 
Lipoprotein-related Receptor 1), Nuc (Nucleolin), PP2A (Protein Phosphatase 2A), uPAR (Urokinase Plasminogen 
Activator Receptor).  
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in turn directly dephosphorylate ERK1/2 66 (Fig. 4.9). It is important to note that all treatments in 
this study were performed for a duration of 2 hours. Thus, at this time point, the low p-ERK1/p-
p38 ratio in the NTNP treatment is indicative of induced PP2A, MKP-1 and MKP-2 phosphatase 
enzyme activites. Although the NTNPs employed in this study were devoid of surface 
functionlizations, they would acquire a corona of surface-adsorbed serum proteins upon delivery 
into the cell culture medium, as has been shown with other acrylamide-based NPs.70,71 
Antithrombin III, a protein component of fetal bovine serum,72 and a ligand also recognized by 
LRP-1,64 is a likely serum protein constitutent of the protein corona that would form around the 
NTNPs, and thus mediate the binding of the NTNPs specifically to LRP-1 (Fig. 4.9).  
Second, the low p-ERK1/p-p38 ratio (0.53: 1) elicited by the F3scramNPs is interesting in that, 
although they were not as effective as the NTNPs in inducing phosphorylation of the p38β/δ and 
JNK1-3 MAPKs, the F3scramNPs were more effective at suppressing the p-ERK1 levels. Based 
on our stuctural simulations of the F3-wild type and F3-scrambled peptide sequences, we 
Fig. 4.10 Simulated secondary structures of the wild-type (a) and scrambled (b) F3 peptides. Five different 
structural simulations for each peptide were generated via the PEP-FOLD peptide structure prediction server 
(http://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD/) and compared. In each set of comparisons, the green 
peptide structure was kept constant against which the other four structures were compared. 
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observed that the N-terminal half of the F3-wild type peptide folds into a stable α-helix, whereas 
this property is completely absent in the F3-scrambled peptide, which adopts a range of 
misfolded states (Figs. 4.10a,b). As such, the misfolded states and incorrect sequence of amino 
acids of the F3-scrambled peptide would abrogate its ability to recognize and bind specifically to 
the cell surface Nucleolin receptors, however internalization of the F3scramNPs may occur via 
scavenger receptors, such as gp18 and gp30. Consistent with this theory, Fleischer and Payne 
recently demonstrated that a loss of α-helicity in the secondary structure of albumin proteins, 
upon binding to cationic polystyrene NPs, diverts their internalization via the albumin receptor to 
via the gp18 and gp30 scavenger receptors.73 However, the signaling pathways associated with 
gp18 and gp30 are currently unknown, and this hypothesis remains to be tested.  
The cell surface Nucleolin receptor, to which the F3wtNPs specifically bind, lack both 
transmembrane and cytoplasmic domains. Therefore, the high p-ERK1/p-p38 ratio (2.48: 1) 
elicited by the F3wtNPs suggests that cell surface Nucleolin receptors associate with 
transmembrane receptor complexes that favor signaling via the ERK pathway over p38/JNK 
pathways. A possible receptor complex is one comprised of the urokinase plasminogen activator 
receptor (uPAR), α5β1-integrin, and epidermal growth factor receptor (EGFR).74,75 Briefly, 
when uPAR is expressed at high-levels, it frequently interacts with, and activates α5β1-integrin 
(the fibronectin receptor), which in turn associates with, and activates EGFR in a ligand-
independent manner by promoting auto-phosphorylation of its intracellular domains. The 
assembly of the uPAR/α5β1-integrin/EGFR complex subsequently recruits focal adhesion kinase 
(FAK), from the cytoplasm to the intracellular domains of α5β1-integrin and EGFR, and 
undergoes phosphorylation. In combination with the phosphorylated intracellular domains of 
EGFR, activated FAK subsequently activates Ras, ultimately leading to activation of the ERK 
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pathway.75,76 Furthermore, activated FAK also suppresses activation of p38 MAPKs by 
inactivating Cdc4274 (Fig. 4.9). Cdc42 is a Rho GTP-binding protein that directly phosphorylates 
MLK1 (the MAP3K enzyme which promotes downstream activation of the p38 and JNK MAPK 
enzymes).77 Briefly, FAK promotes deactivation of Cdc42 by converting it from its GTP-bound 
state (active) to its GDP-bound state (inactive) by recuritment of the GTPase activating protein 
(GAP) known as GRAF (GTPase regulator associated with FAK).78 This hypothesis is supported 
by our observation that the F3wtNPs elicited lower levels of phosphorylated MKK3 and MKK6 
(the MAP2K enzymes that directly phosphorylate the p38α/β/γ/δ isoforms) than the F3wt peptide 
and NTNPs (Fig. 4.3b).  
The involvement of Nucleolin in this signaling complex is two-fold. First, cell surface 
Nucleolin physically interacts, via its C-terminal glycine-arginine-rich domain (GAR domain, 
646-707 aa) with uPAR,79 while α5β1-integrin interacts with uPAR via the NLTY motif of α580 
(Fig. 4.9). Second, the C-terminal 212 amino acids (the fourth RNA-binding domain (RBD) and 
GAR domain) of cytoplasmically-localized Nucleolin interacts with the cytoplasmic domain of 
EGFR, and the overexpression of both leads to EGFR phosphorylation, dimerization and 
enhanced cell proliferation.81 In addition to inducing phosphorylation and dimerization of EFGR 
(or HER1/ ErB1) in a ligand-independent manner, Nucleolin has been shown to induce 
phosphorylation and dimerization of the structurally similar HER2 (ErbB2), HER3 (ErbB3), and 
HER4 (ErbB4) receptors by direct interaction with their cytoplasmic domains.82 MDA-MB-435 
cells specifically, overexpress HER2 receptors, instead of EGFR/HER1,83 in addition to α5β1-
integrin,84 and cell surface Nucleolin,85 but express uPAR at low levels.86 Nonetheless, it is 
highly plausible that, in MDA-MB-435 cells, Nucleolin/uPAR/α5β1-integrin/HER2 complexes 
exist at the cell surface, with intracellular Nucleolin maintaining the HER2 receptors in a 
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dimerized, and constitutively activated state. The F3wtNPs could indeed upregulate the ERK 
MAPK pathway via the Nucleolin/uPAR/α5β1-integrin/HER2 complex by binding directly to 
cell surface Nucleolin receptors. It is important to note that while the GAR (C-terminal) domain 
of surface Nucleolin interacts with uPAR, it would still be able to simultaneously bind the 
highly-basic F3wt peptide via its acidic N-terminal domain.87 Despite the inhibitory effect of 
FAK on Cdc42, and consequently on the p38 and JNK MAPK pathway, the F3wtNPs did activate 
the p38α, β and δ isoforms, as well as the JNK1-3 isoforms, above their respective basal levels 
in the untreated control. This is likely attributable to the possible association of surface-
expressed Nucleolin with the transmembrane LRP-1 receptors,88 such that the LRP-1 receptors 
are co-internalized with the Nucleolin-F3wtNPs complexes from the cell surface. In turn, this 
could lead to activation of the p38 and JNK MAPKs that are associated with the cytoplasmic 
domain of LRP-1 via the JIP1/2 scaffold proteins.  
Finally, given the clearly opposing p-ERK1/p-p38 signaling profiles elicited by the NTNPs 
and F3wtNPs, it was rather interesting that the F3wt peptide elicited higher levels of both 
phosphorylated p-p38 (β and δ isoforms), and phosphorylated p-ERK1 than the F3wtNPs (Fig. 
4.3b). The more potent stimulation of p38β and p38δ phosphorylation by the F3wt peptide is 
likely due a combination of (i) co-activation of the LRP-1 receptors associated with surface-
expressed Nucleolin, and (ii) less efficient recruitment of FAK to the regions of the cell 
membrane where the monovalent F3wt peptides bind to the Nucleolin/uPAR/α5β1-
integrin/HER2 complexes. In contrast, it is plausible that a single, multivalent F3wtNP would 
simultaneously engage multiple surface-expressed Nucleolin receptors, and in the process, 
assemble foci of multiple Nucleolin/uPAR/α5β1-integrin/HER2 complexes at the point of 
contact with the cell membrane. In turn, FAK would be more strongly recruited to that region of 
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surface-bound F3wtNPs, than the surface-bound monovalent F3wt peptides, thus promoting 
deactivation of Cdc42 with subsequent suppression of p38 MAPK phosphorylation. The slightly 
higher levels of p-ERK1 elicited by the F3wt peptide is not surprising given the constitutively 
activated state in which the HER2 receptors are maintained by cytoplasmically-localized 
Nucleolin.82 
 
4.3 Conclusion 
In this study we demonstrate that the non-targeted PAA-NPs are more potent activators of the 
p38 MAPK pathway than the F3wt-targeted PAA-NPs. It is well-documented that the p38 
MAPKs phosphorylate and modulate the activity of key components of the endocytic machinery 
namely, EEA1 and Caveolin-1. We therefore present compelling evidence that the non-targeted 
PAA-NPs, and F3wt-targeted PAA-NPs modulate their intracellular trafficking within nucleolin-
overexpressing tumor cells, as previously reported by our group, via differential activation of the 
p38 MAPK pathway. Furthermore, our detailed phosphoproteomic analysis of key proteins in the 
ERK, JNK, p38 and Akt pathways revealed that the F3wt peptide, non-targeted PAA-NPs, and 
F3wt-targeted PAA-NPs each elicit markedly different signaling profiles in MDA-MB-435 cells, 
which can either promote proliferation, or induce growth arrest of the tumor cells. In particular, it 
appears counter-intuitive to employ the F3wt-targeted PAA-NPs as targeted nano-drug delivery 
system in the treatment of tumors, considering the proliferative MAPK signaling profile that they 
elicited. However, the F3wt-targeted PAA-NPs may be particularly efficacious in activating 
dormant tumor stem cells that remain refractory to conventional chemotherapeutic drugs, and are 
responsible for establishing metastases. Therefore, a potentially viable approach to killing 
domant tumor stem cells is to activate them with the multivalent, F3wt-targeted PAA-NPs, which 
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simultaneously deliver high concentrations of one, or more synergistic cytotoxic 
chemotherapeutic drugs directly into the tumor stem cell following endocytosis of the 
nanoparticle, thereby also circumventing the multi-drug resistance drug-efflux transporters 
located within the cell membrane. This may result in more efficient elimination of tumor stem 
cells with a concomitant reduction in the formation of secondary metastatic tumor sites, and thus 
improve the prognosis of cancer patients. We believe that our phosphoproteomic data provide 
compelling evidence that the design of tumor-targeting nanoparticle systems should also take 
into consideration the MAPK signaling profiles that they elicit on the intended target cell type, 
due to the profound influence that the p38 MAPKs, in particular, have on endocytic trafficking, 
as well as the survival status of the target tumor cell.  
 
4.4 Experimental Section 
Reagents and Materials 
Acrylamide (AA), 3-(acryloyloxy)-2-hydroxypropylmethacrylate (AHM), ammonium persulfate 
(APS), N,N,N`,N`-tetramethylethylenediamine (TEMED), sodium dioctyl sulfosuccinate (AOT), 
Brij 30, L-cysteine, phosphate-buffered solution (PBS) tablets, disodium EDTA salt, sodium 
fluoride, sodium orthovanadate, sodium pyrophosphate, sodium azide, protease inhibitor cocktail 
(P8340), urea, Triton X-100, and Anisomycin were purchased from Sigma-Aldrich (St. Louis, 
MO). N-(3-aminopropyl)-methacrylamide hydrochloride (APMA) was purchased from 
Polysciences (Warrington, PA). Ethanol (100 %) and hexane were purchased from Fisher 
Scientific (Pittsburgh, PA). Heterobifunctional polyethyleneglycol (MAL–PEG–SCM, MW: 
2,000 Da) was purchased from Creative PEG Works (Winston Salem, NC). The MDA-MB-435 
human breast carcinoma cell line was obtained from American Type Culture Collection 
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(Manassas, VA, USA). Dulbecco’s modified Eagle medium (DMEM), Hanks Balanced Salt 
Solution (HBSS; without Calcium/Magnesium), Gibco 0.25 % Trypsin-EDTA, Gibco 100x 
PenStrep-Glutamine and Gibco Heat-Inactivated Fetal Bovine Serum (HI-FBS) were purchased 
from Life Technologies (Carlsbad, CA). The Pierce Bicinchoninic Acid (BCA) Protein Assay 
Kit was purchased from Thermo Fisher Scientific Inc. (Rockford, IL). Probumin Bovine Serum 
Albumin (BSA) was purchased from EMD Millipore (Billerica, MA). Cysteine terminated wild-
type F3 peptides (F3wt-Cys: KDEPQRRSARLSAKPAPPKPEPKPKKAPAKKC) and scrambled 
F3 peptides (F3scram-Cys: PKAARALPSQRSRPPEKAKKPPDKPAPEKKKC) were purchased 
from SynBioSci (Livermore, CA). The phospho-p38α (T180/Y182) DuoSet IC ELISA kit 
(DYC869-B), Human phospho-MAPK Array kit (ARY002B), Substrate Reagent Pack (H2O2 and 
Tetramethylbenzidine), and clear polystyrene plates were purchased from R&D Systems, and 
used according to the manufacturer protocol. Kodak BioMax MS X-Ray film was purchased 
from Fisher Scientific. All solutions were prepared in 18 MΩ water purified in a Barnstead 1 
Thermolyne Nanopure II system. All reagents and materials were used as received without 
further purification. 
 
Synthesis of amine surface-functionalized hydrogel polyacrylamide nanoparticles  
A monomer mixture consisting of 711 mg acrylamide, 55 mg APMA, and 460 µL AHM were 
dissolved in PBS buffer (pH 7.4) and mixed together for 2 hours at room temperature. The 
mixture was emulsified in organic media containing surfactant (45 mL hexane, 1.6 g AOT, and 
3.1 g Brij30) by continuous stirring for 20 minutes under Argon atmosphere in order to purge the 
reaction mixture of oxygen. Thereafter, polymerization was triggered by addition of radical 
initiator (100 µL of 10 % (w/v) ammonium persulfate in DI water and 100 µL of TEMED). The 
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reaction proceeded for 2 hours under mild argon purging and was terminated by exposing the 
reaction to normal atmosphere (radical quenching by atmospheric oxygen). The product was 
recovered through multiple separation steps: (i) removal of hexane by rotary evaporation, and (ii) 
multiple rinses with 100 % (v/v) ethanol to remove the surfactants, followed by multiple washes 
with DI water to remove residual surfactants using an Amicon stirred cell fitted with a 300 kDa 
molecular weight cut-off filter. The final product was lyophilized and kept frozen at -20 °C until 
use. 
 
Surface functionalizations of PAA nanoparticles 
Lyophilized PAA-NPs (50 mg) were dissolved in 2.5 mL PBS buffer (pH 7.4) and sonicated 
until the solution turned transparent, to which 4 mg heterobifunctional PEG (SCM-PEG-MAL) 
was then added and the mixture stirred continuously (~600 rpm) for 30 minutes at room 
temperature. The reaction between the succinimidyl ester group of the PEG crosslinker and the 
primary amine groups on the surface of PAA-NPs yielded maleimidyl ester-terminated PEG-
conjugated PAA-NPs. Thereafter, the PEGylated PAA-NPs were washed three times with PBS 
buffer (pH 7.4) by centrifugation using an Amicon centrifugal filter (Millipore, 100 kDa 
molecular weight cut-off) at 5000xg for 20 min. After washing to remove unbound PEG 
crosslinkers, the surface PEGylated PAA-NPs were then reacted with either 11 mg wild-type F3-
Cys peptide, or 11 mg scrambled F3-Cys peptide in PBS buffer (pH 7.4) and the conjugation 
reaction allowed to run overnight at room temperature under continuous stirring at ~600 rpm. 
The reaction between the thiol group of the carboxy terminal Cys residue of the F3wt/scram peptide 
moieties and the maleimidyl ester termini of the PEG crosslinkers facilitated covalent coupling 
of the F3wt/scram peptide moieties to the PEG crosslinkers already conjugated to the PAA-NP 
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surfaces. The F3wt/scram peptide functionalized PEGylated PAA-NPs were subsequently incubated 
with 1.74 mg L-cysteine under continuous stirring for 2 hours at room temperature to cap any 
unreacted maleimidyl ester groups so as to prevent their reaction with cell surface thiols. 
Thereafter, the F3wtNPs/F3scramNPs were washed five times with PBS (pH 7.4) using an Amicon 
centrifugal filter (100 kDa molecular weight cut-off) at 4000xg for 20 minutes and the final 
volume adjusted to 5 mL with PBS (pH 7.4). The final product was lyophilized and kept frozen 
at -20 °C until use. All steps were performed shielded from light.  
 
Nanoparticle sizing and morphology 
For all DLS sizing measurements, the lyophilized NPs were dissolved in DI water to a final 
concentration of 1 mg.mL-1 and analyzed with a Beckman-Coulter Delsa Nano C particle 
analyzer. All measurements were performed in triplicate. 
 
Nanoparticle zeta potential measurement  
Zeta potential measurements of unmodified PAA-NPs (without PEG or F3 peptides), PEGylated 
PAA-NPs, and the F3wtNPs/F3scramNPs were performed in order to determine their respective 
surface charges. All zeta potential measurements were performed on 1 mg.mL-1 solutions of each 
type of nanocarrier, prepared in DI water, using a Beckman-Coulter Delsa Nano C particle 
analyzer. All measurements were performed in triplicate.  
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Cell culture  
MDA-MB-435 human breast adenocarcinoma cells were cultured aseptically at 37 °C under 5 % 
CO2 humidified atmosphere in BD Falcon Primaria tissue culture dishes (100 mm x 20 mm). 
MDA-MB-435 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10 % (v/v) FBS and 1 % (v/v) penicillin-streptomycin-glutamine (PSG). Cell 
cultures were passaged during exponential growth phase by incubating the cells with 0.25 % 
Trypsin-EDTA solution at 37 °C until the cells attained rounded morphology, followed by 
resuspension of the detached cells in complete culture medium, and sub-culturing into new 
sterile culture dishes. The F3wtNP, F3scramNP and unmodified PAA-NP suspensions were sterile 
filtered with a 0.2 µ syringe filter prior to use in all cell culture experiments.  
 
Treatment of MDA-MB-435 cells for phospho-p38α  ELISA 
MDA-MB-435 cells were harvested by trysinisation with 0.25% Trypsin-EDTA solution at 
37°C, and counted using a hemacytometer. Approximately 9x105 cells were seeded into the 
required number of 100 mm x 20 mm culture dishes, and allowed to multiply over a period of 60 
hours under standard culture conditions. Prior to the start of the experiment, stock solutions of 
the F3wt peptide, NTNPs, F3wtNPs, and Anisomycin were prepared in complete culture medium 
and sonicated for 10 minutes to ensure complete dissolution. These stock solutions were then 
further diluted to their final working concentrations in complete culture medium as follows: F3wt 
peptide (0.22 mg/mL), NTNPs (1 mg/mL), F3wtNPs (1 mg/mL), and Anisomycin (10 µg/mL). 
The MDA-MB-435 cells were rinsed once with HBSS immediately before the start of the 
experiment. The dishes were replenished with culture medium up to a final volume of 5 mL 
containing either one of the above treatments at their respective working concentrations, or 
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culture medium without any treatment (untreated control). The cells were incubated with the 
above-mentioned treatments for the following periods: 15, 30, 60, 120 and 180 minutes under 
standard culture conditions. At the end of each treatment period, the culture media were 
immediately aspirated from each dish, the cells rinsed thoroughly with Calcium/Magnesium-free 
HBSS buffer, and rapidly detached with 1 mL 0.25% Trysin/EDTA solution. The cells were then 
resuspended in culture medium, and pelleted at 150xg for 5 minutes at 4 °C. The supernatants 
were discarded and the cell pellets immediately resuspended in ~500 µL ice-cold cell lysis buffer 
(1mM EDTA, 0.5% Triton X-100, 5 mM NaF, 6 M urea, 1 mM activated sodium orthovanadate, 
2.5 mM sodium pyrophosphate, Sigma protease inhibitor cocktail P8340 (diluted 100-fold), in 
PBS pH 7.2-7.4) and kept on ice for 30 minutes. The lysates were then centrifuged at 2000 xg for 
5 minutes at 4 °C to pellet cell debris. Protein concentrations of the supernatants were then 
determined by micro-BCA protein assay. The concentrations of the supernatants were then 
equilibrated to the lowest sample concentration in the batch, and further diluted 6-fold to reduce 
the urea concentration to 1 M. The supernatants were stored at -80 °C until further use. The 
treatment experiments were performed twice. The concentration of dual-phosphorylated 
(pT180/pY182) p38α MAPK in the equilibrated, 6-fold diluted samples was determined via the 
phospho-p38α MAPK ELISA according to the standard R&D Systems Inc. assay protocol. Each 
sample was assayed in triplicate, and the dual-phosphorylated (pT180/pY182) p38α MAPK 
concentration interpolated from a 2-fold, 8-point standard curve with a high concentration of 
8000 pg/mL phosphorylated p38α MAPK protein. The ELISA assay was developed with a 1:1 
mixture of H2O2 and Tetramethylbenzidine, and stopped with a 2N H2SO4 solution. The 
absorbance of the substrate was measured on a microplate reader at 450 nm with 550 nm 
wavelength correction.  
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Treatment of MDA-MB-435 cells for Human Phospho-MAPK Array Assay 
Based on the results of the phospho-p38α ELISA, an optimal treatment period of 2 hours for the 
F3wt peptide, NTNPs and F3wtNPs was identified. MDA-MB-435 cells were prepared as 
described for the phospho-p38α ELISA assay, and subjected to the above treatments, in addition 
to the F3scramNPs (1 mg/mL) as a further control, for 2 hours under standard culture conditions. 
At the end of the 2 hour treatment period the culture dishes were immediately placed on ice, the 
culture medium aspirated, and ~400 µL of ice-cold array kit lysis buffer added to each dish. The 
cells were detached from the dishes into the lysis buffer using a rubber cell scraper. The cells 
were collected into 1.5 mL microfuge tubes and kept on ice for 30 minutes, after which the 
lysates were centrifuged at 14,000 xg for 5 minutes at 4 °C to pellet cell debris. Protein 
concentrations of the supernatants were then determined by micro-BCA protein assay. The 
concentrations of the supernatants were then equilibrated to the lowest sample concentration in 
the batch, and probed on the MAPK proteome profiler membranes according to the standard 
R&D Systems Inc. assay protocol. The membranes were developed with a chemiluminescent 
reagent provided with the MAPK proteome profiler kit, and the light signals generated were 
recorded on Kodak BioMax MS X-Ray films using an autoradiography cassette. Exposure times 
were typically between 5 and 10 minutes. The developed film was scanned at 800dpi resolution, 
and the individual spot intensities were measured using Image J v1.48 software.  
 
 
 
Statistical Analyses 
The endocytosis inhibition and colocalization data for each cell line were statistically analyzed 
by Student’s t-test using GraphPad Prism v6.00 software for Mac OSX. All analyses were 
performed with a confidence interval set at 95 %. P-values <0.05 were considered significant. 
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Appendix  
 
A4.1 Hydrodynamic size and Zeta Potential (surface charge) characterizations of the 
NTNPs, F3NPwt and F3NPscram  
 
 
 
 
 
 
 
 
 
 
Fig. A4.1 Hydrodynamic diameters (above) of the NTNPs, F3wtNP and F3scramNP as determined by dynamic light 
scattering based on 1 mg/mL suspensions of the respective NPs prepared in 10 mM phosphate buffered saline (PBS, 
pH 7.2). Zeta potentials (below) of the NTNPs, F3NPwt and F3NPscram based on 1 mg/mL suspensions of the 
respective NPs prepared in dH2O.  
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A4.2 Raw data of phosphoproteomic MAPK Arrays obtained for the Untreated Control, 
F3wt Peptide, NTNPs, F3wtNP, and F3scramNP treatments of MDA-MB-435 cells  
 
 
 
 
 
 
 
 
 
Fig. A4.2 Images of phosphoproteomic MAPK membrane arrays developed by chemiluminescence using Kodak 
Biomax MS autoradiography films following probing with whole cell lysates of untreated MDA-MB-435 cells, or 
MDA-MB-435 cells treated with F3wt Peptide (0.22 mg/mL), NTNPs (1 mg/mL), F3wtNP (1 mg/mL), or F3scramNP 
(1 mg/mL) for 2 hours at 37 °C, 5% CO2 humidified atmosphere. 
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A4.3 Fold changes in the levels of phosphorylated proteins in response to the various 
treatments relative to the untreated control MDA-MB-435 cell 
 
 
Fig. A4.3.1 Column chart depicting fold increases and decreases in the levels of phosphorylated signaling proteins 
determined by the phosphoproteomic arrays (Fig. A4.2) in response to the various treatments relative to the 
untreated control MDA-MB-435 cells.  
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Fig. A4.3.2 Column chart depicting fold increases and decreases in the levels of phosphorylated signaling proteins 
determined by the phosphoproteomic arrays (Fig. A4.2) in response to the various treatments relative to the 
untreated control MDA-MB-435 cells. The values for phosphorylated p53 have been omitted to present the fold 
changes in phosphorylation levels of the other signaling proteins more clearly. 
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A4.4 Linear correlation strengths between phosphorylated MAP2K (MKK3/MKK6) levels 
and phosphorylated p38 MAPK levels  
Fig. A4.4.1 Linear correlation strengths between the levels of phosphorylated MKK3 (MAP2K), phosphorylated 
MKK6 (MAP2K) and the levels of phosphorylated p38α, p38β and p38δ MAPKs. Data points for each curve were 
obtained from the untreated control, F3wt peptide, NTNPs, F3wtNP and F3scramNP treatments (2 hours post-delivery). 
	   150	  
 
Fig. A4.4.2 Correlations between the levels of average MAP2K (MKK3 and MKK6) and the levels of 
phosphorylated p38α, p38β and p38δ MAPKs. Data points for each curve were obtained from the untreated control, 
F3wt peptide, NTNPs, F3wtNP and F3scramNP treatments (2 hours post-delivery). 
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Chapter 5 
Future Directions 
 
5.1 Long-term intracellular trafficking studies 
The intracellular trafficking study in Chapter 3 revealed that while the NTNPs exhibited a time-
dependent increase in colocalization with LAMP1 protein (reminiscent of accumulation within 
lysosomes), this was not the case for the F3NPs. Instead, we observed distinct F3NP-laden 
endosomes within the perinuclear space that were devoid of LAMP1 proteins. Future studies will 
focus on determining the precise identity of the subcellular compartments within which the 
F3NPs are contained. Possible compartments include the Golgi network, and the endoplasmic 
reticulum. The presence of the Rab7 GTPase on endosomal membranes is known to ensure their 
delivery to lysosomes, whereas Rab9 GTPase mediates the trafficking of late endosomes to the 
Golgi network.1 Hence, one possible experiment is to employ fluorescent Rab7, and Rab9 
constructs, and chase the intracellular trafficking of the F3NPs relative to these GTPase proteins. 
Furthermore, immunocytochemistry studies beyond 6 hours are necessary to determine the 
subcellular localization of the F3NPs over long periods of time, as this has important 
implications for in vivo drug delivery.  In addition, the F3-targeted NPs employed in this study 
were based on a surface ligand (F3 peptide) density that elicited saturated cellular sequestrations 
(binding and uptake) characteristics in both the 9L and MDA-MB-435 cell lines. Future studies 
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will focus on determining the minimum surface ligand (F3 peptide) density necessary to yield the 
multivalency effect, and thus confer lysosome-evasive properties to the F3NPs.  
The pentavalent HB-19 pseudopeptide, a specific antagonist that binds the C-terminal tail of 
nucleolin,2 was shown to suppress the growth of tumor cells and angiogenesis. It will also be 
interesting to investigate how this multivalent HB-19 pseudopeptide influences the intracellular 
trafficking of the PAA-NPs, relative to the F3-targeted PAA-NPs.  
 
5.2 MAPK cell signaling studies 
Based on our observations from the p38 ELISA and phosphoproteomic arrays, the NTNPs, as 
well as the F3 peptide alone, elicited significantly higher levels of phosphorylated p38β and 
p38δ MAPK isoforms than the F3wtNPs. Given that the p38 MAPKs directly phosphorylate 
EEA1 and caveolin1, this observation provides a signaling mechanism to explain the differential 
intracellular trafficking of the NTNPs and F3wtNPs. Future studies will focus on confirming if 
the NTNPs do indeed elicit greater phosphorylation of EEA1 at Thr-1392, and Caveolin-1 at 
Tyr-14 than the F3NPs. If this is indeed the case, then subsequent experiments will seek to 
determine which p38 MAPK isoform is responsible for mediating the phosphorylation of EEA1 
and Caveolin-1 through the use of selective inhibitors.  
With respect to the JNK pathway, future studies will focus on determining the 
phosphorylation status of the MAP2K enzymes, MKK4 and MKK7 that directly phosphorylate 
JNK1-3, so as to gain a better understanding of the JNK1-3 phosphorylation profiles we 
observed in this study. Furthermore, the phosphorylation status of p53 tumor suppressor protein 
at Thr-81 will also be determined. This is necessary to elucidate if the p38 and JNK MAPKs are 
indeed acting synergistically to induce growth arrest in response to the NTNPs and F3scramNPs. 
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With respect to the ERK pathway, studies of the phosphorylation status of the N-terminal and 
C-terminal domains of RSK1 and RSK2 will also be performed. This is necessary to determine 
(i) the level of direct phosphorylation elicited by ERK1/2 at the C-terminal domains of RSK1/2, 
and (ii) if that translates into similar levels of phosphorylation at the N-terminal domains of 
RSK1/2. Ultimately, this will provide a holistic understanding of the activation status of the 
RSK1 and RSK2 proteins in response to activation of the ERK pathway by the F3 peptide and 
F3wtNPs. Similar studies will be performed to with respect to the Akt1-3 isoforms, as well as 
p70S6k, so as to determine the actual activation status of these proteins in response to the various 
treatments, and thus the implications they have for cell survival.  
In addition, the differential p-ERK/p-p38 ratios elicited by the various treatments were 
remarkable observations. It is therefore necessary to determine if the p-ERKhigh/ p-p38low 
signaling ratio elicited by the F3wtNPs translate into cellular proliferation, and if the p-ERKlow/p-
p38high signaling ratios elicited by the NTNPs and F3scramNPs translate into apoptosis. This will 
be confirmed by performing extended duration treatments with the various NPs and F3wt 
peptides, followed cellular proliferation and apoptosis assays. 
Last, with respect to the NTNPs interactions with cell surface receptors, we also aim to 
characterize the composition of the protein corona that forms around the positively charged 
NTNPs, and further determine the protein-receptor interactions that mediate the internalization of 
the NTNPs. Moreoever, we will also determine if the treatment of MDA-MB-435 cells with the 
F3wtNP translates into stronger recruitment of FAK to the sites of binding, than with the F3wt 
peptides alone.  
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